Hepato-psoriatica : mediaction effect / comorbidity / disease entity by Voort, E.A.M. (Ella) van der
HEPATO-PSORIATICA
Medication effect / Comorbidity / Disease entity
Ella A.M. van der Voort
H
E
PA
T
O
-PSO
R
IA
T
IC
A
    M
edication effect / C
om
orbidity / D
isease entity
E
.A
.M
 van der Voort
HEPATO-
PSORIATICA
Ella van der Voort
Medication effect
Comorbidity
Disease entity

HEPATO-PSORIATICA
Medication effect / Comorbidity / Disease entity
Ella A.M. van der Voort
Colofon
ISBN 978-94-92683-58-8
Cover design by E.A.M. van der Voort
Copyright © 2017 E.A.M. van der Voort
All rights served. No part of this thesis may be reproduced, stored in a retrievel system 
or transmitted in any form or by any means, electronically or mechanically, including 
photocopying, recording, or otherwise, without permission of the author, the copyright 
owner, or when appropriate, of the publishers of the publications.
Layout and Printing: Optima Gra fische Communicatie 
HEPATO-PSORIATICA
Medication effect / Comorbidity / Disease entity
HEPATO-PSORIATICA
Medicatie effect / comorbiditeit / ziekte entiteit
Proefschrift
ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de rector magnificus
Prof.dr. H.A.P. Pols 
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op 
Dinsdag 5 september 2017 om 13:30 uur
door
Ella Anna Maria Kaijser-van der Voort
geboren te Weert
PROmOTIECOmmISSIE
Promotor	 Prof. dr. T.E.C. Nijsten
Overige	leden	 Prof. dr. E.P. Prens
 Prof. dr. J.M.W. Hazes
 Prof. dr. E.M.G.J. de Jong 
Copromotor	 Dr. M. Wakkee
Wie wil zoekt mogelijkheden,
wie niet wilt zoek een reden.

CONTENTS	
Introduction
Chapter 1 General introduction and aims of this thesis. 9
Systemic	inflammation	in	psoriasis 
Chapter 2 Markers of systemic inflammation in psoriasis: a systematic 
review and meta-analysis. 
Br J Dermatol 2013;169(2):266–282
31
Chapter 3 Differences in systemic inflammation between psoriasis, 
psoriatic arthritis and rheumatic arthritis. 
Manuscript in preparation
61
Liver	disease	in	relation	to	psoriasis
Chapter 4 Psoriasis is independently associated with nonalcoholic fatty 
liver disease in patients 55 years old or older: Results from a 
population-based study. 
J Am Acad Dermatol 2014;70(3):517-524
81
Chapter 5 Increased Prevalence of Advanced Liver Fibrosis in Patients 
with Psoriasis: A Cross-sectional Analysis from the Rotterdam 
Study. 
Acta Derm Venereol 2016;96(2):213-217
97
Chapter 6 Enhanced liver fibrosis test (ELF) in psoriasis, psoriatic 
arthritis and rheumatoid arthritis patients: a cross-sectional 
comparison with procollagen-3 N-terminal peptide (P3NP). 
Br J Dermatol 2017;176(6):1599-1606 
115
Chapter 7 Elevated enhanced liver fibrosis test (ELF) score in rheumatic 
arthritis and psoriatic arthritis patients: daily practice cross 
sectional comparative study. Submitted
135
General	discussion	and	summery 
Chapter 8 General discussion and perspectives 149
Chapter 9 Summery/samenvatting 165
Chapter 10 Appendices 175
Abbreviations 177
List of co-authors 178
List of publications 180
Curriculum Vitae 183
PhD Portfolio 184
Dankwoord 185

CHAPTER 1
General introduction  
and aims of this thesis. 
1.1 Psoriasis 
1.2  Related immune-mediated inflammatory disease (IMIDs); 
Psoriatic arthritis and rheumatoid arthritis 
1.3 Non-alcoholic fatty liver disease (NAFLD) and liver fibrosis 
1.4  Cardiovascular and liver specific comorbidities
1.5 Monitoring liver deviations in IMIDs
1.6 Aims of this thesis 

11
General introduction
GENERAL	INTRODUCTION
This introduction will start with a general description of psoriasis, the main disease 
addressed in this thesis. This will be followed by a description of two related immune-
mediated inflammatory diseases namely, psoriatic arthritis, which can co-exist in pa-
tients with psoriasis, and rheumatoid arthritis, a well-established systemic inflammatory 
disease. The third paragraph explains two liver diseases; non-alcoholic fatty liver disease 
and liver fibrosis. In this thesis both liver conditions will be further investigated in their 
connection with psoriasis. The fourth paragraph describes comorbidities in general and 
in the second part of this paragraph zooms in on liver specific comorbidities. This is 
followed by an elaboration on how the liver is currently monitored in immune-mediated 
inflammatory disease. Finally we describe the aims of this thesis. 
PSORIASIS	
Epidemiology
Psoriasis is a serious common inflammatory skin disorder, which affects between the 
0.6% and 4.8% of the population worldwide.1 In the Netherlands the prevalence is 
around the 2%, which represent ±340.000 persons with psoriasis.2 Psoriasis can start 
at any age, but there are two incidence peaks, one between the age of 15 to 30 and 
the other peak is between the age of 50 to 60.1 Males and females are equally affect, 
however there are reports that psoriasis is more severe in men.1 
Clinical	
Psoriasis can be divided into different phenotypes which can co-occur within one pa-
tient. Plaque psoriasis is the most common form and is seen in 90% of the cases. This 
subtype is characterized by red indurated lesions which can affect any skin site; how-
ever usually extensor surfaces of the forearms and shins, peri-umbilical, perianal, and 
retro-auricular regions and the scalp are affected. (Figure 1) Scalp psoriasis is present in 
75%-90% 3 of patients and nail psoriasis has a life time incidence of 80-90%.4,5 Another 
form is pustular psoriasis; this can be generalized on the whole body or be restricted 
to the palms and soles, so called palmoplantar pustulosis. The generalized pustular 
psoriasis is characterized by white coalescing pustules on dark erythematous patches 
and can confluence to large lakes of pus. This can progress rapidly and be potentially life 
threatening. Furthermore guttate psoriasis (droplet), intertriginous or flexural psoriasis 
and the most severe and rare form is erythrodermic psoriasis, which can have serious 
complications. To classify the severity of psoriasis mostly the Psoriasis Area Severity 
Index (PASI) score or the psoriasis global assessment (PGA) are used.6,7 
CHAPTER 1
12
Pathology	
Histopathological features of psoriasis are epidermal acanthosis, hyperkeratosis, 
parakeratosis and elongation of the rete ridges caused by the premature keratinocyte 
maturation. These features are clinically visible as thick red scaly plaques. The granular 
layer is minimal in size or even absent, blood vessels reaching into the tips of the dermal 
papillae and a mixed inflammatory infiltrate with neutrophilic granulocytes within the 
epidermis something leading to Munro’s microabscesses. With immunohistochemical 
staining of CD3 an increased amount of T-lymphocytes can be demonstrated in the 
dermis and epidermis.5 These activated T-cells, dendritic cells and cytokines stimulate 
the differentiation of T cells to Th1 and Th17 cells. The interplay of these adaptive T 
cells (adaptive immune system) and macrophages, mast cells and granulocytes (innate 
immune system) produce several mediators that induce and maintain these psoriatic 
hallmark features in both dermis and epidermis. (Figure 2) 
Etiology
The current concept is that psoriasis is a multifactorial disease in which genetic, (neuro)im-
munological and environmental factors interact and cause a vicious cycle of inflammation 
that is insufficiently controlled by regulatory systems. In this inflammatory disease there 
is a complex pathogenic interaction between the innate and adaptive immune system. 
The risk of getting psoriasis is higher when one or two parents are affected, respec-
tively 28% and 65% and the lifetime disease concordance in monozygotic twin is 
higher with 35-73% compared to 12-20% in dizygotic twins. 9,10 These findings illustrate 
Figure	1.	Clinical presentation of psoriasis
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a genetic predisposition in psoriasis. Genome-wide association studies (GWAS) in 
European-origin have identified loci in 66 genomic regions that are associated with 
psoriasis at genome-wide significance.11 Of these around 18% is also related to psoriatic 
arthritis and 14% to single cutaneous disease.12 Most of these genetic loci and genes are 
involved in the interleukin IL-23/Th17 axis of the psoriasis immunopathogenesis.13 The 
cytokines of importance in this axis are IL-17A, IL-17F, IL-22, IL-26, TNF-alfa and of the 
TH-1 axis; TNF-alfa, IFN-gamma and IL1 and IL2, furthermore IL-23, IL-20 and IL-15 are 
increased in serum and lesional skin.14 The PSOR1 locus on the HLA-Cw6 allele is related 
to the greatest risk factor of early onset psoriasis.15 
Environmental factors; including medicines can trigger psoriasis and can be a reason 
for exacerbation or therapy resistant forms. The most well-known drugs are β blockers, 
ACE-inhibitors, lithium, antimalarials, and non-steroidal anti-inflammatory agents.16 Tu-
Figure	2.	Schema of the evolution of a psoriatic lesion from initiation to maintenance disease. 
Reproduced with permission from Nestle et al 8, Copyright Massachusetts Medical Society.
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mor necrosis inhibitors, which is an effective therapy for psoriasis can paradoxically also 
cause psoriasis pustulosis.17 Other triggers are mild trauma (Koebner phenomenon), 
sunburn, or chemical irritants, infections e.g. streptococcal infections or HIV infection, 
alcohol, obesity, smoking and stress.18-21 
Burden
Psoriasis has a high physical and psychological burden. The psychological burden mea-
sured in quality of life is even higher in psoriasis compared to congestive heart failure, 
myocardial infarction and cancer.22 This may be explained by the visible disfiguration on 
the skin that can trigger negative reactions and low self-image as well as the itching and 
burning and sometimes painful sensation of the psoriasis plaques. The physical burden 
can even be further increased by co-existing diseases like psoriatic arthritis and a higher 
incidence of metabolic syndrome and several other comorbid disease e.g. depression 
and Crohn’s disease.8 The economic consequences are significant, high costs conducted 
to visits to the outpatient clinic, drugs, especially biological therapy, missed working days 
or even unemployed because of their psoriasis. This all together made that the WHO in 
2013 recommended a raised awareness of psoriasis as a major global health problem.5 
Therapy
Approximately three quarter of patients have mild psoriasis and are treated only with 
topical therapies.23 Topical corticosteroids, vitamin D analogues, and emollients are 
the most applied topical treatments. Tacrolimus is mainly used for intertriginous areas 
and the face, while dithranol and coal tar ointment are mostly prescribed in a day care 
setting. Around 25% of the psoriasis patients has a moderate to severe disease sever-
ity that requires more than topical treatment. The next step is often phototherapy; 
narrow-band UVB and sometimes PUVA. When topical and phototherapy fail, or are 
contraindicated, systemic therapy is the next step. The following classic systemic agents 
are available: fumaric acid (induces IL-4 producing Th2 cells and generates type II den-
dritic cells to produce IL-10 instead of IL12/IL23), cyclosporine (calcineurin inhibitor, 
deceases T-cell proliferation), methotrexate (MTX) (folic acid antagonist, reduces cell 
proliferation) (we will discuss this later on in the introduction in more detail), acitretin 
(vitamin A derivate). Biological therapy is a second line therapy when conventional sys-
temic therapies (UVB or PUVA and minimal MTX) were not tolerated, have failed or are 
contra-indicated. Biological therapy, monoclonal antibodies and fusion protein-based 
selective targeting of key mediators of inflammation, have been added to the thera-
peutic options the last decade and more innovative therapies are expected in the near 
future. The biologicals which are currently available on the market are infliximab (anti-
TNF-α, soluble and transmembrane), etanercept (anti-TNF-α receptor fusion protein), 
adalimumab (anti-TNF-α) , ustekinumab (anti IL-12/IL-23), secukinumab (anti-IL-17A).24 
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Ixekizumab (anti -L17) is the most recently approved biological. Also recently, a new 
oral immunomodulative therapy, called apremilast (phosphodiesterase 4 inhibitor) was 
approved in Europe and USA.
RELATED	ImmUNE-mEDIATED	INFLAmmATORy	DISEASES
Psoriasis, Psoriatic arthritis (PsA) and rheumatoid arthritis are immune-mediated inflam-
matory diseases (IMID). 
Psoriatic arthritis
PsA is an seronegative, chronic, inflammatory joint disease, characterized by joint dam-
age, psoriatic skin lesions, and disability.25 The prevalence in the general population is 
around 0.2%.26 Among psoriasis patients, 4.6% suffers from psoriatic arthritis visiting 
only a general practitioner up to around 30% in secondary dermatologic care, and this 
risk increases with psoriasis severity.27,28 Patients have complaints of pain, swelling and 
tenderness of the joints, which reduces daily functioning and the quality of life.29 From 
15,5% up to 90% of the psoriatic arthritis patients suffer from nails involvement.28,30 Pso-
riatic arthritis is also associated with cardiovascular risk factors, like obesity, hyperten-
sion, diabetes and dyslipidemia, which contributes to an increased risk of cardiovascular 
events and mortality.31 In psoriatic arthritis there is a large genetic contribution with 
genes overlapping with psoriasis susceptibility, particularly HLA-Cw*0602, IL23R and 
IL-12B.32 Activated T-cells and macrophages playing an important role in the induction 
of inflammatory and destructive processes in the joints.33 Increased levels of pro-inflam-
matory cytokines like IL-1β, IL-2, IFN-γ and TNF-α, are found in the synovium.33 And also 
the IL23/TH17 axis has been implicated in psoriatic arthritis. (Figure 3)
Rheumatoid arthritis
is a chronic seropositive autoimmune arthritis, which is characterized by synovial in-
flammation and destruction of the joints resulting in disability and decreased quality of 
life.29,34 The prevalence varies from 0.37% to 1.0% and increases in developing countries, 
female gender and higher age.34 Genetic factors are of importance in susceptibility to 
rheumatoid arthritis, with heritability to 60%, with a HLA locus of 30% of the overall 
genetic risk. 34 Also in rheumatoid arthritis there is a complex interplay between the 
innate and adaptive immune system. (Figure 3) Inflammatory infiltrates are found in the 
synovium and synovial fluid. Dendritic cells, mast cells, macrophages, neutrophils and T 
and B-cell producing antibodies and immune complexes playing roles in the develop-
ment of the different factors of rheumatoid arthritis.35 
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NON-ALCOHOLIC	FATTy	LIVER	DISEASE	(NAFLD)	AND	LIVER	FIBROSIS	
Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of liver dam-
age, from simple fatty liver to steatohepatitis, liver fi brosis and cirrhosis and is mostly 
asymptomatic until cirrhosis as a fi nal end point (Figure 4). The severity of fi brosis, the 
precursor of cirrhosis, predicts the occurrence of complications such as portal hyperten-
sion, hepatocellular carcinoma, liver-related morbidity and even mortality. NAFLD is di-
vided into that with primary and that with secondary causes. Primary NAFLD is strongly 
related with metabolic syndrome and can only be diagnosed if causes of secondary 
NAFLD and excessive alcohol consumption have been excluded. Secondary NAFLD 
can be caused by a variety of pharmacological agents (e.g. MTX), medical or surgical 
conditions. The process of a simple fatty liver progressing to cirrhosis with its related 
complications, has a wide range that runs from two years to many decades with a mean 
duration of 26 years.36 Approximately 30-40% of the people with fatty liver disease will 
develop non-alcoholic steatohepatitis (NASH) and almost half of these patients will 
progress to hepatic fi brosis.37 Well known risk factors for this progression of hepatic fat 
accumulation and hepatic fi brosis are age over 50 years, obesity, insulin resistance, type 
Figure	3.	Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all infl ammation the same? 
The cells and cytokines involved in the pathogenesis of psoriasis, psoriatic arthritis, and rheumatoid arthritis. 
Abbreviations; IL, interleukin; PsA, psoriatic arthritis; Pso, psoriasis; RA, rheumatoid arthritis; TGF, tumor growth 
factor; Th, T-helpercells; TNF, tumor necrosis factor.
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2 diabetes mellitus, increased ferritin levels and the patatin-like phospholipase domain-
containing 3 (PNPLA3) I148M polymorphism, however their specifi c contributions and 
the pathological mechanisms are still not well-understood.38-40 
In developing countries the prevalence of NAFLD is estimated around 30% in the gen-
eral population and can be as high as 74% in obese patients. It is the most prevalent 
liver disease and it is expected that in 2020 it will be the main indication for liver trans-
plantation.41 Men are more aff ected that women and NAFLD has a peak incidence in 
the sixth decade of life.42 The diagnose of NAFLD can be made on radiological imaging 
techniques (e.g. ultrasound or magnetic resonance technique)43 or fatty liver index.44 
Besides liver related morbidity and mortality, NAFLD is seen more and more as a multi-
system disease, with an increased risk of type 2 diabetes mellitus, cardiovascular disease 
and chronic kidney disease.45 The majority of the death is attributed to the extra-hepatic 
comorbidities. 
Figure	4.	Spectrum of NAFLD
NAFLD refers to a wide spectrum of liver damage, ranging from mild steatosis to nonalcoholic steatohepatitis, 
advanced fi brosis and fi nally cirrhosis.
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COmORBIDITIES
Systemic	Inflammation	
In many immune‐mediated inflammatory diseases (IMIDs) as well as in cardiovascular 
disease, higher values of cytokines are found not only in the primary affected organ, 
but also in the serum of these patients. A frequently mentioned hypothesis is nowadays 
that this systemic inflammation causes the development of comorbid disease in these 
IMIDs. Examples of frequently measured pro-inflammatory markers in literature are IL-1, 
IL-6, TNF-α and CRP.46 Also adhesion molecules play a role in the inflammatory process, 
like e-selectin and ICAM. Interleukine-10 is mostly measured as an anti-inflammatory 
cytokine, which can be decreased in many inflammatory diseases. 
Association	of	comorbidities	with	psoriasis	and	inflammatory	arthritis
Because of the high disease activity that can affect almost any organ, systemic rheu-
matoid arthritis (RA) is a well-established independent risk factor for various inflamma-
tion related comorbidities including cardiovascular disease. The impact of RA on the 
cardiovascular risk is even comparable with diabetes and has therefore been added as 
a risk factor for assessing the cardiovascular risk profile as is used by the Dutch general 
practitioners cardiovascular risk management guideline (NHG).47 The systemic inflam-
mation confers an additional risk for cardiovascular mortality, even after controlling for 
traditional cardiovascular co-morbidities and risk factors.48 The risk of cardiovascular 
events is decreased in those RA patients using systemic treatments like TNF inhibitors 
and MTX.49 
Also many comorbidities have been associated with psoriasis such as cardiovascular 
disease, diabetes, NAFLD, Crohn’s disease, ulcerative colitis, celiac disease, uveitis, de-
pression, osteoporosis. There might be a small role for a direct effect of inflammation 
in these associations among those psoriasis patients with severe disease, but it is more 
likely that most associations are more complex and multifactorial than in RA.50 For pso-
riatic arthritis patients this may be somewhat different than for psoriasis patients with 
joint involvement, as they may have more systemic inflammation. Especially in psoriasis, 
unhealthy life style factors are often seen, perhaps related to the impaired health re-
lated quality of life of this population, resulting in a higher prevalence of comorbidities 
related to the metabolic syndrome like diabetes. Other explanations for the described 
comorbidities in psoriasis can be related to therapeutic interventions (like cyclosporine 
or acitretin) and therefore the overall effect of treating psoriasis on the cardiovascular 
risk is less clear. 49 Finally, in all comorbidities one should also correct for the overall 
increased use of medical care leading to detection bias (the more you see a doctor….).
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Liver	disease	
The association between NAFLD and psoriasis was fi rst described in two Italian studies 
which showed that patients with psoriasis were 1,5 to 3 fold more likely to have NAFLD 
compared to controls.51,52 The increased prevalence of NAFLD was explained by un-
healthy life style factors and an increased prevalence of metabolic syndrome in psoriasis 
patients. (Figure 5)
Compared to patients with psoriatic arthritis and rheumatoid arthritis, liver toxicity 
due to MTX therapy occurs more frequently in patients with psoriasis.53 In psoriasis the 
prevalence of MTX-induced liver fi brosis and cirrhosis varies from 5.7%-71,8%, depend-
ing on underlying risk factors and comorbidities.54 In rheumatic arthritis, the prevalence 
of mild fi brosis is around 15,3% and 1.3% has severe 1.3% fi brosis, in psoriatic arthritis 
this prevalence is 9.9% and 1.4%, respectively.55 Besides the increased prevalence of 
NAFLD related to comorbid disease and systemic treatment, also a twofold increased 
risk of auto-immune hepatitis has been described in psoriasis patients compared to the 
general population.56 
mONITORING	LIVER	DEVIATIONS	IN	ImIDS	
In	patients	without	systemic	treatment
In psoriasis patients without systemic therapy, no standard investigations in monitoring 
liver disease are recommended. This also holds for psoriatic arthritis and rheumatoid 
arthritis patients.
monitoring	liver	toxicity	during	mTX	use	according	to	diff	erent	guidelines	
MTX is a folic acid antagonist and has anti-infl ammatory, immunomodulatory and 
anti-proliferative mechanisms. Folic acid depended enzyme, e.g dihydrofolaatreduc-
Figure	 5.	 Hepato-psoriatica, the 
complex association between pso-
riasis and NAFLD 
Abbreviations; pso, psoriasis; MetS, 
metabolic syndrome; Med, medica-
tion; NAFLD, non-alcoholic fatty liver 
disease; sys infl ame, systemic infl am-
mation.
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tase, interferes in the DNA and RNA synthesis. The exact working mechanism of MTX 
is still unknown. MTX was first described by Gubner in 1951 and a FDA approval for 
psoriasis was given in 1971. Indications for MTX are broad and range from inflammatory 
skin diseases, to inflammatory joint disease to oncological indications. Minor toxicities 
due to MTX are common and consist of fatigue, nausea, anorexia and stomatitis. Major 
toxicities are bone-marrow toxicity, pulmonary fibrosis and hepatotoxicity. To reduce 
side-effects extra folate intake is advised during MTX treatment. 
Risk factors for developing hepatotoxicity are a history of or current moderate to 
severe alcoholic consumption, persistent liver chemistry deviations in serum, history of 
hepatitis B or C, family history of inheritable liver disease, history of significant exposure 
of hepatotoxic drugs or chemicals and components of the metabolic syndrome; diabe-
tes mellitus, obesity and hyperlipidemia.57
In the following paragraphs we will describe the guideline advice regarding monitor-
ing for hepatotoxicity during MTX use in psoriasis and inflammatory arthritis and this is 
also summarized in Table 1.
Dutch dermatology guideline:58 
The Dutch guidelines for psoriasis were the first major evidence-based guidelines to 
be developed starting in 2003.59 Since then this guideline has been updated regularly 
and a new update will take place this year (2017) again. Procollagen-3 N-terminal Pep-
tide (P3NP) is currently recommended to be determined before and during MTX use 
to monitor for hepatotoxicity. However, in the updated guidelines this recommenda-
tion will probably disappear. Before starting MTX the following laboratory values and 
tests are recommended to monitor for hepatotoxicity: alanine aminotransferase (ALT), 
Table	1.	psoriasis and arthritis guideline on methotrexate use. 
Before	start	(on	indication) During	treatment STOP/	to	hepatologist
Dutch	dermatology ALT, GGT, HBV, HCV (HIV, 
albumine) (P3NP)
ALT, GGT (P3NP) >3x ↑ ALT or GGT in 6 
weeksabnormale P3NP
British	dermatology Liver blood tests, HBV, HCV, P3NP Liver enzymes, 
P3NP every 3 
month,
liver enzymes >2× baseline 
values, persistently 
abnormal P3NP (>4.2 mcg/L 
in at least 3 samples over a 
12-month period or 2 above 
>8 mcg/L ).
European	
dermatology
Liver enzymes, HBV, HCV, P3NP 
when available (albumin) 
Liver enzymes, 
P3NP every 3 
month, (albumin) 
liver enzymes >2× baseline 
values, persistently 
abnormal P3NP (>4.2 mcg/L 
in at least
three samples over a 
12-month period).
Dutch	rheumatology ALT (HBV, HCV, HIV) ALT >3x ↑ ALT
21
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gamma-glutamyltransferase (GGT), hepatitis B virus (HBV), hepatitis C virus (HCV) and 
when indicated human immunodeficiency virus (HIV) and albumin. During treatment 
ALT, GGT and serum albumin when suspicion of hypo albumin. When ALT of GGT is more 
than 3 times elevated, referral to a hepatologist should take place within 6 weeks to 
perform an ultrasound of the liver or fibroscan or if indicated a liver biopsy. MTX should 
be discontinued if the Iiver biopsy shows a Roenigk stadium of Graad IIIB, IV or higher. 
British guidelines:60 
Before starting MTX treatment liver function tests and P3NP should be conducted. The 
cut-off value for P3PNP is < 4.2. Elevation of P3NP above 8.0 mg/mL should prompt fur-
ther hepatic investigation. If the value is between 4.2 and 8 mg/mL MTX can be started, 
but if during treatment values remain increased, referral to a hepatologist is necessary. 
The routine use of liver biopsy for monitoring MTX hepatotoxicity is no longer recom-
mended in the British guidline.60 
European guidelines:61
P3NP should be tested when available before start and every three month during 
therapy. When persistently abnormal P3NP (>4.2 mcg/L in at least three samples over a 
12-month period), further research or referral to a hepatologist should be done.
Dutch rheumatology guidelines:62 
The Dutch rheumatology guidelines recommend before starting MTX therapy to test 
ALT levels. HBV, HCV and HIV should only be tested on indication. During treatment 
monthly ALT control is advised for the first three months and after dose escalation. When 
ALT levels are over 3 times elevated MTX should be stopped and after normalization 
MTX can be reintroduced in a lower dosage. When on lower dosage MTX, ALT elevation 
is persistent, referral to a hepatologist is recommended. 
monitoring	NAFLD/	liver	fibrosis	
Serum GGT, alkaline phosphatase (ALP), ALT and aspartate aminotransferase (AST) levels 
are commonly used to monitor liver damage. ALT is predominantly found in the liver, 
whereas GGT, ALP and AST are expressed in multiple other tissues, including heart, 
skeletal muscle, kidneys, bone and brain. Elevation of serum liver chemistry tests are re-
ported in up to a quarter of individuals in Western population. The majority of liver test 
abnormalities may be attributed to the presence of alcoholic and NAFLD.63 Although 
elevation of ALT and AST is most frequent caused by NAFLD, they do not discriminate 
between simple fatty liver, steatohepatitis or fibrosis. Furthermore, up to 50% of NAFLD 
patients have normal ALT levels64 and in patients with liver fibrosis and cirrhosis, ALT 
levels are often within the normal range.41 Therefore, ALT and AST are apparently poor 
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diagnostic markers for NAFLD and liver fibrosis and may be used to monitor acute liver 
toxicity (i.e. drug induced hepatitis), but creates a false sense of security when it comes 
to monitoring liver fibrosis.
As described previously, P3NP is part of some dermatology guidelines to monitor liver 
fibrosis during MTX therapy. P3NP is a serum marker for collagen turnover and used as 
a marker for measuring hepatic fibrosis.65 Although higher values of P3NP are found in 
patients with liver fibrosis, P3NP is not organ specific, and can also be elevated by active 
arthritis, recent bone fracture or recent myocardial infarction, and often has higher val-
ues among younger people. Furthermore, P3NP is only of use as a serial measurement. 
Probably due to these shortcomings, P3NP has been abandoned in hepatology a while 
ago and will no longer be part of the Dutch psoriasis guideline. 
Liver biopsy is the golden standard for staging hepatic fibrosis, inflammatory activity 
and diagnosing other chronic liver diseases, but it has a lot of disadvantages as a moni-
toring tool. The procedure is invasive, costly, requires specialized expertise, is limited 
by its semi-quantitative nature, sample error, intra-observer variability and not at least 
carries a risk of morbidity and even mortality.66 
There is a high need for a non-invasive marker to monitor for liver fibrosis in psoriasis 
patients and other IMIDs, especially during potential hepatotoxic treatment. Different 
non-invasive methods of liver fibrosis assessment have been identified and widely vali-
dated using imaging techniques and serum biomarkers. Although liver biopsy cannot 
be totally abandoned, these non-invasive techniques reduce the need significantly. One 
of the most frequently used non-invasive methods is transient elastography (TE).67 TE 
measures liver stiffness in a 1 cm wide by 5 cm long volume, which is 100 times greater 
than a liver biopsy.68 TE has a high diagnostic accuracy, independent from the underly-
ing liver disease, to predict advanced liver fibrosis.69 Up to now only two small studies 
have evaluated TE in patients with psoriasis using high dose MTX.70,71 TE is reliable to 
identify advanced stages of fibrosis. A limitation is the need of specialized instruments 
and expertise, and higher unreliable measurements in obese patients. In daily clinic (for 
dermatologist, rheumatologist and general practitioners) a serum biomarker is better 
usable and accessible. Several tests have been developed. The complex direct panels are 
superior to the indirect and single biomarkers. The Enhanced Liver Fibrosis (ELF) test is a 
direct complex panel in detecting liver fibrosis. ELF is an algorithm of three biomarkers, 
P3NP, tissue inhibitor of matrix metalloproteinase 1 (TIMP) and hyaluronic acid (HA). A 
higher concentration of individual biomarkers leads to a higher ELF score and indicates 
a greater likelihood of more severe fibrosis. The ELF test has been extensively validated 
in healthy subjects and multiple liver diseases, e.g. NAFLD, hepatitis B and C, and alco-
holic liver disease.72 The ELF test might be even superior to liver biopsy in predicting 
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clinical outcome in chronic liver disease.73 Other strengths are better automaticity, high 
reproducibility, and less invasiveness. 
AImS	OF	THIS	THESIS
Many comorbidities have been associated with psoriasis, especially related to metabolic 
syndrome and cardiovascular disease. However, little is known about the association 
between psoriasis and NAFLD, which are both linked to the metabolic syndrome with its 
inflammatory components. 
The main topic of this thesis is the relation between psoriasis and liver disease. in the 
first part we focus on systemic inflammation. We start in chapter one with a systemic 
review and meta analyses on systemic inflammation in psoriasis compared to healthy 
controls, taking into account the influence of gender, age and disease severity. In the 
second chapter we put the systemic inflammation of psoriasis patients into a wider 
perspective and compare this systemic inflammation of psoriasis to psoriatic arthritis 
and rheumatoid arthritis. 
In the second part, we will zoom in on the relation on liver disease within psoriasis 
patients. In chapter 4 we investigate the prevalence of non-alcoholic fatty liver disease, 
using ultrasound, in psoriasis subjects compared to the general population in the Rot-
terdam study correcting for confounding factors. In the following chapter we describe 
the prevalence of liver fibrosis and cirrhosis, the next stage of liver disease, using the 
transient elastography (Fibroscan) in the Rotterdam Study in psoriasis compared to 
the general population. Chapter 6 describes the ELF test as a relative new biomarker 
in detecting liver fibrosis in psoriasis and inflammatory arthritis. In the last chapter we 
will focus on the reliability of the ELF test in psoriatic arthritis and rheumatic arthritis 
in relation to systemic inflammation. Finally we will discuss our findings in the general 
discussion and provide recommendations for the future. 
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ABSTRACT
Background: Studies investigating systemic inflammation in psoriasis use different 
serum markers and report discrepant results.
Objectives: To determine whether systemic inflammation is elevated in psoriasis 
patients compared to healthy controls and to measure the extent of this elevation, by 
summarizing available data on serum inflammatory markers.
methods: PubMed, Embase and Web of Science were searched from inception to March 
2011. We included studies comparing the serum inflammatory markers Interleukin (IL)1-
beta, IL-6, IL-10, C-reactive-protein (CRP), Intracellular adhesion molecule-1 (ICAM-1), 
E-selectin or Tumor necrosis factor-alpha (TNFα) in psoriasis with healthy controls. Dif-
ference in serum marker levels between patients and controls were pooled as standard-
ized mean differences (SMD) (Cohen’s d) using random-effects model. 
Results: Seventy-eight studies were eligible. Of the 7852 individuals, 3085 had (severe 
plaque) psoriasis. The pooled SMDs were higher in psoriasis compared to healthy 
controls for IL-6 (d=1.32, 95%CI 0.83-1.81), CRP (d=1.83, 95%CI 0.76-2.90), TNFα (d=1.32, 
95%CI 0.86-1.79), E-selectin (d=1.78, 95%CI 1.32-2.25) and ICAM-1 (d=1.77, 95%CI 1.15-
2.39). The SMD between cases and controls for IL-1β and IL-10 was not significant. Age 
had a significant effect on the SMD for IL-6 and TNFα. For IL-6 the effect size was higher 
for plaque psoriasis studies (d=1.98). The effect size was not influenced by the PASI, 
measurement method or quality assessment. 
Conclusions: The pooled analyses suggest modest, but significantly elevated levels of 
the pro-inflammatory cytokines in the serum of psoriasis patients with predominantly 
severe disease. To what extent this modest increment is clinically relevant could be 
investigated in a synthesis of all studies measuring inflammation before and after anti-
psoriatic therapy.
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INTRODUCTION
Psoriasis is a chronic, relapsing, inflammatory skin disease that affects 2% of the Caucasian 
population.1 This skin condition is histologically characterized by abnormal proliferation 
of keratinocytes and infiltration of immune cells, predominantly T-cells and dendritic 
cells in psoriatic lesions.2 The majority of inflammatory cells and cytokines remain in the 
tissue and a relatively small proportion can be measured in the peripheral blood, such 
as interleukins (ILs)3 which have shown to be elevated in patients with cardiovascular 
disease, metabolic syndrome and diabetes.4,5 
The search for markers in psoriasis was revived as these were not only found in the 
skin, but researchers also identified a spillover of inflammatory markers into the systemic 
circulation, using them to measure disease severity, to objectively monitor treatment re-
sponse, find new targets for therapy and to explain comorbidities in psoriatic patients.6,7 
Much attention has been drawn towards “upgrading” psoriasis from a skin condition 
to a systemic disease as serum biomarkers for inflammation are raised in psoriasis8 and 
patients could therefore have a higher risk of developing systemic comorbidities.6 Data 
on serum levels of pro- and anti- inflammatory cytokines in psoriasis patients compared 
to controls are controversial, with some authors not observing any difference, while 
others report elevated or decreased levels in psoriasis.3 The studies to date have small 
sample sizes, investigate different markers and techniques to assess inflammation; 
moreover measurement of serum inflammation is often not their primary objective.
We conducted the first systematic review and meta-analysis to determine whether six 
well-known pro-inflammatory serum markers IL-1β, IL-6, C-reactive protein (CRP), Tumor 
necrosis factor-alpha (TNFα), Intracellular adhesion molecule-1 (ICAM-1), E-selectin are 
elevated and anti-inflammatory IL-10 decreased in treatment naïve psoriatic patients 
compared to controls. 
mATERIAL	AND	mETHODS
Background	to	literature	search	
We investigated whether certain markers of inflammation were elevated in psoriasis 
patients compared to controls and were interested the role of inflammatory markers in 
the development of comorbidities. We therefore conducted an open literature search 
listing inflammatory markers most commonly mentioned in psoriasis and cardiovascular 
disease (CVD) (Supplementary Figure 1). This is the case for IL-1β, IL-6 and TNFα which are 
produced in adipose tissue, are known to be pro-atherogenic but are also involved in skin 
inflammation in psoriasis as they are produced by the keratinocytes.2,6 CRP is often used 
to measure suspected inflammatory state in psoriasis patients, whereas high sensitivity 
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CRP is used in the prediction of CVD.9-11 The type of CRP measured depended on the 
objective of the study. We included all studies measuring CRP, regardless of the type.
The adhesion molecules E-selectin and ICAM-1 expressed on endothelial cells are equally 
known as mediators of infl ammation in the prediction of CVD.12 (Figure 1, Table 1)
Other than the six above-mentioned pro-infl ammatory markers, we chose IL-10 as 
anti- infl ammatory cytokine to confi rm the hypothesis that IL-10 is below detectable 
levels in psoriasis patients or at the same level as in healthy controls.3,6
Eligibility	criteria
Inclusion and exclusion criteria were determined before the search was conducted. We 
included human studies comparing psoriasis patients with ‘healthy’ controls, in which 
one or more of the following infl ammatory markers were measured in the serum: IL-1β, 
IL-6, IL-10, CRP, TNFα, E-selectin and ICAM-1. Studies were excluded if psoriatic arthritis 
(PsA) was the main exposure. Case reports and letters were excluded. If several stud-
ies reported results from the same study population, the most complete report was 
included. 
Search	strategy
The systematic search was performed by a medical librarian (L.V.) in PubMed, Embase 
and Web of Science from 1988 to March 2011. The search strategy is presented as 
supplementary material Table 1. 
Adipocytes 
IL1 
IL6 
TNFa 
Il10 
IL6 
TNFa 
CRP  
E-selectin 
ICAM 
Keratinocytes 
Endothelial cells 
Figure	1.	A simplifi ed model, depicting the role of the infl ammatory markers in this meta-analysis.
Abbreviations: CRP, C-reactive protein; ICAM intracellular adhesion molecule; IL, interleukin; TNF, tumor necrosis 
factor.
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Data	extraction	and	quality	assessment
Data was collected using a standard data extraction form (Table 2). Information from 
articles in a language other than English, Dutch, French or German was extracted if an 
English abstract and comprehensive tables were available.
The quality of the articles was assessed using a checklist based on the REMARK 
guidelines, also used in other meta-analyses.13,14 The definition of each checklist item 
was discussed; two points were allocated to each positive item, one point to a partially 
fulfilled item and no points were given if the item criterion was not met. The sum of 
these points was divided by the maximum number of points an article could score. 
Study	selection
Two reviewers (E.A.D. and E.A.M.V.) independently screened all titles, abstracts and full 
texts of selected articles and conducted the data extraction and the quality assessment. 
Disagreements were resolved by consensus.
Table	1.	Role of the selected inflammatory markers.
Il-1β IL-1 is a pro-inflammatory cytokine which activates neutrophils, monocytes, eosinophils and 
basophils and triggers production of TNFα, IL-6 by macrophages. Keratinocytes are the main 
source of IL-1β in the skin. 
Il-6 IL-6 is a pro-inflammatory cytokine and is involved in the growth and differentiation of dermal and 
epidermal cells and can directly stimulate T-cell migration to the epidermis. IL-1 and TNFα activate 
keratinocytes to produce IL-6.
Il-10 IL-10 acts as an anti-inflammatory cytokine and can be produced by different cell populations, 
including keratinocytes, T-cell subsets, macrophages and monocytes and is capable of inhibiting 
synthesis of pro-inflammatory cytokines.
TNFα TNFα influences the proliferation, activation and differentiation of many cells and enhances the 
synthesis of IL-1, IL-6 and expression of adhesion molecules such as E-selectin and ICAM-1.
(hs)CRP CRP is a pro-inflammatory acute phase protein produced by the liver and a sensitive marker of 
systemic inflammation. Traditional assays for CRP are insufficiently sensitive for measuring the 
lower serum values associated with atherosclerotic disease. These can be measured by the newer 
hsCRP assays. 
E-selectin E-selectin is a pro-inflammatory soluble cell adhesion molecule expressed on endothelial 
cells activated by cytokines. It is enhanced by TNFα and CRP through endothelial cells. During 
inflammation, E-selectin recruits leucocytes to the site of injury.
ICAM-1 The soluble intracellular adhesion molecule ICAM-1 is induced by TNFα and IL1 and CRP 
through endothelial cells. It is expressed by the vascular endothelium, macrophages and 
lymphocytes. It causes leucocytes to bind to endothelial cells and then to migrate into tissues.
Abbreviations: Il, Interleukin; TNF, Tumor Necrosis Factor; (hs)CRP, (high sensitivity) C-reactive protein; ICAM, Intra-
cellular Adhesion Molecule.
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Table	2.	Characteristics of included studies.
Author,	year Country
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Abdel-Hamid et al,43 2010 Egypt 60 40 48 83.3 11.8 21 43 48 · · · 1 · · · 27/52
Abe et al,44 2002 USA 13 44 77 100 18.9 40 - - 1 · · · · · · 23/56
Ameglio et al,45 1994 Italy 14 41 7 85.7 - 14 43 14 · · · · · · 1 10/52
Anderson et al,46 2010 Sweden 14 47 29 100 8.5 14 47 29 5 5 5 5 · · · 32/56
Ardic et al,47 2010 Turkey 58 36 47 - 13.0 36 40 47 · · · · 9 · · 19/53
Arican et al,48 2005 Turkey 30 35 60 100 9.3 23 35 61 · 1 · 1 · · · 22/52
Asadullah et al,49 1999 Germany 29 - - - - 28 - - · · · 1 · · · 24/52
Balci et al,50 2009 Turkey 51 40 47 100 6.6 32 42 47 · · · · 4 · · 17/56
Bevelacqua et al,51 2006
(mild pso)
Italy 18 36 56 100 - 25 40 56 1 1 · 1 4 · · 23/52
Bevelacqua et al,51 2006 
(severe pso)
Italy 26 46 62 100 - 25 40 56 1 1 · 1 4 · · 23/52
Bonifati et al,52 1994 Italy 20 53 5 90 11.4 10 42 60 · 9 · 1 · · · 26/52
Bonifati et al,53 1995 Italy 19 53 32 100 - 22 57 36 · · · · · 1 · 22/52
Borghi et al,54 2008 Italy 65 54 80 100 21.2 114 54 80 · · 5 · · · · 28/56
Borska et al,55 2006 Czech 56 48 63 - 22.2 40 48 - · · · 1 · 1 1 29/56
Borska et al,56 2008 Czech 55 38 64 - 21.7 47 31 57 · · 1 · · · · 26/56
Bubl et al,57 1994 Germany 41 - - 100 - 31 - - · · · · · · 1 15/55
Carducci et al,58 1994 Italy 25 51 24 92 11.4 50 48 40 · · · · · · 5 15/52
Chandran et al,59 2010 Canada 26 45 46 100 4.9 26 43 46 · · · · 1 · · 26/53
Chodorowska,60 1998 Poland 27 35 100 - 25.8 20 35 100 · · · 1 · · · 28/56
Chodorowska et al,61 2004 Poland 175 38 100 - 29.0 30 40 100 · · · · 1 · · 22/56
Coimbra et al,62 2009 Portugal 56 44 55 100 19.3 37 47 57 · · · · 3 · · 23/56
Coimbra et al,63 2010a Portugal 73 45 55 100 18.0 38 47 45 · · · · 3 · · 29/56
Coimbra et al,64 2010b Portugal 66 43 53 100 18.8 37 50 57 · 1 · 1 3 · · 32/56
Coimbra et al,65 2010c Portugal 34 45 41 100 22.6 20 44 45 · · · 1 · · · 31/56
Coimbra et al,66 2010d Portugal 34 43 47 100 14.8 37 47 57 · · · · 3 · · 34/56
Corbetta et al,67 2006 Italy 10 41 100 100 13.0 10 41 100 · · · 1 · · · 29/56
Ctirad et al,68 2008 Czech 49 38 53 100 20.9 48 30 - · · · · 3 · · 28/56
Czech et al,69 1996 Germany 16 31 56 100 - 16 28 50 · · · · · 1 · 27/56
De Pita et al,70 1996 Italy 30 50 77 90 21.3 11 50 73 · · · · · · 1 29/56
De Pita et al,71 1999 Italy 24 52 63 100 8.8 20 52 60 · · · · · · 1 26/56
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Table	2.	Characteristics of included studies. (continued)
Author,	year Country
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Deeva et al,72 2010 
(severe plaque pso)
Italy 10 33 50 100 44.2 10 37 50 · 9 9 · · · · 23/52
Deeva et al,72 2010 
(mild plaque pso)
Italy 35 50 57 100 8.7 10 37 50 · 9 9 · · · · 23/52
Deeva et al,72 2010 
(erythrodermic pso)
Italy 10 38 50 0 3 64.6 10 37 50 · 9 · · · · · 23/52
Fazio et al,73 1994 Italy 20 53 5 90 11.4 10 42 60 · · · · · · 5 21/53
Galadari and Sheriff,17 2005
(mild pso)
Abu 
Dhabi
24 - 67 - 6.6 10 - 70 · 1 · · · · · 22/53
Galadari and Sheriff,17 2005 
(moderate pso)
Abu 
Dhabi
9 - 78 - 22.5 10 - 70 · 1 · · · · · 22/53
Galadari and Sheriff,17 2005 
(severe pso)
Abu 
Dhabi
5 - 40 - 44.4 10 - 70 · 1 · · · · · 22/53
Gangemi et al,74 2003 Italy 16 41 63 - 35.8 16 40 56 · · · · · · 1 19/53
Gonul et al,75 2009 Turkey 54 39 65 - 8.9 50 38 66 1 1 · 1 · · . 14/56
Griffiths et al,76 1996 Germany 32 42 59 - 15.0 99 28 56 · · · · · · 1 22/52
Groves et al,18 1995 UK 9 - - 0 3 - 17 53 41 · · · · · 1 1 23/52
Jacob et al,77 2003 USA 12 48 58 75 - 5 35 20 5 5 5 5 · · · 15/52
Jadali et al,78 2007 Iran 40 38 55 52.5 6.3 40 39 55 · · 1 · · · · 23/52
Johnston et al,37 2008 Iceland 30 53 53 100 15.3 29 47 45 5 5 · · · · · 29/56
Kagami et al,79 2010 USA 21 42 - - 22.2 17 34 0 · · · 1 · · · 22/56
Kanda et al,80 2010 Japan 61 52 74 100 8.1 31 46 65 1 1 1 1 · · · 24/56
Karabudak et al,81 2008 Turkey 20 23 100 - 13.0 20 21 100 · · · · 4 · · 20/52
Kaur et al,82 2008 (BMI<25) Estonia 10 50 60 100 14.5 22 - - · 1 · · · · · 21/52
Kaur et al,82 2008 (BMI>30) Estonia 12 47 58 100 12.4 22 - - · 1 · · · · · 17/52
Kaya et al,83 2010 Turkey 58 36 47 - - 36 40 47 · · · · 9 · · 6/52
Kitamura et al,84 1999 Japan 30 49 50 0 4 - 20 47 50 · · · 1 · 1 1 19/56
Kowalzick et al,85 1993 Germany 10 46 100 100 18.6 17 33 53 · · · · · · 1 24/56
Krasowska et al,86 1998a Poland 59 - 41 100 23.8 10 - 40 · 1 · · · · · 13/52
Krasowska et al,87 1998b Poland 23 - - - - 20 - - · · · · · · 9 8/56
Krasowska et al,88 2000 Poland 23 39 65 - 25.4 11 36 45 · · · · · · 1 22/56
Laurent et al,89 1981 UK 15 - - - - 21 - - · · · · 5 · · 20/52
Lecewicz-Torun et al,90 1997 Poland 19 35 47 78.9 - 14 38 50 · · · · · · 1 18/52
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Table	2.	Characteristics of included studies. (continued)
Author,	year Country
Psoriasis
Healthy	
controls
markers	and	
measurement	
methods	1
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Long et al,91 2010 China 58 36 62 62.1 23.7 50 36 62 · · · · · 1 1 32/56
Love et al,92 2010 USA 71 42 46 - - 2385 39 50 · · · · 9 · · 26/52
Martinez-Sales et al,93 2010 Spain 20 - - - - 20 - - · 1 · · · 1 · 8/52
Martyn-Simmons et al,94 
2011
UK 60 51 77 100 9.2 117 49 42 · · · · 3 · · 25/53
McLoone et al,95 2004 UK 5 43 100 - - 15 43 100 · · 1 1 · · · 21/56
Mizutani et al,96 1997 Japan 63 47 56 100 - 20 47 55 1 1 · 1 · · · 17/52
Mussi et al,97 1997 Italy 37 53 32 100 11.4 30 49 30 · · · 1 · · · 23/56
Ohtsuka,98 2008 Japan 52 54 62 100 12.8 147 54 62 · · · · 4 · · 15/52
Park and Kim,99 2004 Korea 15 - - - - 15 - - · · · · · 1 · 12/52
Qiu et al,100 2005 China 33 32 55 - 12.9 30 32 57 · 1 · 1 · · · 29/56
Reddy et al,19 2010 Worldwide 105 45 70 100 17.0 30 - - · · 1 1 · · 1 31/56
Rocha-Pereira et al,101 2004 Portugal 60 47 57 100 - 40 47 55 · · · · 4 · . 20/52
Roussaki-Schulze et al,102 
2005
Greece 45 - 69 100 - 45 - - · 1 1 1 · · . 23/56
Schopf et al,103 1993 Germany 17 42 - 94.1 - 17 42 - · · · · · · 1 23/52
Seishima et al,104 1998 (pso) Japan 31 55 61 - - 53 53 57 · 5 · 1 · · · 15/52
Seishima et al,104 1998 
(active GPP)
Japan 9 23 56 0 5 - 53 53 57 · 5 · 1 · · · 15/52
Serwin et al,105 2006 Poland 37 31 62 100 12.7 20 37 - · · · · 4 · · 36/56
Szegedi et al,106 2003 Hungary 18 47 78 100 20.1 10 34 60 · · 1 · · · · 18/52
Szepietowski et al,107 1999 Poland 33 38 64 100 20.7 10 38 60 · · · · · 1 · 24/56
Szepietowski et al,108 2000 Poland 40 47 70 100 26.0 18 43 67 · 1 · · · · · 26/56
Szepietowski et al,109 2002 Poland 20 25 55 100 23.7 20 25 55 · · · · · 1 · 19/52
Takahashi et al,20 2010 Japan 122 48 66 83.6 7.3 78 39 69 · 1 1 1 · · 1 24/56
Toruniowa et al,110 1995 Poland 20 - - - - 14 - - · 1 · · · · · 15/52
Vanizor Kural et al,111 2003a Turkey 30 34 43 - 5.5 30 37 50 · · · · 4 · 1 22/52
Vanizor Kural et al,112 2003b Turkey 35 35 49 - 5.8 35 36 54 · · · · 4 · · 22/52
Yamamoto et al,113 1997 
(plaque pso)
Japan 4 - - 100 25.4 6 58 - · · · · · 1 1 20/52
Yamamoto et al,113 1997 
(GPP)
Japan 6 58 50 0 5 - 6 58 50 · · · · · 1 1 20/52
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Data	synthesis	and	analysis
The primary outcome was the difference in mean serum inflammatory marker levels 
between psoriasis patients and healthy controls for each study. The effect size represent-
ing this difference was calculated using the standardized mean difference (SMD), also 
referred to as Cohen’s d and we reported its respective 95% confidence intervals (CI). In 
studies where the mean was not reported, the median was used. If the SD was not avail-
able, we assumed that the values lay within three SDs from the mean. SMDs were pooled 
using a random effects-model according to the method of DerSimonian and Laird, where 
within-study variance and between-study variance were taken into account. Heterogene-
ity between studies was quantified using I² statistics. In six studies the serum levels were 
given separately according to psoriasis type, severity or Body Mass Index (BMI), instead of 
reporting an overall mean. These were included as such in the meta-analysis; however, the 
control group remained the same for the studied outcome measures. 
Publication bias was investigated graphically by funnel plots and was statistically 
assessed via Egger’s regression. The trim and fill method provided an estimate of the 
number of missing studies and an estimate of the pooled effect size if these studies were 
to be included in the meta-analysis. 
Table	2.	Characteristics of included studies. (continued)
Author,	year Country
Psoriasis
Healthy	
controls
markers	and	
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methods	1
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Yiu et al,114 2010 China 52 44 73 100 14.7 50 43 76 · · · · 9 · · 31/52
Zalewska et al,115 2006 Poland 106 45 72 100 16.7 40 46 58 · 1 · · . · · 9/52
Total · 3085 43	
±	
7.6
57% · 17.7	
±	
10.5
4913 42	
±	
7.8
49% 9 291326221222 ·
Abbreviations: PASI, Psoriasis Area and Severity Index; Il, Interleukin; TNF, Tumor Necrosis Factor; (hs)CRP, (high sen-
sitivity) C-reactive protein; ICAM, Intracellular Adhesion Molecule; pso, psoriasis; GPP, Generalized Pustular Psoriasis.
Areas marked with “-“ indicate missing data and “·“ indicates not applicable.
1 The following measurement methods were used: 1=Enzyme Linked Immuno Sorbant Assay (ELISA), 2= Radio im-
munoassay, 3=Immunoturbidimetry, 4=Nephelometry, 5=other measurement method, 9=method not specified. 
2 Quality assessment score: study score / maximum possible score for the article. 
3 100% erythrodermic psoriasis.
4 100% palmo-plantar psoriasis.
5 100% pustular psoriasis.
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All statistical analyses were performed using Comprehensive Meta-Analysis Version 
2.2 (Biostat, Englewood, NJ, U.S.A.).
meta-regression	and	subgroup	analyses
Sources of heterogeneity between studies were explored by performing meta-regres-
sion analyses for age, gender and psoriasis severity. Subgroup analyses were performed 
based on psoriasis type (only plaque psoriasis versus different or non-specified types), 
laboratory measurements (Enzyme Linked Immuno Sorbant Assay (ELISA) versus other 
techniques or when the measurement method was not specified, and for CRP: ELISA 
versus immunoturbidimetry versus nephelometry versus other or missing method). 
Subgroups were analyzed for quality assessment scores whereby studies above and 
below the upper quartile were compared to each other. For each subgroup the pooled 
SMD and 95%CI was presented.
We excluded all studies with PsA, however we did not exclude studies with a small 
number of PsA patients alongside other psoriasis patients. In order to ascertain that the 
impact of PsA was limited in the meta-analysis, we conducted subgroup analyses com-
paring studies where PsA patients were excluded to the rest of the studies, showing no 
significant difference in point estimates between these two categories. The interpreta-
tion of this analysis was limited due to the small number of studies explicitly mentioning 
that PsA patients were excluded. We therefore decided to refrain from further discussing 
this subgroup analysis in the manuscript.
The present study was conducted and reported according to the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-Analysis of Obser-
vational Studies in Epidemiology (MOOSE) guidelines.15,16 
RESULTS
The search yielded 8447 articles (5385 after exclusion of duplicates), of which 78 were 
included in the meta-analysis. Figure 2 depicts the study selection process. 
A total of 7852 individuals (3085 psoriasis patients) were included. Psoriasis patients 
and healthy controls were comparable as to age (Table 2). The psoriasis type was known 
in 69% of patients. Of these, 94% (n=1971) had plaque psoriasis and 3.4% (n=71) had 
erythrodermic psoriasis. A total of 70% of the studies reported a Psoriasis Area and Se-
verity Index (PASI). Within this group, 75% of the patients were from studies reporting a 
mean PASI >10, indicating that the majority of the studies included patients with severe 
disease (overall mean PASI 17.7±10.5).
41
Meta-analysis on systemic inflammation in psoriasis.
Interleukin-1β
The SMD for studies analyzing IL-1β was -0.32 (95% CI -1.05-0.41) indicating that there 
was no significant difference in serum IL-1β between psoriasis patients and controls 
(Figure 3a). Age and psoriasis severity did not explain the high degree of heterogeneity 
between the studies (I²=93%). When adjusting for gender in the meta-regression, we 
noticed that the higher the percentage of women in the study, the larger the difference 
in IL-1β between psoriasis patients and controls in the study (p=0.001). Regarding the 
subgroup analyses, no significant differences were observed between studies including 
plaque psoriasis only and other studies (p=0.90) (Table 3).
Interleukin-6
Twenty two studies provided plasma IL-6 levels in 994 psoriasis patients and 594 controls 
(Table 2). Figure 3b shows a significantly higher level of IL-6 in psoriasis patients, with 
a pooled SMD of 1.32 (95%CI 0.83-1.81). In the forest plot, the study by Galadari et al 
showed high SMDs ranging from 25 to 36 for the three subgroups of psoriasis severity 17. 
However, the point estimate remained significantly higher for psoriasis when excluding 
this study (d=1.07, 95%CI 0.65-1.49). Meta-regression for age indicates that the older 
the age of the patients in the study, the smaller the SMD between psoriasis patients and 
controls across studies (β=-0.08, p=0.04). Gender and PASI had no effect on the SMD in 
IL-6 (p=0.08 and p=0.66, respectively). The SMD for IL-6 was significantly lower in stud-
ies including only plaque psoriasis (n=13) compared to other studies (n=9) (Table 3), 
Search in PubMed, Embase, Web of Science
Duplicates excluded
5385 articles
280 potentially relevant articles reviewed in full text
95 relevant articles
5105 articles excluded which did not fulfill the 
inclusion criteria after review of titles and 
abstracts
185 articles excluded after assessing full text
 - 78 no cytokines measured in serum 
 - 41 no control group
 - 30 not enough information in abstract/article
 - 15 duplicate study population
 - 12 no psoriasis
 -  9 wrong study type
78 relevant articles included in the meta-analysis
missing data for analyses
 
Figure	2.	Flow diagram of study selection.
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A
Study Statistics for each study Std diff in means and 95% CI
Std diff Lower Upper 
in means limit limit p-Value
Anderson 2010 0.79 0.02 1.56 0.04
Jacob 2003 0.22 -0.82 1.27 0.67
Johnston 2008 0.70 0.18 1.23 0.01
Kanda 2010 -1.02 -1.48 -0.57 0.00
Mizutani 1997 0.00 -0.50 0.50 1.00
Bevelacqua 2006 (mild pso) 0.55 -0.07 1.17 0.08
Bevelacqua 2006 (severe pso) 0.54 -0.02 1.10 0.06
Gonul 2009 -0.63 -1.02 -0.23 0.00
Abe 2002 -4.52 -5.58 -3.45 0.00
-0.32 -1.05 0.41 0.39
-6.00 -3.00 0.00 3.00 6.00
 
B
Study Statistics for each study Std diff in means and 95% CI
Std diff Lower Upper 
in means limit limit p-Value
Takahashi 2010 2.10 1.75 2.45 0.00
Anderson 2010 1.15 0.35 1.95 0.00
Arican 2005 0.95 0.38 1.53 0.00
Coimbra 2010a 1.83 1.36 2.30 0.00
Jacob 2003 0.03 -1.01 1.08 0.95
Johnston 2008 1.36 0.79 1.92 0.00
Kanda 2010 -1.02 -1.47 -0.56 0.00
Kaur 2008 (BMI>30) 1.13 0.38 1.88 0.00
Kaur 2008 (BMI<25) 0.06 -0.69 0.81 0.88
Krasowska 1998a -0.20 -0.87 0.47 0.57
Martinez-Sales 2010 0.69 0.05 1.33 0.03
Mizutani 1997 2.42 1.80 3.04 0.00
Seishima 1998 (pso) -0.24 -0.68 0.21 0.30
Seishima 1998 (active GPP) 2.96 2.08 3.83 0.00
Szepietowski 2000 0.90 0.32 1.48 0.00
Toruniowa 1995 1.70 0.90 2.49 0.00
Zalewska 2006 0.07 -0.29 0.43 0.71
Bevelacqua 2006 (mild pso) 1.08 0.44 1.73 0.00
Bevelacqua 2006 (severe pso) 1.58 0.95 2.21 0.00
Bonifati 1994 3.11 2.01 4.20 0.00
Deeva 2010 (severe plaque pso) 4.20 2.63 5.76 0.00
Deeva 2010 (mild plaque pso) 0.09 -0.62 0.79 0.81
Deeva 2010 (erythrodermic pso) 0.68 -0.22 1.58 0.14
Gonul 2009 0.33 -0.06 0.72 0.09
Roussaki-Schulze 2005 -0.05 -0.46 0.37 0.82
Galadari 2005 (mild pso) 36.22 27.58 44.86 0.00
Galadari 2005 (moderate pso) 30.27 20.60 39.94 0.00
Galadari 2005 (severe pso) 25.05 16.02 34.07 0.00
Qiu 2005 2.38 1.74 3.03 0.00
1.32 0.83 1.81 0.00
-6.00 -3.00 0.00 3.00 6.00
 
C
Study Statistics for each study Std diff in means and 95% CI
Std diff Lower Upper 
in means limit limit p-Value
Takahashi 2010 -6.52 -7.21 -5.82 0.00
Anderson 2010 0.66 -0.11 1.42 0.09
Borghi 2008 -0.35 -0.66 -0.05 0.02
Borska 2008 16.36 14.08 18.64 0.00
Jacob 2003 -6.15 -8.47 -3.84 0.00
Kanda 2010 0.49 0.06 0.93 0.03
McLoone 2004 -0.29 -1.31 0.72 0.57
Reddy 2010 -0.20 -0.61 0.21 0.33
Szegedi 2003 -0.57 -1.36 0.21 0.15
Deeva 2010 (severe plaque pso) 0.00 -0.88 0.88 1.00
Deeva 2010 (mild plaque pso) 0.40 -0.31 1.10 0.27
Jadali 2007 0.41 -0.03 0.85 0.07
Roussaki-Schulze 2005 1.05 0.61 1.50 0.00
0.25 -0.90 1.40 0.67
-6.00 -3.00 0.00 3.00 6.00
 
D
Study Statistics for each study Std diff in means and 95% CI
Std diff Lower Upper 
in means limit limit p-Value
Takahashi 2010 2.30 1.94 2.66 0.00
Anderson 2010 1.06 0.27 1.85 0.01
Arican 2005 1.55 0.93 2.17 0.00
Asadullah 1999 4.71 3.70 5.71 0.00
Borska 2006 -0.13 -0.53 0.28 0.54
Chodorowska 1998 1.45 0.80 2.10 0.00
Coimbra 2010a 1.88 1.40 2.35 0.00
Jacob 2003 0.36 -0.69 1.41 0.50
Kanda 2010 -0.42 -0.86 0.02 0.06
McLoone 2004 0.00 -1.01 1.01 1.00
Mizutani 1997 0.00 -0.50 0.50 1.00
Reddy 2010 -0.37 -0.77 0.04 0.08
Seishima 1998 (pso) 0.00 -0.44 0.44 1.00
Seishima 1998 (active GPP) 7.09 5.65 8.52 0.00
Bevelacqua 2006 (mild pso) 0.90 0.27 1.54 0.01
Bevelacqua 2006 (severe pso) 4.39 3.37 5.40 0.00
Bonifati 1994 0.49 -0.28 1.26 0.21
Corbetta 2006 2.41 1.26 3.57 0.00
Gonul 2009 0.48 0.09 0.87 0.02
Abdel-Hamid 2010 0.42 -0.09 0.92 0.10
Kitamura 1999 0.63 0.05 1.21 0.03
Coimbra 2010c 1.08 0.49 1.67 0.00
Kagami 2010 1.23 0.53 1.92 0.00
Roussaki-Schulze 2005 1.16 0.71 1.60 0.00
Mussi 1997 0.98 0.47 1.49 0.00
Qiu 2005 2.97 2.25 3.69 0.00
1.32 0.86 1.79 0.00
-6.00 -3.00 0.00 3.00 6.00
 
E
Study Statistics for each study Std diff in means and 95% CI
Std diff Lower Upper 
in means limit limit p-Value
Ardic 2010 0.36 -0.06 0.77 0.10
Chandran 2010 0.08 -0.47 0.62 0.78
Chodorowska 2004 1.20 0.79 1.60 0.00
Coimbra 2009 2.53 1.98 3.08 0.00
Coimbra 2010a 2.98 2.41 3.55 0.00
Coimbra 2010b 2.55 2.04 3.07 0.00
Ctirad 2008 1.39 0.94 1.83 0.00
Kaya 2010 0.36 -0.06 0.77 0.10
Laurent 1981 1.22 0.50 1.94 0.00
Love 2010 9.89 9.53 10.26 0.00
Martyn-Simmons 2011 1.32 0.98 1.66 0.00
Ohtsuka 2008 0.76 0.44 1.08 0.00
Rocha-Pereira 2004 2.81 2.25 3.37 0.00
Serwin 2006 3.33 2.51 4.14 0.00
Yiu 2010 0.89 0.49 1.30 0.00
Bevelacqua 2006 (mild pso) 0.00 -0.61 0.61 1.00
Bevelacqua 2006 (severe pso) 1.55 0.93 2.18 0.00
Balci 2009 0.21 -0.23 0.66 0.34
Vanizor Kural 2003a 0.93 0.40 1.47 0.00
Karabudak 2008 1.90 1.15 2.64 0.00
Vanizor Kural 2003b 0.97 0.47 1.46 0.00
Coimbra 2010d 3.06 2.37 3.74 0.00
1.83 0.76 2.90 0.00
-6.00 -3.00 0.00 3.00 6.00
 
G
Study Statistics for each study Std diff in means and 95% CI
Std diff Lower Upper 
in means limit limit p-Value
Takahashi 2010 6.25 5.57 6.92 0.00
Borska 2006 2.10 1.60 2.60 0.00
Reddy 2010 -0.09 -0.50 0.31 0.66
Vanizor Kural 2003a 0.52 0.01 1.03 0.05
Schopf 1993 1.08 0.36 1.80 0.00
Kowalzick 1993 4.00 2.68 5.32 0.00
Yamamoto 1997 (plaque pso) 3.18 1.30 5.07 0.00
Yamamoto 1997 (GPP) 3.42 1.65 5.20 0.00
Long 2010 4.03 3.37 4.68 0.00
Carducci 1994 1.78 1.22 2.34 0.00
De Pita 1996 1.51 0.74 2.27 0.00
Gangemi 2003 0.96 0.23 1.70 0.01
Groves 1995 2.61 1.54 3.69 0.00
Lecewicz-Torun 1997 1.07 0.33 1.80 0.00
De Pita 1999 2.26 1.50 3.02 0.00
Griffiths 1996 0.75 0.34 1.16 0.00
Kitamura 1999 0.33 -0.24 0.90 0.25
Krasowska 1998b 0.97 0.34 1.61 0.00
Bubl 1994 0.61 0.13 1.08 0.01
Fazio 1994 0.45 -0.32 1.21 0.25
Krasowska 2000 0.87 0.12 1.62 0.02
Ameglio 1994 1.48 0.65 2.32 0.00
1.77 1.14 2.39 0.00
-6.00 -3.00 0.00 3.00 6.00
 
F
 
Figure	3 a to g.	
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indicating that the difference in IL-6 levels between psoriasis patients and controls was 
larger in studies not restricted to plaque psoriasis. These studies did not have a higher 
PASI score, nor did they include more erythrodermic patients (Table 2).
Interleukin-10
Pooling of IL-10 levels resulted in a small, positive but not statistically significant SMD 
between psoriasis patients and healthy controls (d=0.25; 95%CI -0.90-1.40) (Figure 3c), 
which could not be explained by age, gender or PASI in the meta-regression, or by pso-
riasis type in the subgroup analyses. 
Tumor	Necrosis	Factor-alpha
The search yielded 24 studies showing an elevated SMD for TNFα of 1.32 (95%CI 0.86-
1.79) (Figure 3d). Meta-regression showed that the older the age of patients within the 
studies, the smaller the difference in TNFα between psoriasis patients and controls (β=-
0.13, p=0.002). Gender and PASI do not explain the difference in effect size between the 
studies.
C-Reactive	Protein
The mean CRP across studies was significantly elevated in psoriasis compared to controls 
(d=1.83, 95%CI 0.76-2.90) (Figure 3e). The meta-regression for PASI showed a slope of 
0.07 with a p=0.057, demonstrating a trend that an increase in PASI is associated with an 
increase in difference in mean CRP between psoriasis patients and controls. Regarding 
the subgroup analyses, no statistically significant differences were observed between 
subgroups for psoriasis type (Table 3).
E-selectin
The combined SMD for E-selectin was nearly twice as high in psoriasis compared to con-
trols (d=1.78, 95%CI 1.32-2.25). Neither age, nor gender or psoriasis severity explained 
the high heterogeneity (I2=78%) between the studies. The measurement method had no 
Figure	3 a to g.	Forest plots showing standardized mean difference and 95% CI of individual studies and 
pooled standardized mean difference and 95% CI in psoriasis patients and healthy controls using random 
effects model.
Abbreviations: Std diff in means, Standardized mean difference; CI, Confidence Interval; pso, psoriasis; BMI, Body 
Mass Index; GPP, Generalized Pustular Psoriasis.
a. Interleukin-1β
b. Interleukin-6
c. Interleukin-10
d. Tumor Necrosis Factor-alpha
e. C-Reactive Protein
f. E-Selectin
g. Intracellular Adhesion Molecule-1
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influence on the heterogeneity because all 11 studies used the ELISA technique. Analyz-
ing the forest plot, the study by Groves et al including 9 patients with erythrodermic 
psoriasis appears to have the highest SMD, indicating that patients in this study with 
severe disease have higher levels of E-selectin than healthy controls18 (Figure 3f ). 
Intracellular-Adhesion-molecule-1
A total of 21 articles including 714 psoriasis patients and 601 controls yielded a sig-
nificant positive association between psoriasis and ICAM-1 (d=1.77, 95%CI 1.15-2.39). 
Meta-regression and subgroup analyses did not show significant results. Interestingly 
the two largest studies including more than 100 therapy naïve psoriasis patients show 
SMDs varying from -0.09 (95%CI -0.50-0.31) to 6.25 (95%CI 5.57-6.92).19,20 The remaining 
studies have SMDs which lie in between (Figure 3g).
Negative	subgroups	findings	
The high level of heterogeneity between studies (all I2>75%), could not be explained 
by the subgroup analyses. These showed that the measurement method did not have 
a significant impact on the SMD for any of the studied markers of inflammation. There 
was also no significant difference between studies with a higher and those with a lower 
quality assessment score, with the exception of IL-10, where nine studies with a higher 
score had a larger pooled effect size than the three studies with a lower score (Table 3).
Publication	bias
The funnel plots for IL-1β, TNFα, CRP and ICAM-1 showed evidence of asymmetry 
(Supplementary Figure 2). The addition of the “missing” studies imputed using the trim 
and fill method shifted the effect size for IL-1β and IL-10 towards significance with ad-
justed point estimates of -0.84 (-1.60 to -0.08)) and 1.96 (0.50-3.43) respectively. For CRP, 
TNFα, E-selectin and ICAM-1, the addition of the “missing” studies only increased the 
magnitude of the pooled effect sizes, which remained significant.
The Egger’s test confirmed the presence of publication bias for TNFα (6.09, 95%CI 
1.42-10.76) and ICAM-1 (5.58, 95%CI 0.003-11.17), however there also appeared to be 
publication bias for IL-6 (p=0.002).
DISCUSSION
The current meta-analysis shows mild systemic inflammation in psoriasis patients 
compared to healthy controls with five of the six investigated pro-inflammatory serum 
markers being increased in psoriasis. The difference is nearly two points at the most 
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and is overall independent of age, gender, disease severity, psoriasis type, measurement 
methods and quality assessment for the different studies.
Contrary to expected, pooled anti-inflammatory IL-10 was not significantly decreased in 
psoriasis patients; of the 13 studies on IL-10, only 3 showed a significantly lower IL-10 in 
psoriasis. The literature on psoriasis suggests that IL-10 deficiency might play a role in its 
pathogenesis21 and a study even showed that antipsoriatic treatment lead to normaliza-
tion of IL-10 values.20 
The cytokines IL-1β, IL-6 and TNFα produced by the keratinocytes are key in the activation 
of innate immunity through activation of dendritic and T-cells.2 These pro-inflammatory 
cytokines are also produced in adipose tissue, hereby linking inflammation of the skin 
with obesity.6 In this meta-analysis, pooled serum IL-1β was the only marker to not be 
significantly elevated in psoriasis patients compared to healthy controls. This was con-
trary to expected because IL-1 triggers the production of IL-6 and TNFα in the molecular 
cascade and should therefore also be elevated.3 This result could be due to a limited 
number of studies on serum IL-1β. Age explained part of the heterogeneity between 
the studies for IL-6 and TNFα, indicating that the older the patients in the study, the 
smaller the SMD between the psoriasis patients and the controls. This could possibly be 
explained by decreasing immunity with increasing age.22
IL-1β and IL-6 act together to enhance CRP.23 IL-6 was elevated in our analyses and can 
therefore explain the increased CRP obtained in psoriasis patients. In search of a novel 
biomarker to monitor disease progression and severity and improve cardiovascular 
risk prediction, CRP is also being used in other comorbidities.9,24,25 In the past decade, 
numerous meta-analyses have investigated the use of CRP in the prediction of CVD, 
concluding that CRP is at the most a moderate predictor of CVD compared to major 
established risk factors.9 10 11 
The soluble adhesion molecules E-selectin and ICAM-1, located at the end of the inflam-
matory cascade, are enhanced by TNFα and CRP through endothelial cells.26,27 Of the 
inflammatory markers studied in this meta-analysis, the SMD between psoriasis and 
controls was the highest for E-selectin and ICAM-1. These adhesion molecules have been 
available for several decades; however their clinical relevance is yet unclear. They can be 
involved in various conditions, from infections, vasculitis, cancer to atherosclerosis and 
CVD.27,28 However, the evidence on adhesion molecules is contradictory, even within the 
same condition such as CVD.12,29 
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In other inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis and an-
kylosing spondylitis, there seems to be a general consensus that inflammatory markers 
are elevated in patients compared to healthy controls.30-32 This consensus is based on 
convenient individual studies rather than on meta-analysis. The concept that the eleva-
tion of inflammatory markers leads to systemic inflammation and comorbidities such 
as CVD seems to be logical, however there is a large gap between measuring systemic 
inflammation in the blood and the registration of events, and it is a further challenge to 
determine whether these events have a causal relationship to the exposure.26 This gap 
should be filled with hard evidence in order to prove a possible relationship between 
exposure and outcome. The present study confirms the elevation of markers in psoriasis, 
however does not investigate the link between this modest elevation and eventual 
metabolic diseases or cardiovascular events.
As to the clinical relevance of these markers of inflammation based on the results of this 
meta-analysis, we believe that they cannot be considered as markers of disease severity 
because they were only modestly increased in psoriasis patients compared to controls 
and the increase was independent of the PASI. However this does not exclude the fact 
that markers of inflammation could be important targets for therapy, such as is the case 
with TNFα and recently Interleukin-17.33
Strengths	and	limitations
This is the first and largest meta-analysis on markers of inflammation in psoriasis com-
bining 78 studies with a psoriasis and comparative group of healthy subjects to pool 
information on seven different serum markers. We performed an extensive systematic 
search using three databases to retrieve articles. We limited selection bias of the articles 
by not restricting the language of the search and included foreign articles if the ab-
stract and full text provided sufficient data. We included a considerably large number 
of studies, which were mainly observational in nature and consisted of small numbers 
of psoriasis patients. We not only investigated pro-inflammatory markers but also anti-
inflammatory IL-10. 
We analyzed baseline values of markers in naïve psoriatic patients and therefore could 
not draw conclusions on the use of serum markers in measuring disease progression. 
Approximately two studies per outcome did not report the mean marker values com-
pletely and therefore could not be included in the meta-analysis, however we do not 
expect this to have influenced our the effect size because these studies showed varying 
results.34-42 
We assume that most patients had moderate to severe disease (75% of studies had a 
PASI>10), possibly limiting the generalizability of our findings. On the other hand, the 
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analyses showed that that the effect size for the serum markers was independent of 
disease severity. 
In order to explain the high degree of heterogeneity between the studies, we con-
ducted several meta-regression and subgroup analyses. The results should be inter-
preted cautiously because they were based on covariates at the level of the study in 
contrast to covariates from individual patient data, possibly leading to aggregation bias.
We used three different methods to assess publication bias and depending on the 
method used there seemed to be publication bias. This bias however did not change the 
direction of the association for any of the markers when using the trim and fill method. 
The quality assessment scores were not high due to incomplete data on several items, 
the latter also influencing our selection of subgroup analyses. We acknowledge that 
REMARK is more a reporting device; nevertheless we did not expect the study quality to 
influence the studied outcomes because we compared objective measurements (serum 
marker levels) which are not dependent on factors such as blinding or allocation con-
cealment. This was confirmed in the subgroup analysis showing no difference in pooled 
estimate between studies with a high and those with a low quality assessment score.
CONCLUSION
Psoriasis patients show at the most mild systemic inflammation compared to controls. 
The elevation of the inflammatory markers is independent of psoriasis type and severity, 
questioning their use as biomarkers. In order to investigate the clinical relevance of this 
modest increase in inflammation, it would be interesting to conduct a review summariz-
ing the evidence on the effect of antipsoriatic therapy on markers of inflammation.
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Supplementary	Figure 1.	Selected inflammatory serum markers based on a selection of markers analyzed 
in psoriasis and cardiovascular disease. 
Abbreviations: Il, Interleukin; hsCRP, high sensitivity C-Reactive Protein; TNFα, Tumor Necrosis Factor alpha; ICAM-
1, Intracellular Adhesion Molecule 1; IFNγ, Interferon gamma; MCP-1, Monocyte Chemoattractant Protein-1
* Il-10 was deliberately chosen as an anti-inflammatory serum marker.
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Supplementary	Figures 2 a to g.	Funnel plots identifying publication bias for all studied outcomes.
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b. Interleukin-6
c. Interleukin-10
d. Tumor Necrosis Factor-alpha
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Table	1.	Search strategy
Database Search string
Pubmed psoriasis[tw] AND (interleukin-1[tw] OR il-1[tw] OR interleukin-10[tw] OR il-10[tw] OR 
interleukin-6[tw] OR il-6[tw] OR tumor necrosis factor*[tw] OR tnf[tw] OR c-reactive 
protein*[tw] OR crp[tw] OR icam[tw] OR sicam[tw] OR intercellular adhesion 
molecule*[tw] OR e-selectin*[tw] OR se-selectin*[tw] OR endothelial leukocyte adhesion 
molecule*[tw] OR elam[tw] OR selam[tw]) NOT (animals[mesh] NOT humans[mesh]) NOT 
(case reports[pt] OR letter[pt])
Embase (psoriasis/syn AND (((interleukin OR il) NEAR/1 (1 OR 6 OR 10 OR 1a* OR 1α OR 1b* 
OR 1β)):ti,ab,de OR (‘tumor necrosis’ NEAR/1 factor*):ti,ab,de OR tnf:ti,ab,de OR 
(‘c-reactive’ NEAR/1 protein*):ti,ab,de OR crp:ti,ab,de OR icam:ti,ab,de OR sicam:ti,ab,de 
OR (‘intercellular adhesion’ NEAR/1 molecule*):ti,ab,de OR ((e OR se) NEAR/1 
selectin*):ti,ab,de OR (‘endothelial leukocyte adhesion’ NEAR/1 molecule*):ti,ab,de OR 
elam:ti,ab,de OR selam:ti,ab,de) NOT ([animals]/lim NOT [humans]/lim)) NOT (‘case 
reports’ OR ‘case report’):ti,ab,de NOT [letter]/lim
Web	of	Science psoriasis AND (((interleukin OR il) SAME (1 OR 6 OR 10 OR 1a OR 1alpha OR 1alfa OR 
1b OR 1beta)) OR “tumor necrosis factor” OR tnf OR “c reactive protein” OR crp OR icam 
OR sicam OR “intercellular adhesion molecule*” OR “e selectin*” OR “se selectin*” OR 
“endothelial leukocyte adhesion molecule*” OR elam OR selam) NOT (animal* NOT 
human*) NOT “case report” NOT “case reports”
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ABSTRACT
Background: psoriatic arthritis (PsA) and rheumatic arthritis (RA) and to a lesser extent 
psoriasis (PSO), all have increased levels of systemic markers.
Objectives: to compare the distribution of parameters of serological inflammation 
between patients with PSO, PsA, RA and controls and to identify factors associated with 
elevated systemic inflammatory markers in a daily practice setting. 
methods: In this daily practice cross-sectional study, all participants with a diagnosis 
of PSO, PsA, and RA were included and compared with controls. Demographic data, 
disease characteristics, medical history, life style factors, previous treatments, quality of 
life indicators and serum was collected per participant. Serum was tested on IL-6, IL-10, 
IL12P70, IL17A, IL17F, IL22, IL23, TNFα and CRP. A mixed regression model was used to 
estimate the effect size of factors associated with levels of CRP, IL6 and-10 after adjusting 
for confounders.
Results: in total 601 patients; 180 PSO (39% female, mean age 49 years), 154 PsA (46% 
female, mean age 52 years), 136 RA (65% female, mean age 61 years) and 131 controls 
(58% female, mean age 54 years) were included. The highest levels of the pro-inflamma-
tory markers were in RA followed by PsA. In the multivariate analysis CRP was associated 
with disease severity ( β6.9 SE 1.8), pain medication ( β4.2 SE 1.9) and SF 36’s physical 
impairment ( β-0.25 SE 0.09); and IL-6 was associated with diagnose, male gender and 
systemic medication and IL-10 with diagnose. 
Conclusion: Overall RA has the most pronounced serological inflammatory profile 
followed by PsA and least inflammation was seen in PSO patients despite the use of 
systemic medication.
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INTRODUCTION	
Psoriasis (PSO) is an immune-mediated inflammatory disease (IMID), but a systematic 
review shows that the blood levels of several key cytokines are at most mildly elevated 
with unsure clinical relevance.1,2 However, systematic inflammation is proposed to be 
the explanation of PSO’s associated comorbidities and the concept of PSO as a systemic 
disease. In contrast to PSO, rheumatoid arthritis (RA) is truly a systemic disease reflected 
its diagnostic ACR/EULAR RA Classification Criteria and pronounced and consistent 
elevated inflammatory parameters such as CRP. PSO and RA are both considered IMIDs 
suggesting in part a common pathogenesis and share several effective therapies. From 
the systemic inflammation and comorbidity perspective, several authors have ‘upgraded’ 
PSO to a systemic disease comparable to RA. This disease overlap is further supported 
by psoriatic arthritis (PsA) that occurs in approximately 10% of PSO patients. However, 
few studies have compared cytokine levels in PSO patients to PsA, RA and controls while 
taking potential cofounders in consideration.3 
In this study we selected the following inflammatory markers: C-reactive protein (CRP), 
interleukin (IL) -6, IL-10, IL12P70, IL17A, IL17F, IL22, IL23 and tumor necrosis factor 
(TNFα). CRP was chosen because firstly, it has been recognized as one of the most 
sensitive markers of inflammation. Moreover, a short half-life of 6–8 h makes it an ap-
propriate tool for following disease course. Secondly, CRP is an independent risk factor 
for cardiovascular disease.4 IL6 was chosen as an overall pro-inflammatory marker and 
Il-10 as an anti-inflammatory marker. IL12P70, IL17A, IL17F, Il-22, IL23, TNFα were chosen 
as pro-inflammatory markers in PSO and rheumatic diseases which are target for the 
biological therapies used in these diseases. 
The objective of this cross-sectional study is to explore the differences in levels of serum 
biomarkers reflecting systemic inflammation in a ‘real-life population’ in PSO patients 
compared to RA patients and subsequently to patients with PsA and controls. We hy-
pothesized that RA expressed more serological inflammatory markers than PSO and that 
PsA would be in between the two other diseases. 
mETHODS	
Study	and	population
The study participants were included from March 2009 until August 2012 as described 
previously.5 PSO patients had chronic plaque PSO and were diagnosed and recruited 
by dermatologists from the department of dermatology of the Erasmus University 
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Medical Center in Rotterdam, the Netherlands. At the same center, the control group 
consisting of individuals with varicose veins or benign moles without PSO, PsA and/or 
RA were recruited. The PsA and RA patients were recruited from the rheumatology de-
partment of the Maxima Medisch Centrum Hospital in Eindhoven, the Netherlands. An 
rheumatologist confirmed PsA and RA diagnosis based on the Classification Criteria for 
Psoriatic Arthritis (CASPAR) and 2010 ACR/EULAR RA Classification Criteria.6 The eligible 
PSO subjects had no history or signs of inflammatory arthritis such as PsA. 
Covariates	Demography,	lifestyle	
Patients were asked to fill in a standardized questionnaire at the day of inclusion to obtain 
data concerning general medical history including comorbid conditions, medication 
use, smoking behavior, alcohol intake, socioeconomic status and (prior) disease specific 
drug use. Furthermore type of arthritis/psoriasis, (earlier) disease specific medication 
use, disease severity, comorbidities and other medication use, were collected by the 
dermatologist or rheumatologist.
Furthermore body mass index (BMI) was calculated as weight (kg)/height (m2). Diabetes 
was defined as 1: Diabetic medication including all insulin preparations and oral agents, 
2: diabetes mentioned in the medical history or 3: an elevated non-fasting glucose level 
(> 6.1 mmol/L) or HbA1c (Glycohemoglobine) (>42 mmol/mol Hb) in the patients’ blood. 
Hypercholesterolemia was defined as serum total cholesterol >6.5 mmol/L, serum 
triglycerides greater than 2.0 mmol/L; serum high-density lipoprotein cholesterol less 
than 0.9 mmol/L, serum low-density lipoprotein cholesterol greater than 2.59 mmol/L or 
drug treatment for low high-density lipoprotein cholesterol or elevated triglycerides or 
elevated high low-cholesterol. Hypertension was defined as drug treatment for elevated 
blood pressure or medical history of hypertension.
Disease	characteristics	
For PSO and PsA patients, Psoriasis Severity Index Score (PASI)<7 was defined as mild; 
PASI 7–12 as moderate and a PASI>12 as severe disease.7 The disease activity and course 
severity in PsA and RA patients were assessed with Disease Activity Score 28 (DAS28) 
(DAS<3.2 was defined as mild, 3.2-5.1 as moderate and >5.1 as severe disease activity8). 
In case of a discrepancy in disease severity score between skin and joints in PsA, the 
most severe stage was taken. This occurred only in 4 patients with skin severity higher 
than joint severity. 
Disease specific medication was divided into four subgroups; (1) patients without medi-
cation or who only used topical products, UV and/or non-steroidal anti-inflammatory 
drugs (NSAIDs); (2) patients who used disease related systemic drugs excluding metho-
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trexate (MTX); (3) MTX use irrespective of any other medication except biologicals; and 
(4) patients who used a biologicals irrespective of medication from group one to three. 
A separate variable was used of NSAID, as this medication is used a lot and it is known 
to have a different effect on inflammatory markers.9 Data on dosing regimens were not 
available.
Quality	of	life
The impact of disease on quality of life was assessed by the generic SF36-questionnaire.10 
The lower the score the more disability. Assessment of the rheumatologic disease was 
done in the following manner; the impact on quality of life was evaluated by the func-
tional index (HAQ = Health Assessment Questionnaire).11 To assess the quality of life on 
the skin disease the Skindex 29 was used.12
Laboratory	values	and	cytokines	levels
None fasting venous blood was drawn from all participants at the day of inclusion and 
centrifuged to separate serum. All serum samples were frozen at -80°C and were later 
analyzed simultaneously as a batch. IL-6, IL-10, IL12P70, IL17A, IL17F, IL22, IL23, TNFα in 
sera were analyzed using ELISA (ebioscience, Affymetrix, San Diego) expressed in ng/
ml in the research laboratory of the department rheumatology of the Erasmus Medical 
Center. 
Leukocytes and high sensitivity C reactive protein (Hs-CRP), were analyzed using stan-
dard enzymatic immunoassays. For the PsA and RA patients, also the following extra 
tests were analyzed: blood sedimentation rate of erythrocyte (BSE) and cyclic citrul-
linated peptide antibody (anti-CCP). 
Statistics	
Covariate distribution among the groups was examined using descriptive statistics of 
SPSS software version 20. The distribution of the general characteristics were compared 
between the different groups using the Chi-square tests and one way ANOVA or Kruskal 
Wallis tests for statistical significance of categorical data and continuous data, respec-
tively. P-values were two-sided and values <0.05 were considered statistically significant.
In order to estimate if covariates predicted CRP and ILs concentrations a regression mod-
els were fitted. A linear backward regression model was used for CRP. As the distribution 
of ILs contained many zero values and non-zero values were non-normally distributed, a 
mixed regression model with a zero adjusted gamma distribution was used. This model 
presented the data in two parts, percentage positive values and the level of the positive 
values. And this model estimates the odds ratio (OR) of non-zero values vs. zero values 
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and also estimates the percentage change in IL for non-zero values. The maximum de-
grees of freedom was determined by dividing the number of non-zero values by 10. The 
distribution of IL-6, IL-10 and contained enough non-zero values to perform a regression 
model. The mixed regression models were performed using the gamlss package from 
R (www.r-project.org, www.gamlss.org). Other analyses were performed using SPSS 
20.0 (IBM, UK). P-values were two-sided and values <0.05 were considered statistically 
significant. 
The study was approved by the Medical Ethics Committee of the Erasmus Medical Cen-
ter in Rotterdam (MEC- 2007-181) and Maxima Medical Center in Eindhoven. Written 
informed consent was obtained from all participants. 
RESULTS
Demographic	and	life	style	
The primary analyses included in total 601 patients; 180 patients with PSO (39% female, 
mean age 49 years), 154 patients with PsA (46% female, mean age 52 years), 136 patients 
with RA (65% female, mean age 61 years) and 131 controls (58% female, mean age 54 
years) (Table 1). BMI was slightly higher in PSO patients. Alcohol use/abuse did not differ 
significantly between the four groups. However, we observed a trend towards increased 
prevalence of alcohol abuse (>3 beverage a day) in PSO patients. Although PSO patients 
were more often current smokers compared to controls and RA patients, total pack years 
and the amount being smoked did not differ between all groups. RA patients had the 
highest level of socio-economic status. 
Disease	characteristics,	quality	of	life	and	medication
PSO patients suffered the longest from their disease (mean 20.6 years compared to 
10.0 and 10.9 years by PsA and RA patients). A mean PASI score, being independent of 
medication use, of 1.5±2.4 in PsA patients and (mean PASI 5.9 ± 5.8) in PSO patients. Half 
of the PSO, PsA and RA patients had a positive family history of PSO or arthritis.
Most patients included in this study were using systemic drugs ( 76% for PSO, 92% PsA 
and 97% RA). MTX was most often used in RA and PsA patients. Combination therapy, 
(MTX with another biological) was also more often used in RA and PsA patients. 31% of 
PSO patients used fumaric acid, 15% MTX, 8% acitretin, 4.4% ciclosporine and 22% used 
a biological (81% anti-TNF blocker). 
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Table	1.	General characteristics of the study population
Psoriasis	
(n=180)
Psoriatic	
arthritis	
(n=154)
Rheumatoid	
arthritis	
(n=136)
Controls	
(n=	131)
Total**	
(n=601)
P-value*
Covariables
Age (years) 49,3 ± 14,3 52,3 ± 11,7 61,4 ± 11,0 53,9 ± 14,4 53,8 ± 13,7 <0,001
Female (%) 38,9 46,1 64,7 58,0 50,7 <0,001
BMI (kg/m2) 27,2 ± 5,8 26,5 ± 4,2 25,9 ± 4,5 27, 5 ± 6,1 26,8 ± 5,3 0,054
Alcohol intake (drinks/day) 0.060
None (%) 43,5 31,7 38,5 36,3 37,8
< 3 (%) 49,4 65,5 59,2 60,5 58,1
>3 (%) 7.1 2.9 2.3 3.2 4.1
Smoking <0,001
Never (%) 28,1 40,5 31,9 52,3 37,4
Former (%) 29,2 42,5 53,3 32,3 38,8
Current (%) 42,7 17,0 14,8 15,4 23,8
Education status 0,008
Low (<6 years) % 23,3 29,3 21,1 33,6 26,6
Medium (6-12 years) % 41,5 30,0 27,1 32,0 33,2
High (>12 years) % 35,2 40,7 51,9 34,4 40,2
Personal medication use (yes, %)
Diabetes 13.4% 5.5% 8.1% 0% 7.2% 0.01
Anticoagulant 16.8% 14.6% 26.1% 30.4% 21.1% 0.01
Antihypertensive 33.6% 34.9% 43.2% 55% 40.3% 0.02
Hypercholesterolemia 25.7% 17.4% 18.9% 23.1% 21.1% 0.58
Pain medication 8.0% 19.3% 18.0% 10.1% 14.2% 0.055
Psycho medication 9.8% 11.9% 8.1% 7.2% 9.4% 0.58
Disease
Onset of disease 27.6 ± 15.7 40.3 ± 22.3 50.1 ± 13.2 - 38.2 ± 19.8 <0.001
Duration of disease, years 20.6 ± 14.8 10.0± 9.40 10.9 ± 9.4 - 14.4 ± 12.8 <0.001
Severity of disease PASI 5.9 ± 5.8# 1.5 ± 2.4# - - 3.89 ± 5.07 <0.001
Severity of disease DAS - 2.16 ± 0.91 2.66 ± 1.00 - 2.39 ± 0.98 0.72
Overall disease severity <0.001
mild 121 (67.2%) 127 (82.5%) 84 (65.6%) - 332 (55.2%)
moderate 37 (20.6%) 25 (16.2%) 42 (32.8%) - 104 (17.3%)
severe 22 (12.2%) 2 (1.3%) 2 (1.6%) - 26 (4.3%)
Quality of life 
Skindex 29 98.6 (IR 89) 46.3 (IR 61) 0 (IR 20) 7.14 (IR 43) 35.7 (IR 90) <0.001
SF-36 
PCS 48.3 ± 9.5 41.0 ± 10.7 37.7 ± 11.4 48.9 ± 10.2 44.1 ± 11.4 <0.001
MCS 48.5 ± 9.5 50.4 ± 9.5 51.3 ± 10.4 50.1 ± 9.5 50.0 ± 9.7 0.03
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The SF 36 showed on the condition of physical functioning, health, pain and general 
health a lower score at the arthritis patients. The subgroups of emotional problems, 
energy/fatigue, emotional well-being and social functioning scored equal between 
PSO patients and the arthritis patients. PSO patients had significantly the lowest on the 
mental component. 
Inflammatory	markers
The results of the inflammatory markers included multiple zero’s. The data is presented 
in two parts, percentage positive values and the level of the positive values. The per-
centage of positive values of the pro-inflammatory markers IL6 and IL17A, presented 
as dichotomous variables ,were significantly higher in RA patients (32.9% and 5.1%) 
compared to PsA (22.6% and 0%) and PSO (14.1% and 0%) patients. We observed the 
opposite effect for anti-inflammatory marker IL10 . The highest values of IL10 were 
observed in PSO patients (29%) lowest values in RA patients (3%). TNF-alfa had in the 
Table	1.	General characteristics of the study population (continued)
Psoriasis	
(n=180)
Psoriatic	
arthritis	
(n=154)
Rheumatoid	
arthritis	
(n=136)
Controls	
(n=	131)
Total**
(n=601)
P-value*
HAQ - 0.66 ± 0.60 1.04 ± 0.62 - 0.84 ± 0.68 <0.001
Medication use (n, (%))
None  3.3% 5.2% 2.9% - 6.7%
Cutaneous only 21.1% 3.2% - - 12.9%
Prostagladinesynthetase 
inhibors only
- 9.1% 2.9% - 6.2%
DMARD and PSO 
medication
MTX (only) 10% 30.5% 27.9% - 21.9%
Other 43.9% 37.7% 56.6% - 45.5%
Prednison - 9.7% 15.4% - 12.4%
Biologicals 23.3% 12.9% 12.5% - 16.8%
Laboratory data
Leukocytes 7.14 ± 2.06 7.2 ±5.8 9.24 ± 13.8 - 7.8 ± 8.5 0.09 
CRP 2.00 (IR 3) 3.00 (IR 3) 4.00 (IR 6) - >0.001
BSE - 6.0 (IR 10) 11.0 (IR 19) - >0.001
CCP - 24.0 (IR 1) 390 (743) -
Data are represented as mean (± standard deviation), median (25^th -75^th percentile) or percentages. Based on 
One-Way ANOVA, Kruskal-Wallis or Chi-square test. Abbreviations: cat, categorical; BMI, Body Mass Index; PASI, 
psoriasis area severity index; SF-36, Short Form (36) Health Survey ; HAQ, Health Assesment Questionnaire; MTX, 
methotrexate; PCS, physical component summary; MCS, mental component summary; CRP, C reactive protein; 
BSE, blood sedimentation rate of erythrocyte ; CCP, cyclic citrullinated peptide antibody; ** Total of the applicable 
groups 
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PsA the most positive values (13%) followed by RA (9%). Il12P70, Il17F, IL22 and IL23 
showed no signifi cant diff erent between the groups in percentage positive values. Table 
2 showed the percentage values above the measure threshold and the overall means of 
the diff erent infl ammatory markers stratifi ed for disease. In fi gure 2 showed the percent-
Table	2.	Infl ammation markers stratifi ed for disease.
% (n)
Controls Psoriasis Psoriatic arthritis
Rheumatoid 
arthritis
P-value* Total 
% pos
mean 
with SD
% pos
mean 
with SD
% pos
mean with 
SD
% pos
mean with 
SD
% pos
mean with 
SD
IL-6
14.1% 19.4±55.6 14.5% 1.8±1.8 22.6% 30.5±86.7 32.9% 13.4±19.8 0.01 0.52
21.3% 
(66)
17.3±52.5
IL-10
18.3% 2.59±2.77 28.9% 5.87±3.92 3.6% 9.83±1.33 2.5% 3.11±2.28 0.00 0.007
12.9% 
(40)
4.97±3.9
IL12P70
5.6% 27.9±51.1 6.6% 2.07±3.14 2.4% 45.0±61.0 5.1% 2.72±4.60 0.64 0.35
4.8% 
(15)
14.86±33.3
IL17A
0% 0.0 ±0.0 0% 0.0 ±0.0 0% 0.0 ±0.0 5.1% 20.8±16.2 0.008 -
1.3% 
(4)
20.8±16.2
IL17F
1.4% 589.1 1.3% 57.8 4.8% 283.3±497.0 7.6% 93.4±168.0 0.13 0.52
3.9% 
(12)
195±323
IL22
0% 0.0 ±0.0 0% 0.0 ±0.0 0% 0.0 ±0.0 2.6% 95.8±5.6 0.25 -
0.8% 
(2)
95.8±5.6
IL23
1.4% 0.88 1.3% 1.0 2.4% 0.35±0.07 2.5% 1.65±1.9 0.92 0.82
1.9% 
(6)
0.98±1.03
TNF-alfa
0% 0.0 ±0.0 7.1% 80.7±79.5 13.0% 89.9±48.3 9.0% 102.8±79.7 0.036 0.89
6.8% 
(16)
93.8±65.1
Data are represented as positive values of dichotomous variables and data are represented as total mean with SD
 
 
 
Organ involvement 
Figure	1.	A hypothetical model of the etiology of the prevalence of comorbidities in PSO, PsA and RA
Abbreviations: PSO, psoriasis; PsA, psoriatic arthritis; RA, rheumatic arthritis
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age positive values and de median of the diff erent infl ammatory markers stratifi ed for 
disease, except for IL17A, only RA has 5.1% positive values with a medium of 20.4. In 
the control group, PSO and RA there were no values above 0. Overall RA has the most 
 
0
1
2
3
4
5
6
0%
5%
10%
15%
20%
25%
30%
35%
co pso psa ra
IL-6 % positive value
IL-6 median
%
 p
os
iti
ve
 v
al
ue
s 
M
edian values (ng/m
l) 
 
0
2
4
6
8
10
12
0%
5%
10%
15%
20%
25%
30%
35%
co pso psa ra
IL-10 % positive value
IL 10 median
%
 p
os
iti
ve
 v
al
ue
s 
M
edian values (ng/m
l) 
Figure	2a Figure	2b
 
%
 p
os
iti
ve
 v
al
ue
s 
M
edian values (ng/m
l) 
0
5
10
15
20
25
30
35
40
45
50
0%
1%
2%
3%
4%
5%
6%
7%
co pso psa ra
IL12P70 % positive value
IL12P70 median
M
edian values (ng/m
l) 
 
%
 p
os
iti
ve
 v
al
ue
s 
M
edian values (ng/m
l) 
M
edian values (ng/m
l) 
0
100
200
300
400
500
600
700
0%
1%
2%
3%
4%
5%
6%
7%
8%
co pso psa ra
IL17F  % positive value
IL17F median
%
 p
os
iti
ve
 v
al
ue
s 
Figure	2c Figure	2d
0
0,2
0,4
0,6
0,8
1
1,2
1,4
1,6
1,8
0,0%
0,5%
1,0%
1,5%
2,0%
2,5%
3,0%
co pso psa ra
IL23  % positive value
IL23 median
 
%
 p
os
iti
ve
 v
al
ue
s 
M
edian values (ng/m
l) 
M
edian values (ng/m
l) 
%
 p
os
iti
ve
 v
al
ue
s 
 
0
10
20
30
40
50
60
70
80
90
100
0%
2%
4%
6%
8%
10%
12%
14%
co pso psa ra
TNF-alfa  % positive value
TNF-alfa median
%
 p
os
iti
ve
 v
al
ue
s 
M
edian values (ng/m
l) 
M
edian values (ng/m
l) 
%
 p
os
iti
ve
 v
al
ue
s 
Figure	2e Figure	2f
Figure	2 a to f.	Infl ammatory makers in PSO, PSA, RA and controls. 
Percentage of non-0 values and the median of these non-0 values of the infl ammatory makers in PSO, PSA, RA 
and controls. 
Abbreviations: PSO, psoriasis; PsA, psoriatic arthritis; RA, rheumatic arthritis
P values of 0 values: Chi-square test; P values of the median of the positive values: Kruskal-Wallis test
p<0.05 for IL6 value 0 and median; IL 10 value 0 and median; IL17A value 0, TNF-alfa value 0. 
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pronounced serological inflammatory profile followed by PsA and least inflammation 
was seen in PSO patients despite the use of systemic medication
The	regression	model
After adjusting for sex, disease severity, pain medication, SF36 physical, SF36 mental, 
alcoholic use, diagnose, medication use, BMI, age, diabetic, education and smoking in 
the linear regression model, higher disease severity and more pain medication were as-
sociated with an increased CRP (β=6.9 p<0.001 and β=4.2 p=0.03) A higher SF36 physi-
cal score (i.e., less impairment) was correlated with a lower CRP value (β=-0.2 p=0.006). 
(Table 3) Using Nagelkerke R square on the final adjusted backward model, 13% for the 
CRP value was explained by the included risk factors.
For IL6, diagnoses, age, sex and medication were included in the full adjusted multivari-
able linear combined regression model and for IL10, these were diagnoses and age. 
(Table 4) For IL6, only men had a higher likelihood of not having a zero value (OR 0.5 
95%CI 0.27-0.88). After excluding the zero values, a diagnose of RA, PsA, female gender 
and systemic medication were significant predictors for an increased risk of an elevated 
IL6 score. The odds of not having an absence of IL10 was elevated in PsA (OR 6.08 95%CI 
5.9-6.2) and even more in RA (OR 8.4 95%CI 1.8-39.4) compared to controls. If the value 
was positive, PSO and PsA had a positive correlation with a higher IL-10 value. 
Table	3.	linear regression model for CRP
CRP value 
β SE P-value
Crude	univariate	model
diagnose 0.39 0.94 0.68
Age	and	sex	adjusted
Age, years 0.13 0.06 0.03
Sex, female 1.4 1.48 0.35
diagnose 0.43 0.92 0.65
multivariable	adjusted
Sex, female 3.52 1.91 0.07
Disease severity 6.88 1.75 <0.0001
Pain medication 4.23 1.91 0.03
SF 36 physical -0.25 0.09 0.006
Multivariate linear regression model with backward method.
The following variables were excluded in the analyses in the following order: SF36 mental, alcoholic use, diagnose, 
medication use, BMI, age, diabetic, education and smoking
Multivariate adjusted R square 0.127
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DISCUSSION
In this study, we analyzed cross-sectional and under ‘daily life’ conditions, the level of 
inflammatory parameters adjusted for disease, medication and comorbidities. 
Serum IL6 levels are higher in RA and PsA patients compared to PSO patients and 
controls, which is in line with the existing literature.13 Even after adjusting for covariates, 
the diagnose of a rheumatic diseases, this remained significant for the different diseases. 
As an anti-inflammatory cytokine, the proportion of positive IL10 or the mean/median 
(including zeros) serum levels was significant higher in PSO compared to PsA and RA as 
expected. However when the IL10 value was positive, the value was significant the high-
est in the PsA groups followed by PSO. It is described previously that PsA have higher 
values of IL-10 compared to healthy controls.14 Also here the value of the control group 
Table	4.	Multivariate adjusted model
Beta SE
OR 
non-0 
vs 0 95%CI Beta SE
% Change 
if not 0 95%CI
IL-6
Diagnose
control REF 2,80 0,69 1550% 323% - 6335%***
Psoriasis 0,05 0,63 1,05 0,30 - 3,65 REF
RA -1,09 0,71 0,34 0,08 - 1,37 2,43 0,55 1040% 287% - 3253%***
PSA -0,59 0,69 0,55 0,14 - 2,15 2,76 0,55 1477% 438% - 4526%***
AGE
years -0,01 0,01 0,99 0,97 - 1,01 -0,02 0,02 -2%
SEX
Female REF REF
Male -0,71 0,30 0,49 0,27 - 0,88* -1,04 0,35 -65% -82% - -29%**
Medication
Local -0,05 0,61 0,95 0,29 - 3,17 -0,39 0,69 -33% -83% - 162%
Systemic -0,23 0,38 0,79 0,38 - 1,66 1,21 0,47 236% 34% - 742%**
MTX REF REF
biological 0,39 0,50 1,48 0,56 - 3,95 0,94 0,62 156% -25% - 773%
IL-10
Diagnose
control REF REF
Psoriasis -0,59 0,40 0,56 0,25-1,22 0,83 0,29 129% 29% - 308%**
RA 2,13 0,79 8,39 1,79-39,38** 0,18 0,62 20% -64% - 304%
PSA 1,81 0,01 6,08 5,93-6,24** 1,36 0,54 288% 35% - 1019%*
AGE
years 0,003 0,013 1,00 0,98-1,03 0,002 0,009 0% -2% - 2%
Abbreviations: OR, odds ratio; PsA, psoriatic arthritis; RA, rheumatic arthritis. p-value WALD, *<0.05, **<0.01, 
***<0.001
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were lower than expected. Moreover the median CRP was significant higher in RA , fol-
lowing by PsA and PSO.15 Only controls had the highest score, which may be explained 
by the phlebology tertiary center patients and the fact that most of the patients with 
PSO, PsA and RA were on treatment, which could have decreased the levels of CRP.3 
These three (anti)-inflammatory markers confirm the idea that RA is a more systemic 
disease compared to PSO.
Another pro-inflammatory marker TNFα shows a significant more positive values in PSO, 
PsA and RA compared to the controls. The diseases are mutually comparable, with also 
comparable use of anti-TNF therapy. 
The proportion of positive values of the other cytokines; IL12P70, IL17A, IL17F, IL 22, 
IL 23, was low, and there were no significant differences, however we could see some 
trends with overall higher values in arthritis disease (PsA and RA) compared to PSO. The 
low amount of positive values may be explained due to low levels and sensitivity issues 
of the detection assays and the fact that almost all patients are on (systemic) therapy. It 
is known that these cytokine levels decrease after successful therapy.16-18 
Strengths	and	Limitations
This study included a relatively large cohort of real life data on well-defined PSO, PsA 
and RA patients. PSO, PsA and RA patients were diagnosed by a rheumatologist or 
dermatologist, including use of disease activity measurement scales. This minimizes the 
introduction of misclassification bias. Psoriasis is a clinical diagnosis easily made after 
physical examination and for PsA patients there is specificity and sensitivity of over 99% 
using CASPAR.19 In contrast to other studies, we collected and adjusted for the most 
important confounders for systemic inflammation in IMIDS.
A limitations is the different location were the PSO and the PsA patients were included. 
This may implicated that the psoriasis patients are more relatively severe affects com-
pared to the arthritis patients because the former were recruited in a tertiary center. 
To minimize this potential bias, disease severity and site of inclusion was added in our 
multivariate model. Furthermore the Dutch areas where both recruiting hospitals are 
situated do not differ with respect to demographic characteristics and degree of urban-
ization (Rotterdam vs Eindhoven). Therefore, the effect of the use of different hospital 
departments for PSO and control versus PsA on the study findings appears to be limited. 
Also the controls patients had some remarkable increased levels of inflammatory mark-
ers which could be explained be the fact that they were recruited in a tertiary center, 
however we have tried to minimalize this by using patients with naevi and phlebology 
patients. The duration and dosage of the used drugs was not documented, but in this 
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study we did not focus on treatment effects and we were able to adjust for treatment 
exposure in the comparison across diseases. 
Notwithstanding the fact that the inflammatory markers showed an expected trend, an 
unexpected large proportion of the serological measurements’ were below the detect-
able level. By using mixed regression model with a zero adjusted gamma distribution, 
the effects of the negative assessments were minimized. We cannot rule out the possi-
bility that non-significant results could the results from the heterogeneity of the studied 
population and small sample size in subgroups analyses though correcting for a lot of 
confounders.
CONCLUSIONS
Globally RA demonstrated to have the most pronounced inflammatory status followed 
by PsA and least inflammation was seen in PSO patients . Future, prospective, random-
ized, controlled studies are needed to better understand the impact of systemic therapy, 
disease and lifestyle factor on the extent of systemic inflammation in PSO, PsA and RA.
75
Systemic inflammation in PSO, PsA and Ra
REFERENCES
 1. Dowlatshahi EA, van der Voort EA, Arends LR et al. Markers of systemic inflammation in psoriasis: 
a systematic review and meta-analysis. The British journal of dermatology 2013; 169: 266-82.
 2. Boehncke WH, Schon MP. Psoriasis. Lancet 2015.
 3. Wu JJ, Rowan CG, Bebchuk JD et al. Association between tumor necrosis factor inhibitor (TNFi) 
therapy and changes in C-reactive protein (CRP), blood pressure, and alanine aminotransferase 
(ALT) among patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis. Journal of the 
American Academy of Dermatology 2015; 72: 917-9.
 4. Beygi S, Lajevardi V, Abedini R. C-reactive protein in psoriasis: a review of the literature. J Eur Acad 
Dermatol Venereol 2014; 28: 700-11.
 5. Hajdarbegovic E, Nijsten T, Westgeest A et al. Decreased prevalence of atopic features in patients 
with psoriatic arthritis, but not in psoriasis vulgaris. Journal of the American Academy of Dermatol-
ogy 2013; 68: 270-7.
 6. Rudwaleit M, Taylor WJ. Classification criteria for psoriatic arthritis and ankylosing spondylitis/
axial spondyloarthritis. Best practice & research. Clinical rheumatology 2010; 24: 589-604.
 7. Hudak PL, Amadio PC, Bombardier C. Development of an upper extremity outcome measure: the 
DASH (disabilities of the arm, shoulder and hand) [corrected]. The Upper Extremity Collaborative 
Group (UECG). Am J Ind Med 1996; 29: 602-8.
 8. van Riel PL, Schumacher HR, Jr. How does one assess early rheumatoid arthritis in daily clinical 
practice? Best Pract Res Clin Rheumatol 2001; 15: 67-76.
 9. Roubille C, Richer V, Starnino T et al. The effects of tumour necrosis factor inhibitors, methotrex-
ate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheu-
matoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Annals of 
the rheumatic diseases 2015; 74: 480-9.
 10. Linde L, Sorensen J, Ostergaard M et al. Health-related quality of life: validity, reliability, and 
responsiveness of SF-36, 15D, EQ-5D [corrected] RAQoL, and HAQ in patients with rheumatoid 
arthritis. The Journal of rheumatology 2008; 35: 1528-37.
 11. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical ap-
plications. Health and quality of life outcomes 2003; 1: 20.
 12. Prinsen CA, Lindeboom R, de Korte J. Interpretation of Skindex-29 scores: cutoffs for mild, moder-
ate, and severe impairment of health-related quality of life. J Invest Dermatol 2011; 131: 1945-7.
 13. Villanova F, Di Meglio P, Nestle FO. Biomarkers in psoriasis and psoriatic arthritis. Annals of the 
rheumatic diseases 2013; 72 Suppl 2: ii104-10.
 14. Elkayam O, Yaron I, Shirazi I et al. Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with 
psoriatic arthritis. Rheumatology international 2000; 19: 101-5.
 15. Asahina A, Umezawa Y, Yanaba K et al. Serum C-reactive protein levels in Japanese patients with 
psoriasis and psoriatic arthritis: Long-term differential effects of biologics. J Dermatol 2015.
 16. Suarez-Farinas M, Li K, Fuentes-Duculan J et al. Expanding the psoriasis disease profile: interroga-
tion of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol 2012; 
132: 2552-64.
 17. Romani J, Caixas A, Carrascosa JM et al. Effect of narrowband ultraviolet B therapy on inflam-
matory markers and body fat composition in moderate to severe psoriasis. The British journal of 
dermatology 2012; 166: 1237-44.
CHAPTER 3
76
 18. Montaudie H, Albert-Sabonnadiere C, Acquacalda E et al. Impact of systemic treatment of psoria-
sis on inflammatory parameters and markers of comorbidities and cardiovascular risk: results of a 
prospective longitudinal observational study. J Eur Acad Dermatol Venereol 2014; 28: 1186-91.
 19. Chandran V, Schentag CT, Gladman DD. Sensitivity and specificity of the CASPAR criteria for pso-
riatic arthritis in a family medicine clinic setting. The Journal of rheumatology 2008; 35: 2069-70; 
author reply 70.


Part 2
Liver disease in relation to psoriasis 

CHAPTER 4
Psoriasis is independently associated with 
nonalcoholic fatty liver disease in patients 
55 years old or older: Results from a 
population-based study. 
E.A.M. van der Voort
E.M. Koehler
E.A. Dowlatshahi
A. Hofman
B.H. Stricker
H.L.A. Janssen
J.N.L. Schouten
T. Nijsten
J Am Acad Dermatol. 2014;70(3):517-524
CHAPTER 4
82
ABSTRACT
Background: Recent case-control studies observed an increased prevalence of non-
alcoholic fatty liver disease (NAFLD) in psoriasis patients, which is relevant in selecting 
optimal psoriasis treatment. 
Objective: To compare the prevalence of NAFLD in people with psoriasis and those 
without psoriasis. 
methods: This large prospective population-based cohort study (part of the Rotterdam 
study) enrolled elderly participants (>65 years). NAFLD was diagnosed as fatty liver on 
ultrasonography in the absence of other liver diseases. Participants with psoriasis were 
identified using a validated algorithm. Multivariable logistic regression model was used 
to assess whether psoriasis was associated with NAFLD after adjusting for demographic, 
life-style characteristics and laboratory findings. 
Results: In total, 2,292 participants were included (mean age 76.2±6.0 years; 58.7% 
female; mean BMI 27.4±4.2kg/m2) of whom 118 (5.1%) had psoriasis. The prevalence 
of NAFLD was 46.2% in psoriasis subjects compared to 33.3% for the reference group 
without psoriasis (p=0.005). Psoriasis was significantly associated with NAFLD; after 
adjustment for alcohol consumption, pack-years and smoking status, presence of meta-
bolic syndrome and alanine aminotransferase, psoriasis remained a significant predictor 
of NAFLD (adjusted OR=1.7, 95%CI 1.1-2.6). 
Limitations: This was a cross-sectional study
Conclusion: Elderly participants with psoriasis are 70% more likely to have NAFLD than 
those without psoriasis independent of common NAFLD risk factors.
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver dis-
ease in Western countries, and is considered the hepatic manifestation of the metabolic 
syndrome.1 It was estimated that NAFLD will be the leading cause of liver transplanta-
tion by 2020.2 The prevalence of NAFLD, diagnosed by ultrasonography, ranges from 
15-34% and can be as high as 74% in obese patients.3-6 Although the condition is mostly 
asymptomatic, it is the most common cause of abnormal liver enzymes in Caucasian 
populations.7 NAFLD refers to a wide spectrum of liver damage, ranging from mild ste-
atosis to non-alcoholic steatohepatitis (NASH) 8, advanced fibrosis and liver cirrhosis. The 
prevalence of NASH and cirrhosis due to NAFLD in the general population is estimated 
to be 5% and 1%, respectively. The pathophysiology of how NAFLD develops into a 
NASH or cirrhosis remains unclear.
Recently, three hospital-based observational studies suggested that psoriasis patients 
are 1.5 to 3 folds more likely to have NAFLD.9-11 Furthermore, psoriasis patients are more 
likely to suffer from methotrexate-induced liver damage compared to healthy controls 
and patients with rheumatoid arthritis.8 This increased risk of NAFLD and subsequent 
risk of liver damage was explained by an increased prevalence of NAFLD risk factors 
such as obesity, diabetes mellitus and alcohol consumption among psoriasis patients. 
12-14 Because of the strong association of both psoriasis and NAFLD with these metabolic 
conditions and the potentially increased chronic systemic inflammatory status in both 
diseases, it is still unclear whether psoriasis is an independent risk factor for NAFLD.
In this study, we assessed whether elderly participants with psoriasis have a higher 
prevalence of NAFLD compared to a reference population and to what extent this as-
sociation depends on other known risk factors for NAFLD. 
mETHODS
Participants
This study is part of the Rotterdam Study, an on-going large prospective population-
based cohort study, which started in January 1990.15 All inhabitants who were aged 
55 years and older, living in Ommoord, a district in Rotterdam (The Netherlands), were 
invited to participate. The rationale and study design have been described previously.15 
Abdominal ultrasonography was introduced to the core protocol at the fifth survey of 
the Rotterdam Study (February 2009-February 2012), which constitutes the baseline sur-
vey for the present study. Clinical skin examinations for the screening of dermatological 
CHAPTER 4
84
conditions started in September 2010. In addition, each participant completed an ex-
tensive interview, fasting blood was collected and anthropometric measurements were 
conducted. Detailed information on drug prescriptions was dispensed from automated 
pharmacies, where nearly all participants (98%) are registered. 
Diagnosis	of	psoriasis
Psoriasis was diagnosed either by trained physicians in Dermatology at the research 
center, or by records of general practitioners (GP). Participants, which were not seen at 
the research center, were identified using a validated algorithm based on hard copy and 
electronic medical records of all subjects using anti-psoriatic drugs or who had a diag-
nostic code for psoriasis were screened for the diagnosis of psoriasis in the GP notes, 
medical specialist reports and hospital discharge letters. The participants seen at the 
research center were used as gold standard. Participants with a history of possible anti-
psoriatic drug use, but without a diagnosis of psoriasis, were excluded from the analysis. 
The validated algorithm had a sensitivity 98%, specificity 98%, positive predictive value 
62% and a negative predictive value of 99.9%. A detailed description of the psoriasis 
selection was described previously.16 Participants without psoriasis were defined as the 
reference cohort. 
The date of onset of psoriasis was the date of the first diagnosis of psoriasis in the 
medical records, first anti-psoriatic medication available in the pharmacy database or 
the self-reported date of onset, whichever came first. Psoriasis severity of participants 
evaluated at the research center was scored using the Psoriasis Area Severity Index 
(PASI).17 
Diagnosis	of	NAFLD
Abdominal ultrasonography was performed by certified and experienced technicians 
on Hitachi HI VISION 900 in all study participants. Images were re-evaluated by a hepa-
tologist (J.N.L.S.) with more than ten years’ experience in ultrasonography. The diagnosis 
and grading of fatty liver was determined according to the protocol by Hamaguchi et al 
18. Severity of fatty liver was classified as ‘no fatty liver’ (score 0-1), ‘mild fatty liver’ (score 
2-3), or ‘moderate-to-severe fatty liver’ (score 4-6). Participants with any of the following 
possible secondary causes of fatty liver were excluded from the analyses: 1) excessive al-
cohol consumption 2) positive HBsAg or anti-HCV, 3) use of oral pharmacological agents 
historically associated with fatty liver (i.e. amiodarone, corticosteroids, methotrexate, 
and tamoxifen). None of the psoriasis participants used methotrexate at the time of the 
ultrasound. Other rare causes of chronic liver disease (e.g. autoimmune liver diseases, 
alpha-1 antitrypsin deficiency, Wilson’s disease) were not accounted for. The impact 
of misclassification bias is likely to be small because most of these rare diseases in a 
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population sample affect young patients and those treated with corticosteroids were 
excluded from the analysis. 
Covariables
Participants were interviewed at home using a standardized questionnaire to obtain 
data concerning demographics, medical history, comorbid conditions, smoking behav-
iour, alcohol intake, and (prior) drug use. Data from the first interview prior to ultrasound 
examination were used. Excessive alcohol consumption was defined as more than 14 
drinks weekly for men and women. Pack-years of smoking were calculated as years of 
smoking (excluding years of non-smoking) multiplied by the average number of packs 
(containing 20 cigarettes) smoked per day. 
Anthropometric measurements were performed by well-trained nurses. Body Mass 
Index (BMI) was calculated as weight(kg)/length(m2). Waist and hip circumference were 
measured in centimeters. The average of two blood pressure measurements, obtained at 
a single visit in sitting position after a minimum of 5 minutes rest, was used for analysis. 
Fasting blood samples were collected on the morning of ultrasound examination. 
Blood lipids, glucose and alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), and gamma-glutamyltransferase (GGT) were analysed. Insulin, HBsAg and anti-
HCV antibodies were measured by automatic immunoassay (Roche Diagnostics GmbH, 
Mannheim,DE). 
The metabolic syndrome was defined, according to Adult Treatment Panel III cri-
teria, as the presence of at least three of the following five traits: 1) abdominal obe-
sity, defined as a waist circumference in men>102cm and in women>88cm, 2) serum 
triglycerides≥1.7 mmol/L or drug treatment for elevated triglycerides, 3) serum HDL 
cholesterol<1.0mmol/L in men and <1.3mmol/L in women or drug treatment for low 
HDL-C, 4) blood pressure≥130/85mmHg or drug treatment for elevated blood pressure, 
5) fasting plasma glucose≥5.6 mmol/L or drug treatment for elevated blood glucose.19 
Insulin resistance index was calculated using the Homeostasis Model Assessment of 
Insulin Resistance (HOMA-IR): fasting glucose (mmol/L) x fasting insulin (mU/L)/22.5.20
Statistical	analysis
The Chi-square tests and Student’s t tests or Wilcoxon rank sum tests were used to test 
for statistical significance of differences in distributions of categorical data and continu-
ous data, respectively, between participants with and without psoriasis. 
The association between NAFLD and psoriasis was assessed by multivariate logistic 
regression analysis resulting in adjusted odds ratios (OR) and 95% confidence intervals 
(CI). The first multivariable model adjusted for age and gender. In the fully adjusted mul-
tivariable logistic regression model, we decided a priori to adjust for age, gender, alcohol 
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consumption, smoking, the presence of the metabolic syndrome and ALT. In this model, 
metabolic syndrome was entered as a single covariate instead to avoid over-adjustment. 
The quantitative variables are handled as continue variables in the analyses. 
A multivariable ordinal regression analysis was used to assess the impact of psoriasis 
on the severity of NAFLD (no, mild and moderate to severe), which was the dependent 
variable in this analysis. 
P-values were two-sided and values <0.05 were considered statistically significant. 
Statistical analyses were performed using software (SPSS 20.0, IBM Corp, Armonk, NY).
The study was approved by the Medical Ethics Committee of the Erasmus Medical Center 
in Rotterdam. Written informed consent was obtained from all participants. 
The present study was reported according to the STROBE guidelines.21
RESULTS
Study	population
Data on psoriasis diagnosis was available for all 3,205 participants who underwent an 
abdominal ultrasonography. After excluding cohort members with a history of possible 
anti-psoriatic drug use (e.g., medicated shampoos), but no diagnosis of psoriasis in their 
medical files or during clinical examination from the reference group, 2,617 participants 
remained (Figure 1). In total, 325 participants were excluded for the presence of second-
ary causes of fatty liver resulting in 2,292 eligible participants for the analyses. 
 
3205 participants with liver ultrasonography
118 psoriasis
participants
2292 eligible participants
2617 participants with liver ultrasonography
and conclusive psoriasis dataExcluded:
91 medication
0 methotrexate
0 TNF inhibitor
33 amiodarone
55 corticosteroids
3 tamoxifen
23 positive HBV, HCV
220 >14 alcohol beverage
55 NAFLD
(46.2%)
2174 reference
participants
724 NAFLD
(33%)
Excluded:
588 uncertainty about case
verification of psoriasis
 
 Figure	1.	Flowchart of the participants of the Rotterdam study included in this study. 
Abbreviations: TNF, Tumor Necrosis Factor; HBV, hepatitis B viral infection; HCV, hepatitis C viral infection; NAFLD, 
non alcoholic fatty liver diseases.
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Psoriasis	population
Of the 2,292 participants, 118 (5.1%) had psoriasis. The remaining 2,174 was defined as 
reference population. The average age of both populations was 76 years and 58.4% of 
the reference population was female compared to 62.4% of the psoriasis population 
(p=0.47; Table 1). Almost all participants in both groups were Caucasian. 
The median duration of psoriasis since first diagnosis was 10.5 years (interquartile 
range 13.4 years). At time of the analyses, one third of participants defined as having 
psoriasis received a dermatological examination at the research center and had a mean 
PASI of 2.9±2.8. In the past 20 years, 14% of 118 participants with psoriasis had been 
exposed to ultraviolet therapy (UVB and/or psoralen+UVA) and 10% had been treated 
with systemic therapy. None of the psoriasis participants were treated with systemic 
medication at time of the analyses. In only 5 out of the 118 participants with psoriasis, 
ultrasonography had been performed before the diagnosis of psoriasis (median dura-
tion of 2.5 month).
NAFLD	prevalence
Among the psoriasis patients, 46.2% were reported to have NAFLD compared to 33.3% 
of the people in the reference population (p=0.005). Risk factors for NAFLD such as age, 
sex, ethnicity, BMI and alcohol intake did not significantly differ between participants 
with psoriasis and those without this skin disease. Although BMI as continuous vari-
able was not statistically different between the two groups (p=0.07), participants with 
psoriasis were significantly more likely to have a BMI>30kg/m2 and an increased waist 
circumference. Participants with psoriasis were also significantly more likely to be cur-
rent smokers (14.9% vs 8.2%, p=0.01) and to meet the criteria for metabolic syndrome 
(62.2% vs 52.2%, p=0.05).
Inversely, 7.0% of participants with NAFLD had psoriasis, as did 4.2% of participants 
without NAFLD (p=0.007). Prevalence of the metabolic syndrome was higher in partici-
pants with NAFLD (72%) than in participants without NAFLD (42%, p<0.001). ALT, AST, 
GGT and HOMA-IR were significantly higher in participants with NAFLD (all p-values 
<0.01). No difference was seen in alcohol intake or pack-years in current smokers be-
tween participants with or without NAFLD.
Factors	associated	with	NAFLD	
Logistic regression analyses showed that psoriasis was associated with a significantly 
increased prevalence of having NAFLD of 70% (crude OR=1.70, 95%CI 1.17-2.46) and the 
risk remained increased after adjustment for age and gender (adjusted OR=1.70, 95%CI 
1.17-2.47). After adjusting for alcohol consumption, pack years of smoking, smoking 
status, ALT and presence of the metabolic syndrome in a multivariable logistic regres-
sion model, participants with psoriasis remained 70% more likely to have NAFLD on 
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Table	1.	General characteristics of the study population according to presence of psoriasis.
Covariables
Total	
(n=2292)
Reference	
(n=2174)
Psoriasis	
(n=118)
P-value*
100% 94.9% 5.1%
Age (years) 76.2 (±6.0) 76.2 (±6.0) 76.0 (±6.5) 0.86
Female (%) 58.6 58.4 62.4 0.47
Caucasian (%) 95.1 95.0 97.1 0.33
BMI (kg/m2) 27.4 (±4.2) 27.3 (±4.1) 28.0 (±4.8) 0.07
BMI category 0.25
Normal; BMI < 25 (%) 30.3 30.3 29.1
Overweight; 25 ≤ BMI < 30 (%) 47.1 47.3 41.9
Obese; BMI ≥ 30 (%) 22.7 22.3 29.1
Alcohol intake (drinks/week) 3.8 (±3.8) 3.7 (±3.7) 4.0 (±3.8) 0.50
Smoking (Status) 0.04
Never (%) 36.7 36.8 34.2
Former (%) 54.8 55.0 50.9
Current (%) 8.5 8.2 14.9
Metabolic syndrome (%) 52.7 52.2 62.2 0.05
Fasting glucose >100 mg/dL or
drug treatment for elevated blood glucose
48.1 48.1 48.2 0.89
Waist circumference
>88cm (♀) or >102 cm (♂)
41.5 40.8 54.7 0.004
Triglycerides >150 mg/dL or
drug treatment for elevated triglycerides 43.4 43.4 44.1 0.92
HDL-C <40 mg/dL(♂) or <50 mg/dL(♀) or
drug treatment for low HDL-C 41.4 41.2 45.0 0.46
BP ≥130/85 mmHg or
drug treatment for elevated BP 93.7 93.8 91.5 0.30
ALT (U/L) 18 (14-23) 18 (14-23) 17 (14-22) 0.18
AST (U/L) 25 (22-29) 25 (22-29) 24 (20-27) 0.01
GGT (U/L) 22 (17-32) 22 (17-32) 23 (18-33) 0.22
HOMA-IR 2.6 (1.8-4.0) 2.6 (1.7-4.0) 2.8 (1.9-5.2) 0.09
Nonalcoholic fatty liver disease (NAFLD) (%) 34.0 33.3 46.2 0.005
Severity of NAFLD 0.01
Mild (%) 5.6 5.4 9.3
Moderate-severe (%) 28.2 27.8 36.4
Data are represented as mean (± standard deviation), median (25^th -75^th percentile) or percentages.
*Significance level between reference population and psoriasis. Based on T-test, Wilcoxon rank sum test or Chi-
square test
Abbreviations: BMI, Body Mass Index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gam-
ma glutamyl transferase; HOMA-IR, Homeostasis Model Assessment of Insulin Resistance; HDL-C, high-density li-
poprotein cholesterol; BP, blood pressure. 
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ultrasound examination compared to the reference population (fully adjusted OR=1.70, 
95%CI 1.13-2.58; Table 2). No statistical interaction was observed between psoriasis 
and alcohol consumption. Moreover, restricting the regression analysis to nondrinkers, 
psoriasis remained significantly associated with NAFLD (p=0.03). 
Ordinal regression analysis showed a significant association between psoriasis and 
the severity of non-alcoholic fatty liver (crude OR=1.54, 95%CI 1.11-2.15). After adjusting 
for alcohol consumption, pack-years of smoking, smoking status, ALT and presence of 
the metabolic syndrome, the presence of psoriasis increased the likelihood of having 
more severe NAFLD by approximately 60% (adjusted OR=1.58, 95%CI 1.06-2.38). 
DISCUSSION
In this large population-based cohort study of elderly people, psoriasis was indepen-
dently associated with NAFLD and increased the likelihood of having NAFLD by ap-
proximately 70%. In our study, the prevalence of NAFLD in participants with psoriasis 
in a general population was significantly higher than in our reference population (46% 
vs 33%). These prevalence estimates are comparable to results of an Italian case-control 
study (47%) including 130 psoriasis patients from a tertiary center (mean age 51.2, 
PASI>10 in 55%,) and 260 age, sex and BMI matched controls. 9 A higher prevalence 
Table	2.	Association between psoriasis and NAFLD in logistic regression analysis. 
Crude	/	Adjusted	OR	(95%	CI) P-value
Crude	univariate	model#
Psoriasis 1.70 (1.17-2.46) 0.005
Age	and	sex	adjusted
Psoriasis 1.70 (1.17-2.47) 0.006
multivariable	adjusted*
Age, years 0.98 (0.96-1.00) 0.01
Sex, female 1.19 (0.96-1.48) 0.10
Metabolic syndrome 3.51 (2.86-4.32) <0.001
Smoking 0.2
Never 1
Past 0.88 (0.67-1.15) 0.34
Current 0.99 (0.96-1.01) 0.07
Pack years 1.01 (1.01-1.02) <0.001
Alcoholic beverages weekly 0.99 (0.96-1.01) 0.35
ALT (U/L) 1.01 (1.01-1.02) <0.001
Psoriasis 1.70 (1.13-2.58) 0.01
#Nagelkerke adjusted R square=0.005; *Nagelkerke adjusted R square=0.19 
Abbreviations: OR, odds ratio; CI, confidence interval; ALT, alanine aminotransferase
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of 59% was described in another cross-sectional Italian study that enrolled consecu-
tive out-clinic psoriasis patients in a tertiary referral center (mean age 50.1, PASI>10 in 
66%).11 An Indian hospital-based case-control study reported a prevalence of NAFLD 
of only 17% among 333 outpatient clinic psoriasis patients (mean age 46.3, PASI>10 
in 14%) which was estimated to be twice as high as the 300 age, sex and BMI matched 
controls.10 This lower prevalence in Indian patients can partly be explained by using an-
other definition of NAFLD (liver steatosis on ultrasound combined with laboratory liver 
enzyme abnormalities) and/or a different distribution of other risk factors for NAFLD 
in this non-Western population. Furthermore, prevalence differences are likely to be 
explained by various clinical settings and baseline characteristics (e.g., age, disease se-
verity, and presence of metabolic syndrome [ranging between 28%-49%] in the different 
studies). Compared to the other studies, the Dutch psoriasis patients were most likely to 
fulfil the criteria for metabolic syndrome, which may be due to the more elderly study 
population.
In the present study, one third of the reference population had NAFLD, a prevalence 
that is comparable to previously published data in the general population of Western 
countries, suggesting a good internal validity of the study.7, 22, 23 24
Metabolic syndrome was the strongest predictor of having NAFLD followed by excessive 
smoking, more than doubling of upper limit of ALT and psoriasis increased the likelihood 
of NAFLD by approximately 70%. Even in the fully adjusted model of the most com-
mon known risk factors of NAFLD, these will explain together not even 20% (adjusted R 
square=0.191) and psoriasis accounted for less than 1% of the variability of developing 
NAFLD. This implies that the pathogenesis of NAFLD appears to be multifactorial in 
origin and the underlying mechanisms causing NAFLD are still largely unclear. Other risk 
factors of NAFLD such as genetic predisposition, lifestyle factors, drugs/toxin exposure, 
pro-inflammatory status and/or chronic oxidative stress that were not assessed in this 
and other psoriasis studies, may explain a part as well. 
NAFLD is considered the hepatic manifestation of the metabolic syndrome and seems to 
be an independent predictor of cardiovascular disease (CVD).1, 25, 26 The slightly elevated 
pro-inflammatory markers found in psoriasis, NAFLD, the metabolic syndrome and 
CVD, causing a “chronic inflammatory state”, display considerable overlap. For example, 
increased levels of interleukin-6, CRP and TNFα have been demonstrated in all of these 
conditions. TNFα in particular is hypothesised to play a role in the development of both 
psoriasis and NAFLD.4, 27, 28 Notwithstanding this considerable overlap of inflammatory 
markers, this does not prove any causal relationship between these different condi-
tions.29 
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The pathogenesis of both psoriasis and NAFLD is multifactorial and complex. In both 
conditions environmental components and genetic factors are likely to play an important 
role as well. However, the exact underlying genetic mechanisms are largely unknown. In 
NAFLD PNPLA3 deserves most attention. PNPLA3 is associated with increased hepatic 
fat levels and hepatic inflammation and has been validated in a series of studies. The 
genes that are most likely to be affected in psoriasis are PSORS1-10, which influences 
the immune system and skin. As far as we know, there is no genetic overlap between 
psoriasis and NAFLD.30, 31 
Although the majority of participants in this population-based study had mild psoriasis, 
the prevalence of NAFLD in severely affected patients from a tertiary center was com-
parable to that observed in a sample of patients with predominantly mild disease from 
the general population. This accordance we hypothesize that the association between 
psoriasis and NAFLD is maybe irrespective of psoriasis severity. Physicians prescribing 
drugs with potential liver-toxicity should be aware of the possible presence of NAFLD 
in both mild and severely affected psoriasis patients due to a higher risk of developing 
(drug-induced) advanced stage chronic liver disease.32, 33 It could be argued that refer-
ral of psoriasis patients with a suspicion of NAFLD (e.g. due to presence of metabolic 
syndrome or liver enzyme abnormalities) to a hepatologist should be considered prior 
to starting liver-toxic medication,34 but screening for NAFLD is not routinely advised by 
the “Practice guideline of NAFLD by the American Association for the Study of Liver Dis-
eases, the American College of Gastroenterology, and the American Gastroenterological 
Association”.35
Strengths	and	limitations
Among the strengths of this study are its population-based design, the large number 
of participants and the extensive availability of demographic, disease and life-style fac-
tors. In the adjusted models, we were able to include most of the known confounders 
that could influence the association between NAFLD and psoriasis. The study was also 
performed in a district of Rotterdam well-representative of the Dutch elderly general 
population. An intrinsic limitation of the cross-sectional study design is that the tempo-
ral relationship remains unclear and that a direct causal relationship between psoriasis 
and NAFLD cannot be established. The case definition (i.e., psoriasis) was based on an 
algorithm with a high specificity and sensitivity (both 98%). Data on psoriasis severity 
was only available in a subset of patients (who were seen by a resident in dermatology) 
making the interpretation of the subgroup analysis hazardous. Since the population 
consisted of elderly participants, the results may not be generalized to younger sub-
jects. The elderly population also explains the high prevalence of psoriasis compared 
to other population based studies.36 However, NAFLD mainly affects middle-aged and 
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elderly people, and its prevalence increases with age.35, 37-41 The short average duration 
of psoriasis with 10.5 years was not expected for this elderly population, which may 
suggest the existence of information bias. However, as this was not a major endpoint of 
this study, this is not very likely to have influenced our results. Ultrasonography is not 
able to differentiate between simple fatty liver and steatohepatitis. However, perform-
ing liver biopsies, the golden standard for discerning between stages of liver disease, in 
a population-based setting is unethical and not feasible. A final limitation concerns the 
self-reporting of alcohol consumption, which may imply that excessive alcoholic intake 
was underreported in both psoriasis and reference populations. 
In conclusion, psoriasis seems to be independently associated with NAFLD in this 
cross-sectional population-based study of elderly Dutch individuals. The increased 
prevalence of NAFLD in participants with psoriasis should alert physicians to consider 
possible chronic hepatic involvement prior to administering therapies with potentially 
liver toxicity. 
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ABSTRACT
Prevalence of non-alcoholic fatty liver disease is increased in patients with psoriasis. It is 
unknown whether liver fibrosis relates to psoriasis. We investigated the association be-
tween psoriasis and liver fibrosis compared to participants without psoriasis within the 
population-based Rotterdam study. All participants were screened for liver fibrosis using 
transient elastrography. Liver stiffness measurement of >9.5kPa suggested advanced 
liver fibrosis. Psoriasis was identified using a validated algorithm. 1535 participants 
were included (mean age 70.5±7.9 years; 50.8% female; median BMI 26.4kg/m2(IQR 
24.2-28.9) of who 74 (4.7%) had psoriasis. The prevalence of advanced liver fibrosis was 
8.1% in psoriasis patients compared to 3.6% in the reference group (p=0.05). The risk 
of advanced liver fibrosis in psoriasis patients remained comparable after adjustment 
for demographics, life-style characteristics and laboratory findings (OR 2.57 (95%CI: 
1.00-6.63). This study suggests that elderly with psoriasis may be twice as likely to have 
advanced liver fibrosis irrespective of common risk factors. 
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INTRODUCTION
In psoriasis patients, an increased prevalence of non-alcoholic fatty liver disease (NAFLD) 
has been observed.1-4 NAFLD is currently the most common chronic liver disease in 
Western countries, and considered the hepatic manifestation of the metabolic syn-
drome.5 The reported prevalence of NAFLD in psoriasis patients varies from 46 to 59% in 
Western countries independent of psoriasis severity.1,3,4 The term NAFLD encompasses a 
wide spectrum of liver damage, ranging from simple fatty liver and non-alcoholic steato-
hepatitis (NASH), to advanced fibrosis, including liver cirrhosis and its complications (e.g. 
portal hypertension and hepatocellular carcinoma).6 Although most of the patients with 
NAFLD have asymptomatic simple steatosis, which will not progress to more advanced 
stages of liver disease, a minority will develop advanced liver fibrosis. The prevalence of 
NASH, severe fibrosis and cirrhosis due to NAFLD in the general population is estimated 
to be 6%, 4.2% and 1.1%, respectively.6,7 
No data are available on the prevalence of advanced liver fibrosis in patients with pso-
riasis. Based on an increased prevalence of NAFLD in psoriasis patients, an increased 
prevalence of advanced liver fibrosis may be expected. A non-invasive and reproducible 
method for assessing liver fibrosis is by transient elastrography (TE; Fibroscan®).8 TE has 
a high diagnostic accuracy, independent of the underlying liver disease, in predicting 
advanced liver fibrosis.8 Up to now three small studies have evaluated TE in patients with 
psoriasis using high dose methotrexate (MTX).9-11 It has been observed that psoriasis 
patients are more likely to develop MTX induced liver toxicity compared to patients with 
rheumatoid arthritis and Crohn’s disease using this drug; however, it is unknown if this is 
due to psoriasis and/or their different profile of risk factors for liver toxicity.12,13
For our study, we used data from the Rotterdam Study: an on-going large prospective 
population-based cohort study in middle-aged and elderly participants. The specific 
design of the Rotterdam Study provides the opportunity to systematically evaluate liver 
disease in all participants with the use of the Fibroscan. The main objective of our study 
is to investigate if participants with psoriasis have a higher risk of advanced liver fibrosis 
as measured by TE compared to participants without psoriasis in the population-based 
Rotterdam Study 14 and how this association is affected by known risk factors for liver 
fibrosis. In addition, we performed subgroup analyses for participants with NAFLD.
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mETHODS
Study	population
This study has been conducted within The Rotterdam Study, which started in January 
1990. 14 All inhabitants, aged 55 years and older, living in Ommoord, a district in Rot-
terdam (The Netherlands), were invited to participate. The rationale is to study factors 
that determine the occurrence of chronic diseases in elderly people. The study design 
has been described previously. 14 TE was introduced to the core protocol in January 2011 
and ultrasound at the fifth survey of the Rotterdam Study (February 2009 - February 
2012), which constitutes the baseline survey for the present study. Clinical skin examina-
tions for the screening of dermatological conditions started in September 2010. In ad-
dition, each participant completed an extensive interview, fasting blood was collected 
and anthropometric measurements were conducted. Detailed information on drug 
prescriptions were derived from automated pharmacies, where nearly all participants 
(98%) are registered. 
Assessment	of	psoriasis
Psoriasis was diagnosed either by trained physicians in dermatology at the research 
center, or by records of general practitioners (GP). Among participants who were seen at 
the research center a Psoriasis Area and Severity Index (PASI) was conducted to estimate 
disease severity. Hard copy and electronic medical records of all participants using 
anti-psoriatic drugs or who had a diagnostic code for psoriasis were screened for the 
diagnosis of psoriasis in the GP notes, medical specialist reports and hospital discharge 
letters. Participants with a history of possible anti-psoriatic drug use, but without a 
diagnosis of psoriasis, were excluded from the analysis. A more detailed description of 
this selection process was described previously.15 Participants without psoriasis were 
defined as the reference cohort. 
The date of onset of psoriasis was the date of the first diagnosis of psoriasis in the 
medical records, first anti-psoriatic medication available in the pharmacy database or 
the self-reported date of onset, whichever came first. 
Diagnosis	of	liver	fibrosis
Measurement of liver stiffness was performed using TE (Fibroscan, EchoSens, Paris, 
France) by a single, certified and experienced operator. The right lobe of the liver was 
assessed through the intercostal space in patients lying on their back with the right arm 
in maximal abduction. The examination lasted about 5-10 minutes. If the distance from 
the skin to the liver was more than 2,5 cm an XL-probe was used instead of the normal 
M-probe. The liver stiffness measurement (LSM) was expressed in kilopascals (kPa). TE 
was considered reliable if ≥10 validated measurements were recorded with at least 60% 
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success rate and the interquartile range (IQR) was less than 30% of the median LSM. LSM 
>9.5 kPa was used as a cut-off for the presence of advanced liver fibrosis and >13 kPa 
was used for cirrhosis. This cut-off level was deliberately chosen, for it yields high posi-
tive predictive value for presence of advanced fibrosis in various liver diseases, including 
(N)AFLD. 8,16-18 
Diagnosis	of	NAFLD	
Abdominal ultrasonography was performed by certified and experienced technicians 
on Hitachi HI VISION 900 in all study participants. Images were re-evaluated by a hepa-
tologist (JNLS) with more than ten years’ experience in ultrasonography. The diagnosis 
of fatty liver was made based on specific ultrasound criteria according to the protocol 
by Hamaguchi et al.19 Participants with any of the following possible secondary causes 
of fatty liver were excluded from the NAFLD analyses: 1) excessive alcohol consumption 
2) positive HBsAg or anti-HCV, and 3) use of oral pharmacological agents historically 
associated with fatty liver (i.e. amiodarone (n=13), corticosteroids (n=28), methotrexate 
(n=0), and tamoxifen (n=2)). 
Co-variables
Participants were interviewed at home using a standardized questionnaire to obtain 
data concerning demographics, medical history, comorbid conditions, smoking behav-
iour, alcohol intake, and (prior) drug use. Data from the first interview prior to TE were 
used. Excessive alcohol consumption was defined as more than 14 drinks weekly for 
men and women. Pack-years of smoking were calculated as years of smoking (exclud-
ing years of non-smoking) multiplied by the average number of packs (containing 20 
cigarettes) smoked per day. 
Anthropometric measurements were performed by well-trained nurses. Body Mass 
Index (BMI) was calculated as weight(kg)/ length(m2). Waist and hip circumference were 
measured in centimeters. The average of two blood pressure measurements, obtained at 
a single visit in sitting position after a minimum of 5 minutes rest, was used for analysis. 
Fasting blood samples were collected on the morning of ultrasound examination. 
Blood lipids, glucose and alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), gamma-glutamyltransferase (GGT), and platelets were analysed using automatic 
enzymatic procedures and insulin, HBsAg and anti-HCV antibodies were measured by 
automatic immunoassay (Roche Diagnostics GmbH, Mannheim, DE). 
The metabolic syndrome was defined, according to Adult Treatment Panel III criteria, 
as the presence of at least three of the following five traits: 1) abdominal obesity, defined 
as a waist circumference in men >102cm and in women >88cm, 2) serum triglycerides 
≥1.7 mmol/L or drug treatment for elevated triglycerides, 3) serum HDL cholesterol 
<1.0mmol/L in men and <1.3mmol/L in women or drug treatment for low HDL-C, 4) 
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blood pressure ≥130/85mmHg or drug treatment for elevated blood pressure, 5) fasting 
plasma glucose ≥5.6 mmol/L or drug treatment for elevated blood glucose.20 Insulin 
resistance index was calculated using the Homeostasis Model Assessment of Insulin 
Resistance (HOMA-IR): fasting glucose(mmol/L) x fasting insulin(mU/L)/22.5. 21
Statistical	analysis
Chi-square tests, Student’s t-tests or Wilcoxon rank sum tests were used to test for statis-
tical significance of differences in distribution of categorical data and continuous data 
between participants with and without psoriasis. 
The association between liver fibrosis and psoriasis was investigated by logistic regres-
sion, where LSM >9.5 kPa by TE suggested presence of advanced liver fibrosis. Two 
multivariable models were used: one adjusted for age and gender and in the second 
model we a priori decided to adjust for age, gender, alcohol consumption, presence of 
the metabolic syndrome, steatosis and ALT (all risk factors of liver fibrosis). Metabolic 
syndrome was included as a single co-variable instead of the five cardiovascular risk 
factors as mentioned previously to avoid over-adjustment. As a sensitivity analysis a 
linear regression model was used to investigate the association between the presence 
of psoriasis and LSM (log-transformed) as a continuous variable. Furthermore, since 
an increased prevalence of NAFLD was previously reported in psoriasis patients,1-4 all 
analyses were also repeated among participants with NAFLD separately.
P-values were two-sided and values <0.05 were considered statistically significant. 
Statistical analyses were performed using SPSS 20.0 (IBM, UK).
The study was approved by the Medical Ethics Committee of the Erasmus Medical Center 
in Rotterdam. Written informed consent was obtained from all participants. 
RESULTS
Study	population
TE and conclusive psoriasis data were available for 2466 participants of the Rotterdam 
Study (Figure 1). From this population 1535 participants had a reliable TE (62.2%), which 
was similar between the psoriasis and reference population. Participants with a pace-
maker (1.4%), an unreliable TE (27.9%) or failure of the TE (9.8%) were excluded. The 
proportion of overweight and obese participants was significantly higher among those 
with a failure (88.7%, p<0.001) or unreliable (74.9% p<0.001) TE compared to those with 
a reliable TE (64.8%). Regarding reliability of TE, no differences were observed between 
the psoriasis and reference population. 
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Of 1535 participants, 74 (4.8%) had psoriasis; the remaining 1461 participants were 
defi ned as the reference population. The distribution of age and gender was compa-
rable between both groups, and the majority were Caucasian. Metabolic syndrome 
and obesity (BMI and waist circumference) were not signifi cantly diff erent between the 
participants with psoriasis and the reference population although metabolic syndrome 
was slightly more present in the participants with psoriasis. (Table 1) At the time of the 
analyses the median disease duration of psoriasis was 11.2 years (IQR15.8 years) and no 
participant was using systemic anti-psoriatic drugs. Furthermore, by then almost half 
of the psoriasis participants had received a dermatological examination at the research 
center, and had a median PASI score of 2.0 (IQR 3.2), representing a predominately mild 
psoriasis population.
Liver	fi	brosis	evaluation
The risk factors for liver fi brosis were generally comparable between participants with 
and without psoriasis (Table 1). However, the prevalence of steatosis, diagnosed by 
ultrasonography was greater in participants with psoriasis versus the reference popula-
tion (44.3% versus 34.0%, respectively, p=0.02). (Figure 2) The prevalence of advanced 
fi brosis, defi ned as a LSM>9.5kPa, was 8.1% in the psoriasis participants and 3.6% in the 
reference participants, which is an almost two-and-a-half times higher risk of advanced 
fi brosis for psoriasis participants (crude OR 2.39; 95%CI 0.99-5.76). The characteristics of 
participants with psoriasis with advanced fi brosis are summarized in table 2.
After adjustment for age and gender, psoriasis remained signifi cantly associated with 
advanced liver fi brosis (LSM >9.5kPa) (adjusted OR 2.36, 95%CI 0.95-5.85). The odds 
ratio increased slightly to 2.57 (95%CI 1.00-6.63) after additional adjustment for age, 
gender, alcohol consumption, ALT, presence of the metabolic syndrome and steatosis in 
a multivariable logistic regression model. (Table 3)
 
Figure	1.	Flowchart of the participants of the Rotterdam study included in this study. 
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Table	1.	General characteristics of the study population stratified by psoriasis and NAFLD
Co-variables
All participants Participants with NAFLD
Reference	
(n=1461)
Psoriasis	
(n=74)
Pa-
value
Reference	
(n=375)
Psoriasis	
(n=20)
Pa-
value
95.3% 4.7% 94.9% 5.1%
Age (years) 70.5±8.0 71.2 ±6.5 0.34 69.6±7.6 73.6±6.5 0.02
Female (%) 51.1 44.6 0.27 50.4 60.0 0.40
Caucasian (%) 95.4 98.6 0.21 94.5 94.7 0.72
BMI (kg/m2) 26.4 (24.2-28.9) 26.6 (24.1-28.5) 0.47 29.0 (26.9-31.2) 28.5 (26.7-32.5) 0.74
Alcohol intake 
(drinks/week)
5.0 (0.6-7.5) 7.5 (0.9-7.5) 0.07 2.63 (0.56-7.5) 4.97 (0.23-7.5) 0.75
Alcoholic more than 
14 weekly (%)
13.2 17.8 0.26 n/a n/a n/a
Viral hepatitis (%) 0.8 1.4 0.57 n/a n/a n/a
Hepatotoxic 
medication (%)
2.8 2.7 0.96 n/a n/a n/a
Smoking (Status) 0.45 0.63
Never (%) 34.6 27.4 33.3 25.0
Former (%) 53.9 60.3 59.7 70.0
Current (%) 11.5 12.3 6.9 5.0
Metabolic syndrome 
(%)b
46.5 52.1 0.36 68.5 83.3 0.18
Fasting glucose 
>100 mg/dL or 
drug treatment 
for elevated blood 
glucose
47.0 41.4 0.40 66.3 60.0 0.62
Waist 
circumference
>88cm (♀) or 
>102 cm (♂)
34.2 45.8 0.07 61.6 81.2 0.12
Triglycerides >150 
mg/dL or
drug treatment 
for elevated 
triglycerides
41.7 41.1 0.93 52.5 64.3 0.39
HDL-C <40 mg/
dL(♂) or <50 mg/
dL(♀) or drug 
treatment for low 
HDL-C
37.3 37.5 0.97 47.4 42.9 0.74
BP ≥130/85 
mmHg or
drug treatment 
for elevated BP
91.7 88.1 0.34 96.0 93.8 0.66
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Linear regression analysis also showed that psoriasis is a predictor for the severity of 
fibrosis measured as log-LSM (crude β 0.04, standard error (SE) 0.02 P=0.03). After adjust-
ing for age, gender, alcohol consumption, ALT and presence of the metabolic syndrome 
and steatosis this correlation remained the same (adjusted β 0.04, SE 0.02 P=0.04). 
NAFLD	population
A subgroup analysis was performed for participants with NAFLD. Of 2502 participants, 
400 were excluded because of the presence of secondary causes for liver steatosis. A 
third of the remaining 2102 participants had NAFLD (n=704), and of these 39 (5.5%) 
had psoriasis. In this subgroup analysis 395 participants had reliable TE data (56%). The 
psoriasis participants were significantly older (74 vs 70 years p=0.02) than the refer-
ence participants, but the distribution of the other co-variables such as, gender, BMI, 
metabolic syndrome and liver enzyme tests were comparable. Using TE, a significantly 
greater prevalence of advanced fibrosis was demonstrated in participants with psoriasis 
versus the reference population (15% vs 4% p=0.02). Moreover, more participants with 
Table	1.	General characteristics of the study population stratified by psoriasis and NAFLD (continued)
Co-variables
All participants Participants with NAFLD
Reference	
(n=1461)
Psoriasis	
(n=74)
Pa-
value
Reference	
(n=375)
Psoriasis	
(n=20)
Pa-
value
95.3% 4.7% 94.9% 5.1%
ALT (U/L) 18 (14-24) 18 (14-24) 0.89 22 (16-28) 22 (17-25) 0.94
AST (U/L) 25 (22-29) 24 (21-31) 0.67 25 (22-29) 25 (21-30) 0.63
GGT (U/L) 23 (17-34) 25 (19-37) 0.20 26 (19-37) 26 (21-40) 0.55
Bilirubin 8 (6-11) 9 (6-12) 0.52 8.0 (6.0-11.0) 6.5 (5.8-11.0) 0.24
Platelet count (G/L) 258 (217-301) 271 (231-332) 0.008 255 (211-311) 271 (186-323) 0.98
HOMA-IR 2.5 (1.6-3.7) 2.5 (1.8-3.7) 0.66 3.9 (2.6-5.9) 4.2 (2.9-5.4) 0.90
Steatosis on 
ultrasound (%)
34.0 44.3 0.016 n/a n/a n/a
Cirrosis on Fibroscan 
(%)
1.1 3.4 0.13 1.6 8.6 0.005
Advanced liver 
fibrosis on Fibroscan 
(%)
3.6 8.1 0.045 4.0 15.0 0.022
Fibroscan stiffness 
(kPa)
4.9 (4.1-6.2) 5.4 (4.4-6.6) 0.10 5.3 (4.4-6.7) 6.3 (4.9-7.3) 0.066
Data are represented as mean (± standard deviation), median (interquartile range) or percentages.
Abbreviations: BMI, Body Mass Index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gam-
ma glutamyl transferase; HOMA-IR, Homeostasis Model Assessment of Insulin Resistance; HDL-C, high-density li-
poprotein cholesterol; BP, blood pressure; N/A, not applicable.
aSignificance level between reference population and psoriasis. Based on T-test, Wilcoxon rank sum test or Chi-
square test. bMetabolic syndrome was defined as the presence of at least three of the five traits.
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psoriasis had a LSM>13kPa, suggesting liver cirrhosis, than the reference population 
(8.6% vs 1.6% p=0.005). (Table 1)
Logistic regression analyses in this NAFLD population showed that psoriasis partici-
pants had a four times greater risk for advanced liver fibrosis compared to the reference 
population (crude OR 4.2, 95%CI 1.1-16.0). This risk remained four times increased after 
adjustment for age, gender, alcohol consumption, ALT and presence of the metabolic 
syndrome in a multivariable logistic regression model (fully adjusted OR=4.1, 95%CI 
1.01-17.0).
Table	2.	Characteristics of 6 psoriasis patients with advanced fibrosis and psoriasis 
Participantsa Gender Age 
(years)
BMI 
(kg/m2)
MS Alcoholic 
drinks
weekly
MTX 
use
NAFLD Liver 
stiffness
 (kPa)
ALT PASI
1 M 87 23.1 Yes 18 no n/a 11.7 12 0.4
2 F 66 24.1 Yes 18 no n/a 25.4 32 3.0
3 M 81 28.5 Yes 0 no yes 15.5 12 capitis
4 M 76 28.1 Yes 5 no no 10.2 19 -
5 F 75 23.5 Yes 8 no yes 46.4 19 3.3
6 M 80 33.9 Yes 5 no yes 9.6 16 -
a None of these participants have a viral hepatitis or used hepatotoxic mediation. 
Abbreviations: BMI, Body Mass Index; ALT, alanine aminotransferase; MS, metabolic syndrome; n/a, not applicable
Table	3.	Univariate and multivariate adjusted model assessing the association between psoriasis and ad-
vanced liver fibrosisa 
Normal liver vs. fibrosis
OR	(95%	CI) P-value
Crude	univariate	modelb
Psoriasis 2.39 (0.99-5.76) 0.052
Age	and	sex	adjusted
Psoriasis 2.36 (0.95-5.85) 0.06
multivariable	adjustedc
Age, years 1.13 (1.08-1.17) <0.001
Sex, female 1.90 (1.03-3.49) 0.04
Metabolic syndrome 1.63 (0.89-3.02) 0.12
Alcoholic beverages weekly 0.99 (0.95-1.03) 0.75
ALT (U/L) 1.03 (1.02-1.05) <0.001
steatosis 1.51 (0.81-2.80) 0.19
Psoriasis 2.57 (1.00-6.63) 0.051
aAdvanced liver fibrosis defined as LSM >9.5
 bNagelkerke R square=0.007; cNagelkerke R square=0.164.
Abbreviations: OR, odds ratio; CI, confidence interval; ALT, alanine aminotransferase
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Furthermore, in a linear regression analysis, the association between psoriasis and liver 
fibrosis (continuous LSM) was confirmed as well (crude and fully adjusted β 0.07, SE 0.04 
P=0.04). 
DISCUSSION
This is the first large population-based cohort study of middle-aged and elderly people 
which demonstrates that participants with psoriasis have a two-fold higher risk of ad-
vanced liver fibrosis than participants without this skin disease. This risk increases up 
to four times among the subgroup of participants with NAFLD and is independent of 
systemic anti-psoriatic drugs and other known risk factors associated with liver fibrosis, 
such as alcohol consumption and BMI, that may have been more prevalent in psoriasis 
patients. Previous studies focused on liver fibrosis in the context of MTX induced hepato-
toxicity, but these studies have limited sample sizes and were restricted to patients with 
severe psoriasis eligible for liver biopsy in tertiary centers.22-25 In contrast to the 8.1% of 
 
Figure	2.	Distribution of reliable liver stiffness measurements in psoriasis and reference participants.
Transient elastrography was used to measure the liver stiffness measurements. P=0.08 
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psoriasis patients with advanced liver fibrosis using TE in this study, the prevalence of 
advanced liver fibrosis in the highly selected patients treated with methotrexate ranged 
from 6.9% to 69.5%.25 The prevalence of liver fibrosis in our non-psoriatic reference 
population (3.6%) is similar to that observed in other population based studies confirm-
ing the validity of the ascertainment of liver fibrosis using TE.26,27
In patients with inflammatory diseases like ulcerative colitis, Crohn’s disease and psoria-
sis, TE is mainly used to monitor MTX-induced hepatotoxicity.9,10,13,28,29 In a recent small 
study of Bray et al, TE was compared to liver biopsy in 21 patients (median age 59 years, 
43% female), of whom 48% had a reliable examination. They concluded that a combi-
nation of TE and procollagen III N-terminal propeptide could be used for monitoring 
drug safety.10 Another diagnostic study among 24 psoriasis patients suggested that the 
combined use of Fibrotest and TE may be beneficial in establishing the grade of liver 
fibrosis in MTX-induced liver fibrosis in psoriasis patients.9 Two studies in Crohn’s disease 
patients demonstrated that severe liver fibrosis is rare in patients who receive high dose 
methotrexate regimens,13,29 nevertheless both studies recommend TE in the follow-up 
of these patients. 
ALT is often used in daily practice as a diagnostic marker to detect liver damage, 
but its accuracy remains controversial. In this study, in both the logistic and the linear 
analyses continuous ALT level was significantly associated with LSM>9.5kPa, suggest-
ing the presence of advanced liver fibrosis with greater liver stiffness (as continuous 
measurement). However, this ALT increment was in almost all of the participants within 
the normal range of ALT level. Furthermore, median ALT levels were normal in the total 
study population as well as in the NAFLD population. Neither did any of the six patients 
with psoriasis and advanced fibrosis show elevated ALT levels. Our findings are compa-
rable to a previous study with participants from the Rotterdam Study7 and a recently 
published systematic review.25 Altogether, ALT seems to be a poor diagnostic marker 
for NAFLD and liver fibrosis and therefore may be limited to monitor acute liver toxicity 
(i.e. drug induced hepatitis), but not for the development of liver fibrosis in psoriasis 
patients. Other diagnostic tests including TE, Fibrotest, PIIINP, and the Enhanced Liver 
Fibrosis (ELF™) test are more accurate in detecting liver fibrosis and seem more appropri-
ate to monitor drug-induced effects in the follow-up of psoriasis patients if indicated. 
In clinical practice it could therefore be considered that patients with psoriasis and 
an increased hepatic risk profile at baseline may be referred to a hepatologist for a TE 
before commencing potentially hepatotoxic medication. During systemic therapy TE 
may be repeated at a regular interval, also depending on the baseline TE, to monitor 
for signs of liver fibrosis A liver biopsy should be considered in patients with a LSM of > 
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9.5kPa depending on the patients’ clinical background and is strongly recommended in 
patients with a LSM of > 13kPa.26,27
A direct causal relationship between psoriasis and advanced liver fibrosis cannot 
be established in this cross sectional study because we lack the longitudinal compo-
nent. The logistic and linear adjusted regression models suggest an association and a 
possible correlation between psoriasis and advanced liver fibrosis, even in this study 
population that consisted of participants with mild psoriasis who did not use systemic 
anti-psoriatic medication. There have been studies that evaluated pre-treatment liver 
biopsies in rheumatoid arthritis and described liver abnormalities in nearly all patients 
suggesting that underlying pathophysiological mechanisms of the disease may play a 
role as well.13,30,31 Conventional explanations for the association of NAFLD and advanced 
liver fibrosis and psoriasis are the increased presence of components of the metabolic 
syndrome, increased alcohol intake and the use of hepatotoxic medication, but the 
distribution of these factors was comparable between the psoriasis patients and the 
reference population. The low-grade chronic inflammatory state, seen both in psoriasis 
and NAFLD may play a role in the development of advanced fibrosis, but this needs to be 
studied in more detail before it proves to be the missing link in the relationship between 
these diseases.32-34 Also, the inflammation does not explain the fact that methotrexate 
toxicity is seen more often in psoriasis patients than rheumatic patients or Crohn’s 
disease, 12,13 two inflammatory diseases known to have a higher inflammatory state 
than psoriasis.35,36 Other hypotheses that explain the observed increased prevalence of 
advanced liver fibrosis in psoriasis are possible genetic similarities, life style factors such 
as nutrition that were not included in the analyses or another still unknown common 
pathway for psoriasis and liver fibrosis.
Strengths	and	limitations
The strengths of this study are its population-based design, the large number of 
participants and the extensive availability of demographic, pharmacological, disease 
and life-style factors and serological markers of liver damage. In the adjusted models, 
we were able to include most of the known confounders that could influence the as-
sociation between both advanced liver fibrosis and NAFLD with psoriasis. The study 
was also performed in a district of Rotterdam well representative of the Dutch elderly 
general population. Notwithstanding the large number of participants, the available 
cases with psoriasis and liver fibrosis remain small explaining the borderline significance 
often found in this study and the wider range of the confidence interval in the NAFLD 
subpopulation. However, the different analytic approaches and subgroup analysis all 
show the same trend suggesting the validity of the findings. An intrinsic limitation of 
the cross-sectional study design is that the temporal relationship remains unclear and 
that a direct causal relationship between psoriasis and advanced liver fibrosis cannot be 
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established. The case definition (i.e., psoriasis) is based on an algorithm, which included 
a clinical examination by a trained physician, with a high specificity and sensitivity (both 
98%).15 Since the population consisted of elderly participants, the results may not be 
generalized to younger subjects with psoriasis. The elderly population also explains the 
high prevalence of psoriasis compared to other population-based studies.37
At present, liver biopsy is still the golden standard for the assessment of liver fibrosis. 
However, performing liver biopsies in a population-based setting is unethical and not 
feasible. Furthermore this invasive method is associated with patient discomfort and, in 
rare cases, with serious complications in 1% or more of patients.38 In addition, accuracy 
of liver biopsy is limited due to sampling error and intra- and interobserver variability.39 
Therefore, different non-invasive methods have been evaluated in recent years, includ-
ing routine biochemical and haematological tests, surrogate serum fibrosis markers and 
TE.40,41 TE can be learned easily and has an excellent reproducibility, with an intraobserver 
and interobserver agreement of 98%.42 A recent meta-analysis concluded that a higher 
stage of liver fibrosis (a higher cut-off value) improves test accuracy.8 We used a cut-off 
value of 9.6 kPa (≤ F3) which is the highest value to detect liver fibroses next to liver cir-
rhosis (>13 kPa; F4). Another shortcoming in our study is the failure rate or unreliable TE 
in one-third of the participants. This mostly affected the overweight and obese patients 
irrespective of using an XL probe. This may have led to a selection bias and may have led 
to an underestimation of the prevalence of advanced liver fibrosis in our study. However, 
the failure rate of the TE was equally distributed amongst participants with and without 
psoriasis suggesting a nondifferential misclassification bias. 
Conclusion
This study suggests that middle-aged and elderly people with predominately mild pso-
riasis and without any systemic psoriasis medication, have an increased risk of advanced 
liver fibrosis independently of other known risk factors, especially in participants with 
pre-existing NAFLD. The clinical implications of the study findings are that it questions 
the usefulness of ALT in monitoring the development of liver fibroses and stimulates 
the use of other diagnostic approaches such as the TE, especially in psoriasis patients 
with (components of ) metabolic syndrome that are being screened prior to and during 
potentially hepatotoxic therapies.
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ABSTRACT
Background: Recently the enhanced liver fibrosis (ELF) test, a combined use of three 
serum biomarkers to detect liver fibroses, was introduced to screen, diagnose and/
or monitor liver conditions in large groups of patients with liver diseases and healthy 
controls, but it has not been used in inflammatory skin or joint diseases. 
Objective: To evaluate the distribution of the ELF test, apply existing cut offs for he-
patic patients and healthy controls, and compare it to the corresponding procollagen-3 
N-terminal peptide (P3NP) test among patients with psoriasis (PSO), psoriatic arthritis 
(PsA), rheumatoid arthritis (RA) and controls.
methods: In total 531 patients were included in this cross sectional study. Demographic, 
lifestyle and disease-specific data were collected. ELF and P3NP test was performed. 
Results: The prevalence of an increased ELF (>11) and P3NP was highest in RA patients 
(7.7% and 6.1%) followed by PSO patients (1.7% and 5.2%) and PsA (0.7% and 1.3%). 
Mean score ELF: PSO 9.09±0.86; PsA 8.96±0.76; RA 9.55±1.04. All subgroups with moder-
ate to severe disease severity had higher ELF scores (ELF>9.8: PSO 27.0%vs 18.3%, PsA 
19.2%vs12%, RA 45.8%vs30.5%) and P3NP values. The distribution of the ELF score was 
smaller compared to P3NP value (mean 9.15±0.92 and 8.37±4.30; range 6.53-13.05 and 
0.53-63.88). 
Conclusions: ELF score and P3NP values are elevated in PSO, PsA and RA. ELF may be 
superior to P3NP alone but further research should be done to validated ELF test suscep-
tible for developing liver fibrosis for PSO, PsA and RA. 
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INTRODUCTION	
Compared to the general population, patients with psoriasis (PSO) have approximately 
twice the risk of developing nonalcoholic fatty liver disease (NAFLD) and liver fibrosis.1-4 
This is partly due to the use of hepatotoxic drugs and shared comorbidities, but pos-
sibly also through other independent mechanisms.2,3 Furthermore, PSO patients using 
methotrexate (MTX) have a higher likelihood of developing liver fibrosis as compared 
to those with psoriatic arthritis (PsA) and rheumatic arthritis (RA) using MTX.5 A recent 
systematic review reported that the prevalence of methotrexate-induced liver fibrosis 
and cirrhosis (Roenigk stage ≥3a) in PSO patients varies from 5,7%-71,8% 6, depending 
on underlying risk factors and comorbidities. The incidence of MTX-induced liver fibrosis 
in patients with RA and PsA seems to be much lower, with 15.3% for mild, 1.3% for severe 
liver fibrosis and 0.5% for cirrhosis in RA and 9.9%, 1.4% and 1.4% in PsA, respectively.5
Cirrhosis is the main cause of morbidity and mortality in chronic liver disease, but 
is often asymptomatic until the synthetic and filtering functions of the liver are finally 
compromised and/or portal hypertension develops. Hepatic fibrosis is also difficult to 
detect with standard noninvasive techniques: it can develop despite normal liver func-
tion tests and normal images from ultrasound and radionuclide scans.7 Although liver 
biopsy remains the golden standard, it carries a risk for serious complications in > 1% of 
patients. Hence, there clearly is a need for an accurate, valid and reliable non-invasive 
diagnostic test to detect early liver fibrosis.8 
The European psoriasis EDF guidelines recommend to determine procollagen-3 N-
terminal peptide (P3NP) as a marker for liver fibroses prior to starting methotrexate as 
well as serially every 2–3 months throughout treatment, for patients at risk and where 
available.9-11 P3NP has however not been accepted as the standard by other specialties, 
including hepatology, requires serial measurements, is quite expensive, is not specific to 
liver fibrosis and may be falsely elevated in patients with inflammatory diseases such as 
an active arthritis. 
A relatively new noninvasive test is the Enhanced Liver Fibrosis (ELF) test. The ELF test 
employs a combined automated in-vitro immunoassay for the quantitative measure-
ment of three serological markers; P3NP, tissue inhibitor of matrix metalloproteinase 1 
(TIMP1) and hyaluronic acid (HA). The individual results of these markers are combined 
in an algorithm to produce an ELF score,12,13 which has been validated as a biomarker of 
fibrosis in healthy subjects and in patients with a wide range of chronic liver diseases, 
including nonalcoholic fatty liver disease, hepatitis C and primary biliary cirrhosis.14-17 
This has resulted in proposed cut off values for liver fibrosis and cirrhosis. Furthermore, 
it has been shown that the ELF test is superior to liver biopsy in predicting the clini-
cal outcome in chronic liver disease.13 A recent pilot study suggested that a single ELF 
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measurement may be at least equivalent or possibly superior to single as well as serial 
P3NP in the detection of liver fibrosis in 27 patients with PSO treated with MTX as part 
of routine clinical practice.18
The objective of this cross-sectional study is to evaluate and compare the distribution, 
cut off scores and values and predictors of the elevated noninvasive liver fibrosis tests 
ELF and P3NP in three different patient populations being PSO, PsA and RA. Secondary 
to explore if the ELF test can be a potentially valuable tool to monitor liver fibrosis in 
inflammatory diseases especially for those treated by hepatotoxic medication.
mETHODS	
Study	design	and	population
The study subjects were included from March 2009 until August 2012, which has been 
described previously.19 The patients with PSO had chronic plaque psoriasis and were 
diagnosed and recruited by dermatologists from the department of dermatology Erasmus 
Medical Center in Rotterdam. At the same center, the control group consisting of individuals 
with varicose veins or benign moles without PSO, PsA and/or RA were recruited. The PsA 
and RA patients were recruited from the rheumatology department of the Maxima Medisch 
Centrum in Eindhoven. An expert rheumatologist confirmed PsA and RA diagnosis based on 
the Classification Criteria for Psoriatic Arthritis (CASPAR) and 2010 ACR/EULAR RA Classifica-
tion Criteria.20 All PSO subjects had no history or signs of inflammatory arthritis. 
Co-variables	and	disease	characteristics
The following data were collected in a standardized manner, at the same day the patient 
was included: demographic data (age, gender, weight, height), disease onset, disease dura-
tion, general medical history including comorbidities, concomitant medication, current and 
previous disease specific medication and lifestyle (including alcohol intake and smoking). 
Body mass index (BMI) was calculated as weight (kg)/height (m2). Patients were defined 
as having diabetes if they used diabetic medication including all insulin preparations 
and oral agents, had diabetes mentioned in their medical history or had an elevated 
serum glucose level (> 6.1 mmol/L) or HbA1c(Glycohemoglobine) (>42 mmol/mol 
Hb). Hypercholesterolemia was defined as serum total cholesterol >6.5 mmol/L, serum 
triglycerides >2.0 mmol/L; serum high-density lipoprotein cholesterol < 0.9 mmol/L, se-
rum low-density lipoprotein cholesterol > 2.59 mmol/L or drug treatment for low high-
density lipoprotein cholesterol, elevated triglycerides or elevated high low-cholesterol. 
Hypertension was determined based on a medical history of hypertension or the use 
of blood pressure lowering drugs. Excessive alcohol consumption was defined as more 
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than 3 drinks per day for men and women. Pack-years of smoking were calculated as 
years of smoking (excluding years of nonsmoking) multiplied by the average number of 
packs (containing 20 cigarettes) smoked per day. 
For psoriasis and PsA patients, Psoriasis Severity Index Score (PASI)<7 was defined as 
mild; PASI 7–12 as moderate and a PASI>12 as severe disease.21 The disease activity and 
course severity in psoriatic and rheumatic arthritis patients were assessed with Disease 
Activity Score 28 (DAS28) and a DAS<3.2 was defined as mild, 3.2-5.1 as moderate and 
>5.1 as severe disease activity. 22, 23 In case of a discrepancy in disease severity score 
between skin and joints in PsA, the most severe stage was taken. This occurred only in 4 
patients with skin severity higher than joint severity. 
Disease specific medication was divided into four subgroups; (1) patients without 
medication or who only used topicals, UV and/or non-steroidal anti-inflammatory drugs 
(NSAIDs); (2) patients who used disease related systemic drugs excluding MTX; (3) MTX 
use irrespective of any other medication except biologicals; and (4) patients who used a 
biologicals irrespective of medication from group one to three. Data on dosing regimens 
were not available.
Laboratory	analysis
Serum samples were collected at the same visit and stored at −80°C until assayed. 
Serum samples were analyzed for levels of HA, TIMP-1 and P3NP using the proprietary 
assays developed for the ELF test by Siemens Healthcare Diagnostics Inc. These assays 
are magnetic particle separation immunoassays, and samples were analyzed on an 
ADVIA®CentaurXP immunoassay system (Siemens Medical Solutions Diagnostics Inc., 
Tarrytown, NY, USA). Results were entered into the manufacturer’s published algorithm 
to derive an ELF score. These samples were analyzed by an independent reference labo-
ratory (Star-MDC, Rotterdam, NL).The analyses were all performed on the same day to 
avoid measurement bias.
The ELF (ELF) score was calculated using the algorithm: DS = 6.38 – (ln (age) 9 0.14) 
+ (ln (HA) 9 0.616 + (ln (P3NP) 9 0.586) + (ln (TIMP1) 90.472). Validated ELF test cut off 
values to high specificity identification of fibrosis, have been determined for healthy 
blood donors (>9.8) and patients with chronic liver diseases (>11), but this has not yet 
been validated in PSO, PsA and RA.10,24 The cut off values for P3NP in PSO patients with 
MTX are >12.2 for a liver biopsy indication and >15.3 for withdrawal MTX.11 
Serum alanine aminotransferase (ALT), aspartate transaminase (AST), gamma glutamyl 
transferase (GGT), alkaline phosphatase (ALP) and C reactive protein (CRP) were mea-
sured using standard enzymatic immunoassays.
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Statistics
Statistical analysis was performed using SPSS software version 20. Variables were de-
scribed using standard descriptive statistics. Continuous variables were expressed as 
mean ± SD or as median ± interquartile range; and categorical data as number and per-
centage. The unpaired t test and analysis of variance (ANOVA) test and, when indicated, 
two-tailed Mann– Whitney and Kruskall–Wallis tests were used to perform comparison 
between two or more groups, respectively. Bonferroni and Dunn’s tests were used for 
multiple comparisons. χ2 and Fisher’s exact tests were used to compare categorical 
variables. Parametric and non-parametric correlations were calculated using Pearson’s 
and Spearman’s rank correlation tests, respectively.
The distribution of the general characteristics were compared between the different 
groups using the Chi-square tests and one way ANOVA or Kruskal Wallis tests for statisti-
cal significance of categorical data and continuous data, respectively.
In order to identify the clinical variables independently associated with P3NP and ELF 
scores in the whole cohort, multivariate logistic regression analyses were performed. 
The first multivariable model adjusted for age and gender. In the fully adjusted model, 
multivariable logistic backward regression model was selected to determine which 
confounder substantially affected the test outcome considering the other variables 
in the model. Based on the literature we selected age, gender, alcohol consumption, 
smoking, ALT, CRP, BMI, disease type and activity and liver toxic medication as potential 
relevant confounders. The variables ALT, CRP and BMI were however excluded from the 
fully adjusted multivariable model because of too much missing data. The Nagelkerke R 
square was used to calculate the proportion of explained variation in the final adjusted 
backward model. Furthermore, missing data on the ELF test (n=70; 8,5%) were due to 
technical problems or insufficient stored samples, and hence considered to have oc-
curred at random. These cases were therefore excluded in further analyses. 
The study was approved by the Medical Ethics Committee of the Erasmus Medical 
Center in Rotterdam. Written informed consent was obtained from all participants.
RESULTS
In total, 531 subjects with ELF scores and P3NP values were included for further analyses. 
Of these 119 had PSO, 151 PsA, 130 RA and 131 were control subjects. On average the RA 
population was the eldest (mean age 62.0+/-11.7) and the PSO population the youngest 
(mean age 49.8+/-14.3; table 1). Furthermore, the populations differed significantly in 
the proportion of females, which was lowest in the PSO (37.8%) and highest in the RA 
group (64.6%; P=<0.001). 
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Table	1.	General characteristics of the study population
psoriasis	
(n=119)
Psoriatic	
arthritis	
(n=151)
Rheumatoid	
arthritis	
(n=130)
Controls	
(n=131	)
Total
(n=531)
P-value*
Covariables
Age (years) 49.8 ± 14.3 52.8 ± 11.7 62.0 ± 11.7 54.4 ± 14.4 54.3 ± 13.7 <0.001
Female, n (%) 45 (38%) 70 (46%) 85 (65%) 76 (58%) 276 (52%) <0.001
BMI 27.2 ± 5.8 26.5 ± 4.2 25.9 ± 4.5 27.5 ± 6.1 26.8 ± 5.3 0.054
Alcohol intake (drinks/day) 0.07
None (%) 43,2 30.9 39.2 36,3 37,1
≤ 3 (%) 47.7 66.2 58.4 60,5 58,7
> 3 (%) 9.0 2,9 2.4 3.2 0.8
Smoking <0,001
Never (%) 27.7 40,5 32.3 52,3 37,4
Former (%) 29.4 42,5 52.6 32,3 38,6
Current (%) 42,9 17,0 15.0 15,4 23,9
Personal medication use, n(%)
Diabetes drugs* 16 (12.1%) 8 (7.3%) 11 (9.8%) 4 ( 5.7%) 39 (9.2%) 0.41
Antihypertensives 40 (22.2%) 38 (24.7%) 50 (36.8%) 38 (29%) 166 (27.6%) 0.08
Lipid lowering agents 80 (44.7%) 38 (24.7%) 25 (18.4%) 16 (12.4%) 159 (26.6%) <0.001
Disease activity, n(%) - <0.001
mild 80 (67.2%) 124 (82.1%) 84 (65.6%) - 288 (72.0%)
moderate 25 (20.6%) 25 (16.6%) 42 (32.8%) - 92 (23.0%)
severe 15(12.2%) 2 (1.3%) 2 (1.6%) - 19 (4.8%)
PASI 5.9 ± 5.8 1.5±2.4 - - - <0.001
DAS28 - 2.16±0.91 2.66±1.00 - - <0.001
Current medication use, n (%)§ <0.001
None/ cutaneous 35 (29.4%) 13 (8.6%) 4 (3.1%) - 52 (9.8%)
Other systemic medication 42 (35.3%) 49 (32.5%) 34 (26.2%) - 125 (23.5%)
Methotrexate 18 (15.1%) 69 (45.7%) 77 (59.2%) - 164 (30.9%)
Biologicals 24 (20.2%) 20 (13.2%) 15 (11.5%) - 59 (11.1%)
Laboratory data (non fasting) 
AST (U/L)* 29.9±10.6 28.3±9.7 27.5±16.3 - 28.6±10.8 0.61
ALT (U/L)* 34.6±25.1 31.2±22.2 26.2±16.7 - 30.1±21.4 0.017
GGT (U/L)* 40.4±34.6 34.5±33.3 33.2±22.8 - 39.5±61.2 <0.0001
ALP (U/L)* 75.0± 15.9 76.6±19.7 82.3±31.9 - 79.0±25.9 <0.0001
CRP (U/L)* 2.7 ±2.9 5.7 ±10.5 9.9 ±19.0 - 6.8 ± 13.9 0.004
Data are represented as mean (± standard deviation) or percentages. 
Abbreviations: PASI, Psoriasis Severity Index Score; DAS28, Disease Activity Score 28; BMI, Body Mass Index; AST, 
aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyl transferase; ALP, alkaline phos-
phatase; CRP, C reactive protein;
Normal values: AST 0-34 (U/L), ALT 0-44 (U/L), GGT 0-54 (U/L), ALP 0-114(U/L)
§ Disease specific medication: subdivided into four subgroups; (1) without medication or only cutaneous medica-
tion, UV and/or non-steroidal anti-inflammatory drugs; (2) systemic drugs excluding methotrexate (MTX), (3) MTX 
use irrespective of other medication except biologic therapy.; (4) biologic therapy irrespective of medication from 
group one to three.
* missing data if >7%: diabetic total = 29.6%; AST control= 93.1%; AST Pso=34.5%; AST RA=78.5%; ALT control = 
93.1%; ALT PSO=29.4%; ALT RA 13.8%; GGT control=93.1%; GGT PSO=29.4%; GGT RA=80%; ALP control=93.1%; 
ALP Pso=59.7%; ALP RA=13.8%; CRP control=96.2%; CRP PSO=84.0%
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Disease	characteristics	and	medication	
Psoriasis patients had the longest mean disease duration (20.1±14.5 years) compared to 
PsA and RA (9.9±9.3 and 10.7±8.4 years respectively, p<0.001) with a mean PASI of 5.9 ± 
5.8 in PSO compared to 1.5±2.4 in PsA patients. (Table 1) The mean DAS28 score for PsA 
patients was 2.16±0.91 and 2.66±1.00 for RA. 
Table	2.	Demographic and clinical details of patients with and without elevated ELF and/or P3NP test 
Variables ELF	Score p-value P3NP p-value
<9.8 %(n) ≥9.8 %(n) ≤ 12.2 %(n) >12.2 %(n)
Age mean age
Sex 75.9% (195) 24.1% (62) 0.25 91.4% (234) 8.6% (22) 0.72
men
female 80.3% (220) 19.7% (54) 90.5% (248) 9.5% (26)
Body Mass Index 0.25
Healthy 81% (170) 19% (40) 0.58 92.9% (195) 7.1% (15)
Overweight 77.9% (162) 22.1% (46) 91.3% (189) 8.7% (18)
Obese 76.2% (77) 23.8% (24) 87.1% (88) 12.9% (13)
Disease etiology <0.001 0.08
PSO 79% (94) 21.0% (25) 94.0% (109) 6.0% (7)
PsA 86.8% (131) 13.2% (20) 94.0% (142) 6.0% (9)
Ra 63.8% (83) 36.2% (47) 86.4% (114) 13.6% (18)
Controls 81.7% (107) ;8.3% 24 () 89.3% (117) 10.7% (14)
Disease severity 0.02 0.01
mild 81.0% (234) 19.0% (55) 94.4% (270) 5.6% (16)
Moderate 67.1% (55) 32.9% (27) 84.5% (71) 15.5% (13)
severe 66.7% (14) 33.3% (7) 81.0% (17) 19.0% (4)
Diabetes 54.8% (17) 45.2% (14) 0.007 83.9% (26) 16.1% (5) 0.28
Dyslipidemia 68.1% (81) 31.9% (38) 0.002 86.4% (102) 13.6% (16) 0.056
Hypertension 64% (96) 36% (54) <0.001 84.9% (129) 15.1% (23) 0.007
Smoking 0.11 0.25
Never 80.8% (160) 19.2% (38) 88.4% (176) 11.6% (23)
Former 73.9% (153) 26.1% (54) 92.3% (192) 7.7% (16)
Current 82.6% (100) 17.4% (21) 93.2% (110) 6.8% (8)
Excess alcohol intake 85.7% (18) 14.3% (3) 0.39 95.2% (20) 4.8% (1) 0.51
Medication 0.74 0.74
cutaneous 76.9% (40) 23.1% (12) 90.2% (46) 9.8% (5)
systemic 77.6% (97) 22.4% (28) 93.5% (115) 6.5% (8)
MTX 78% (128) 22.0% (36) 91.5% (151) 8.5% 14 ()
biological 72.9% (43) 27.1% (16) 88.3% (53) 11.7% (7)
Hepatotoxic medication* 74.3% (153) 25.7% (53) 0.09 91.3% (190) 8.7% (18) 0.88
Abbreviations: PSO, psoriasis; RA, rheumatoid arthritis; PSA, psoriatic arthritis; P3NP, procollagen-3 N-terminal 
peptide; ELF, Enhanced liver fibrosis test; MTX, methotrexate
* hepatotoxic medication is defined as: amiodarone , corticosteroids, MTX and tamoxifen .
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At the moment of inclusion 3.3% of the PSO, 5.2% of PsA and 3% of RA patients used 
no disease specific medication. Topical medication was used 76.1% in PSO and 50% in 
PsA patients, and 5% (all PSO) had UVB phototherapy. NSAIDs were used by 39% of the 
PsA and 55% of the RA patients. 
MTX was the most frequently used systemic drug in PsA and RA patients (52.3%vs66.9%), 
followed by hydroxychloroquine. In PSO patients, fumaric acid was most frequently used 
(31%), while 16.8% used MTX.
In total 222 (42%) subjects used potentially hepatotoxic medications, of whom 186 
used MTX, 36 systemic corticosteroids and one patient received isoniazid. Furthermore, 
there were no know other causes of chronic liver disease (e.g. autoimmune liver diseases, 
alpha-1 antitrypsin deficiency, cholestatic liver diseases or Wilson’s disease).
Lifestyle	and	comorbidities
In the group of patients with an increased ELF (>9.8) score, diabetes (6.2%vs15.4%, 
p=0.007), dyslipidemia (19.6%vs33.0%, p=0.002)and hypertension (23.1%vs46.6%, 
p<0.001) were more prevalent. 
In contrast, BMI, smoking and excessive alcohol intake was not more prevalent in this 
group. (table 2) 
ELF	test	vs	P3NP:	distribution	and	categorization	
In the total population the ELF score ranged between 6.53 and 13.05 with an overall 
mean score of 9.2±0.92 and median of 9.06 interquartile range (IQR) (7.86- 10.26). This 
range was much smaller compared to P3NP, which varied between 0.53 and 63.88 with 
an overall mean value of 8.37±4.30 and a median of 8.50 IQR (5.62-11.38). For the disease 
groups separately a comparable narrow spread of the ELF test was seen compared to 
the P3NP outcomes as shown in Figure 1 and Table 3. The controls showed a similar 
distribution compared to those with inflammatory diseases.
Table	3.	Median values of P3NP and ELF stratified by disease 
Psoriasis Psoriatic arthritis
Rheumatoid 
arthritis
Controls Total P-value
P3NP 7.56 (2.92) 7.23 (2.8) 7.87 (4.08) 7.49 (2.54) 7.50 (2.88) 0.26
ELF 8.96 (1.20) 8.93 (0.98) 9.48 (1.17) 9.05 (1.33) 9.06 (1.2) <0.001
Data are presented as median with IQR 
Abbreviations: P3NP, procollagen-3 N-terminal peptide; ELF, Enhanced liver fibrosis test
Elf >11(chronic liver disease), ELF >9.8( healthy blood donors), P3NP> 12.2 (biopsy indication for MTX users with 
psoriasis), P3NP >15.3 (indication on psoriasis patients to withdrawal of MTX)
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Sixteen of the 531 (3.0%) subjects had an abnormal ELF test, based on the higher cut 
off  value for chronic liver diseases (ELF≥11), compared to 21.8% (n=116) based on the 
cut off  value for healthy blood donors (ELF>9.8). In total 9.1% of the study population 
had a P3NP value of >12.2 (i.e. indication for liver biopsy ), and 4% had a P3NP value that 
would require withdrawal of MTX(>15.3; see table 4) None of the PSO patients, however 
had a liver biopsy. 
Subgroup	analyses	
The highest proportion of increased ELF scores and P3NP values were seen in RA pa-
tients (7.7% and 6.1% respectively, using the high cut off  values), followed by PSO (1.7% 
and 5.2%) and fi nally PsA (0.7% and 1.3%; table 4). After stratifying for disease activity 
scores, as shown in Figure 2, higher proportions of elevated ELF scores and P3NP values 
were seen for those with more active disease. 
A quarter of the patients who used hepatotoxic medication had an elevated ELF score 
(>9.8). 
 
 
 
Straight line 
Dotted line  
Figure	1.	Distribution of the values of P3NP and ELF stratifi ed on diagnoses
Abbreviations: P3NP, procollagen-3 N-terminal peptide; ELF, Enhanced liver fi brosis test; PSO, psoriasis; RA, rheu-
matoid arthritis; PSA, psoriatic arthritis
Distribution of the values of P3NP and ELF stratifi ed on diagnoses.
Cut-off  values: P3NP (>12.2) biopsy indication for MTX users with PSO, P3NP (>15.3) indication on PSO to with-
drawal of MTX; ELF (>9,8) healthy blood donors, ELF (>11) chronic liver disease
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In the group of patient with an increased ELF (>9.8) score or P3NP (>12.2) values, 
there was no significant difference between the different medication subgroups. For 
ELF, these proportions were 10.3% for those using none or topical treatments, 24.1% 
among those on systemic not MTX, 31.0% for MTX and 13.8% for those using biologicals. 
Figure 3 showed data based on stratification on current, past and never MTX use. 
In PSO patients, those who used MTX seemed to have increased ELF scores and P3NP 
values compared to ever and never MTX users. For PsA and RA, this is less clear. 
Table	4.	Different cut-off values of ELF and P3NP test
Values	%	(n) Reference	group PSO(119) PSA(151) RA (130) CO (131) Total	(531)
P3NP >12.2
biopsy indication for MTX 
users with PSO 6.0% (7) 6.0% (9) 13.6% (18) 10.7% (14)
9.1% (48)
P3NP >15.3 
indication on PSO to 
withdrawal of MTX 5.2% (6) 1.3% (2) 6.1% (8) 3.8% (5)
4.0% (21)
ELF >9,8 healthy blood donors 21.0% (25) 13.2% (20) 36.2% (47) 18.3% (24) 21.8% (116)
ELF >11 chronic liver disease 1.7% (2) 0.7% (1) 7.7% (10) 2.3% (3) 3.0 (16)
Elf >11(chronic liver disease), ELF >9.8( healthy blood donors), P3NP> 12.2 (biopsy indication for MTX users with 
psoriasis), P3NP >15.3 (indication on psoriasis patients to withdrawal of MTX)
Abbreviations: PSO, psoriasis; RA, rheumatoid arthritis; PSA, psoriatic arthritis; P3NP, procollagen-3 N-terminal 
peptide; ELF, Enhanced liver fibrosis test
Table	5.	multivariate logistic regression unadjusted and age/gender adjusted model 
ELF >9.8 P3NP >12.2
Crude	/	Adjusted	OR	(95%	CI) Crude	/	Adjusted	OR	(95%	CI)
Crude	univariate	model
Disease
control 1.0 (ref ) 1.0 (ref )
PSO 1.186 (0.635-2.215) 0.537 (0.209-1.380)
PSA 0.681 (0.357-1.299) 0.530 (0.221-1.267)
RA 2.525	(1.429-4.461) 1.320 (0.627-2.778)
Age	and	gender	adjusted
Age, years 1.081	(1.058-1.104) 1.027	(1.004-1.051)
Gender
women 1.0 (ref ) 1.0 (ref )
men 1.635	(1.028-2.601) 1.042 (0.566-1.922)
Disease
control 1.0 (ref ) 1.0 (ref )
PSO 1.505 (0.755-3.00)  0.578 (0.223-1.493)
PSA 0.798 (0.400-1.594)  0.553 (0.230-1.327)
RA 1.877	(1.011-3.485)  1.145 (0.534-2.453)
Cut-off values: P3NP (>12.2) biopsy indication for MTX users with PSO, ELF (>9,8) healthy blood donors.
Abbreviations: PSO, psoriasis; PSA, psoriatic arthritis; RA, rheumatoid arthritis; P3NP, procollagen-3 N-terminal 
peptide; ELF, Enhanced liver fibrosis test
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Figure	2.	Proportion of patients with elevated P3NP and ELF values based on disease activity
Abbreviations: PSO, psoriasis; RA, rheumatoid arthritis; PSA, psoriatic arthritis; m= mild (PASI < 7; DAS28 <3.2) and 
ms = moderate / severe disease ((PASI ≤7; DAS28 ≤3.2)). P3NP, procollagen-3 N-terminal peptide; ELF, Enhanced 
liver fibrosis test
Vertical border are % of patients with a positive value. 
Cut-off values: P3NP (>12.2) biopsy indication for MTX users with PSO, P3NP (>15.3) indication on PSO to with-
drawal of MTX; ELF (>9,8) healthy blood donors, ELF (>11) chronic liver disease
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Figure	3.	Proportion of patients with elevated P3NP and ELF values; based on never, ever and current 
methotrexate use.
Abbreviations: PSO, psoriasis; RA, rheumatoid arthritis; PSA, psoriatic arthritis; MTX+ current MTX use; MTX= ever 
MTX use, but not current; MTX- never MTX use; P3NP, procollagen-3 N-terminal peptide; ELF, Enhanced liver fibro-
sis test
Cut-off values: P3NP (>12.2) biopsy indication for MTX users with PSO, P3NP (>15.3) indication on PSO to with-
drawal of MTX; ELF (>9,8) healthy blood donors, ELF (>11) chronic liver disease
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Predictors	of	elevated	ELF	test
In the age and gender adjusted multivariable logistic regression model, a higher age, 
male gender and RA were significant predictors for an increased risk of an elevated ELF 
score (i.e. >9.8) compared to only a higher age for P3NP (table 5). In the fully adjusted 
logistic regression model, disease activity and age were important confounders, but 
for the ELF score male gender and hepatotoxic medications were additional significant 
confounders (table 6). Remarkably, alcohol intake was protective for a high test score. An 
explanation for this may be that the selection bias for prescribing MTX. There were no 
subject on MTX who had excessive alcoholic use. Using Nagelkerke R square on the final 
adjusted backward model, 30% for the ELF test compared to 10% for the P3NP test, was 
explained by the included risk factors. (table 6). 
Table	6.	multivariate analyses 
ELF P3NP
Adjusted	OR	(95%	CI) Adjusted	OR	(95%	CI)
Age, years 1.095	(1.071-1.120) 1.026	(1.003-1.049)
Sex
women 1.0 (ref )
men 2.081	(1.252-3.459)
Alcoholic use
No 1.0 (ref ) 1.0 (ref )
Yes 0.435	(0.260-0.726) 0.448	(0.234-0.859)
Liver toxic medication
No 1.0 (ref )
Yes 2.816	(1.142-6.944)
Disease activity
mild 1.0 (ref ) 1.0 (ref )
moderate 1.826 (0.971-3.434) 2.779	(1.249-6.181)
severe 5.850	(1.740-19.673) 5.672	(1.616-19.902)
Medication
cutaneous 1.0 (ref ) 1.0 (ref )
systemic 1.384 (0.837-3.568)
MTX 0.466 (0.134-1.618)
biological 1.786 (0.602-5.300)
Nagelkerke R square final model 0.307 0.102
Abbreviations: P3NP, procollagen-3 N-terminal peptide; ELF, Enhanced liver fibrosis test
Multivariate logistic regression model with backward method. The following variables were excluded in the analy-
ses in the following order; ELF: smoking, disease; P3NP: smoking, sex, medication, liver toxic medication, disease.
BMI is not in the multivariable model because there has been no relation described with the ELF test. ALT and CRP 
are not included in the multivariate model because of too much missing data. 
linear regression: Elf dependent and P3NP independent: B=0.139, p<0.0001, adjusted R square 0.423
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DISCUSSION	
This cross sectional study explores the levels of ELF scores and P3NP values in three dif-
ferent inflammatory diseases. The highest proportion of elevated ELF scores and P3NP 
values were seen in RA, followed by PSO and PsA. However, in all diseases the overall 
range of the ELF score was smaller than for P3NP. 
European guidelines currently advise sequential measuring of serial P3NP for detect-
ing liver fibrosis in patients using MTX.11 However it is important to note that serum 
P3NP has several limitations; it is not specific for fibrosis in the liver, can only be inter-
preted serially and is not be properly validated.18 These limitations advocate the search 
for a more reliable, non-serial test to screen for liver fibrosis especially when hepatotoxic 
medication is prescribed. 
The ELF test has been shown to be a well validated, non-serial, non-invasive liver 
fibrosis test in healthy controls as well in a multiple chronic liver disease like alcoholic 
liver disease, NAFLD and viral hepatitis, with a sensitivity of 83% (95% CI=0.80–0.86)
and a specificity of 73% (95% CI=0.69–0.77).17,25 A recent pilot study in patients with 
psoriasis already suggested that single ELF score may be superiour to single P3NP value. 
18 The ELF test has not yet been properly validated for inflammatory diseases and no 
cut off value has been described so far. In this article we have therefore selected the 
validated cut off values for chronic liver disease and healthy blood donors, as we expect 
the disease specific threshold for these inflammatory diseases will be somewhere in 
between these values. As P3NP is part of the ELF test, a certain effect of inflammation 
on the outcome of the ELF score can be expected, although this effect is less than for a 
single P3NP test.7,24,26,27 
In the multivariate model, as expected, higher age, male gender, hepatotoxic medica-
tion and active disease were associated with the ELF score.25 For P3NP comparable trend 
was visible, however moderate disease was also associated. Remarkably, alcohol intake 
was protective for a high test score. An explanation for this may be the selection bias for 
not prescribing MTX. In case of high alcoholic intake less hepatotoxic therapies will be 
prescribed. 
Contradictory to the available literature, RA patients had the highest values of P3NP 
and ELF score on both cut off values in our study in de unadjusted model, which may 
suggests a higher prevalence of liver fibrosis. Alternatively, it could reflect arthritis activ-
ity, 27 instead of liver fibrosis, but this effect was not seen in the PsA subgroup.26 On the 
contrary, selection bias for the inclusion criterion to conduct a liver biopsy (i.e. long term 
MTX use), may have led to underestimating the true prevalence of liver fibrosis in RA 
patients in the literature.28,29 
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For now, the position of the ELF test in clinical practice could be in the work up for sys-
tematic antipsoriatic drugs of all patients because it could direct in selecting potential 
hepatotoxic medication or not. This implementation in practice is especially valid for 
countries where P3NP monitoring is recommended in the treatment guidelines because 
of ELF’s advantages. The ELF test could also be used to monitor patients using hepa-
totoxic drugs annually, but optimal frequency needs to be investigated. In the current 
absence of validated ELF cut-off points for inflammatory diseases yet, we suggest to use 
the cut off point for healthy people. Although the use of the healthy cut off values would 
lead to false positive cases, a negative test is sufficiently reliable to exclude those with 
liver conditions. Altogether if the ELF value is above the 9.8 additional investigations 
such as transient elastography or referral to a hepatologist is warranted.
Strengths	&	Limitations
This real life cross-sectional study provides a useful comparison of the test outcomes for 
liver fibrosis in various inflammatory diseases, which makes extrapolation of the results 
to the clinical practice more possible. However due to the heterogeneity of the data, it 
harder to find significant associations. Furthermore, we have tried to investigate the as-
sociation between the potentially important confounders and abnormal liver tests using 
multivariable analyses and stratification of the data. However, the cross-sectional study 
design does not allow to draw conclusions about temporal relationships. Secondly, the 
data on liver disease were extracted from the general medical history, without specific 
question on liver disease. However, by asking about the general medical history we as-
sume that we did not miss major liver diseases and additionally we do know that there 
we no liver biopsies taken in our population. Despite this, it could have been possible 
than patients with mild or subclinical liver diseases may have been a priori unknown 
leading to none differential reporting bias or a minimal increased proportion of positive 
test results. 
Another limitation of this study is the lack of validation of the ELF test by a golden 
standard. Although a liver biopsy is the golden standard for liver fibrosis, it is unethical 
to perform this on a large groups of patients including healthy controls. Neither the 
P3NP test can serve as a gold standard, both due to its own practical limitation, but 
also because P3NP is part of the ELF test which would result in circulation bias. Finally, 
the cut-off points for the ELF test have not been validated for PSO, PsA or RA , and were 
extrapolated from the hepatology literature. Given the considerable influence of disease 
prevalence on the predictive values of diagnostic tests, the results from liver disease 
hospital-based studies cannot be transferred to our own, ‘low prevalence’ population 
without resulting in an unacceptably number of false positive and negative results. This 
issue also probably holds true for healthy blood donors, which a priori have a lower 
prevalence of liver fibrosis than those patients with an inflammatory disease. 
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Conclusion	&	Future	prospective	
This study suggests that the ELF test may be a promising noninvasive screening and 
monitoring tool for liver fibrosis by dermatologists and rheumatologists, but further 
research is needed to validate the ELF-test, through dermatologist, rheumatologists 
and hepatologists together, by using another noninvasive test e.g. ultrasound transient 
elastography (FibroScan®) and determine the appropriate cut-off values in PSO, PsA and 
RA patients.
Secondly, increased ELF scores are found by PSO, PsA and especially by RA patients 
and were associated with increased age, male, use of liver toxic medication and severe 
disease. A challenge in interpreting these results clinically is the lack of validated cut-off 
points to diagnose hepatic fibrosis in population-based cohorts. Despite this, our results 
suggest that liver fibrosis may more frequent in patients with inflammatory arthritis 
than would be expected based on the available literature. 
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ABSTRACT
Background: Recently the enhanced liver fibrosis (ELF) test was introduced as noninva-
sive biomarker for liver fibrosis in patients with liver diseases and healthy controls, but it 
has not been tested in inflammatory joint diseases. Liver fibrosis is prevalent in arthritis, 
especially in methotrexate users. 
Objective: To evaluate the applicability of ELF test among an outpatient group with 
psoriatic arthritis (PsA) and rheumatoid arthritis (RA), and to test whether ELF is related 
to disease activity. 
methods: In this daily practice cross sectional study ELF test was performed in 281 
patients. Furthermore, demographic and disease-specific data were collected. 
Results: Increased ELF (>9.8 and >11) was found in 36.2% and 7.7% of RA patients and in 
13.2% and 0.7% of PsA patients. In the multivariate linear model for PsA and RA patients, 
ELF was minimal associated with disease activity. 
Conclusions: ELF may be a promising non-invasive screening tool for PsA and RA to 
monitor liver fibrosis. ELF is minimal related to disease activity. However further research 
is needed to find clinically meaningful cut—off values for inflammatory diseases and to 
explore the increased risk of liver fibrosis. 
137
ELF in RA and PSA
INTRODUCTION
The incidence of liver fibrosis in patients with rheumatic arthritis (RA) has been de-
scribed to range between 15.3% for mild fibrosis and 1.3% for severe fibrosis. In RA, 0,5% 
of patients has liver cirrhosis.1 In psoriatic arthritis (PsA) this ranges between 9.9% and 
1.4% resp., while 1.4% actually has cirrhosis.1 In these two diseases the use of hepato-
toxic drugs, especially methotrexate (MTX), as well as presence of comorbidities and/or 
systemic inflammation may result in decreased liver function. 2
Liver fibrosis is often asymptomatic for years until cirrhosis develops and therefore it 
is difficult to detect with standard noninvasive techniques. It can develop despite nor-
mal liver function tests and normal images from ultrasound and radionuclide scans.3 
Although liver biopsy is the golden standard to detect liver fibrosis and cirrhosis, the 
potential risk of complications restricts its use to those patients with a strong indica-
tion. Hence, there clearly is a need for an accurate, valid and pragmatic non-invasive 
diagnostic test to detect liver fibrosis early.4 
The Enhanced Liver Fibrosis (ELF) test is a relatively new noninvasive test that combines 
an automated in-vitro immunoassay for the quantitative measurement of three serologi-
cal markers being procollagen-3 N-terminal peptide (P3NP), tissue inhibitor of matrix 
metalloproteinase 1 (TIMP1) and hyaluronic acid (HA). The results are then combined 
in an algorithm to produce an ELF score.5,6 The ELF score has been validated as a bio-
marker of fibrosis in healthy subjects and in patients with a wide range of chronic liver 
diseases.7-10 This has resulted in validated cut off values for liver fibrosis and cirrhosis. 
Furthermore, it has been shown that the ELF test can predict the clinical outcome in 
chronic liver disease.6 
The objective of this cross-sectional daily practice study is to evaluate the applicability 
of the ELF test in PsA and RA patients and whether abnormal tests outcomes are related 
to different markers of disease activity and increased inflammatory stage of PsA and RA. 
Secondly we aim to evaluate the effect of MTX use on the ELF test. This is important, 
because ELF can be a potentially valuable tool in the future to monitor liver fibrosis in 
inflammatory joint diseases, especially for those treated by hepatotoxic medication. 
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mETHODS	
Study	design	and	population
The study subjects were included from March 2009 until August 2012, which have been 
described previously.11 The PsA and RA patients were recruited from the rheumatology 
department of the Maxima Medical Center in Eindhoven. An expert rheumatologist 
confirmed PsA and RA diagnosis based on the Classification Criteria for Psoriatic Arthritis 
(CASPAR) and 2010 ACR/EULAR RA Classification Criteria.12 
Co-variables	and	disease	characteristics,	
The following data were collected in a standardized manner directly after inclusion: 
demographic data, disease specific information, general medical history, medication 
use and lifestyle. 
The disease activity and course severity in psoriatic and rheumatic arthritis patients 
were assessed with Disease Activity Score 28 (DAS28). The DAS28 score was categorized 
into mild<3.2, moderate 3.2-5.1 and severe >5.1.13 
Disease specific medication was divided into four subgroups; (1) no medication or 
non-steroidal anti-inflammatory drugs (NSAIDs) only; (2) disease related systemic drugs 
excluding MTX; (3) MTX irrespective of any other medication except biologicals; and (4) 
biologicals irrespective of medication from group one to three. Data on dosing regimens 
were not available.
Laboratory	analysis
Serum was collected at the time of clinical assessment and stored at −80°C until assayed. 
Serum samples were analyzed for levels of HA, TIMP-1 and P3NP using the proprietary 
assays developed for the ELF test by Siemens Healthcare Diagnostics Inc. The analyses 
were all performed on the same day to avoid measurement bias. Validated ELF test cut 
off values to high specificity identification of fibrosis, have been determined for healthy 
blood donors (>9.8) and patients with chronic liver diseases (>11), but this has not yet 
been validated in PsA and RA.14,15 
Serum alanine aminotransferase (ALT), aspartate transaminase (AST), gamma glu-
tamyl transferase (GGT), alkaline phosphatase (ALP), C reactive protein (CRP), blood 
sedimentation rate (BSE) and anti-cyclic citrullinated peptides (CCP) were measured 
using standard enzymatic immunoassays.
Statistics
Statistical analysis was performed using SPSS software version 20. Variables were 
described using standard descriptive statistics. The distribution of the general charac-
teristics were compared between the different groups using the Chi-square tests and 
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one way ANOVA or Kruskal Wallis tests for statistical significance of categorical data and 
continuous data, respectively. P-values were two-sided and values <0.05 were consid-
ered statistically significant.
In order to identify the clinical variables associated with ELF scores , stratification 
analysis for DAS28 score, anti-CCP, CRP levels, BSE and MTX use were conducted. 
A linear univariate model was conducted for ELF on CRP, anti-CCP, BSE and DAS28. 
In the linear multivariate regression model on the ELF, Age, Sex, MTX, BMI, smoking, 
Table	1.	General characteristics of the patients 
Psoriatic	arthritis Rheumatoid	arthritis 
(n=151) (n=130)
Covariables
Age (years) 52,8 ± 11,7 62,0 ± 11,7
Female (%) 45.7 64,6
Alcohol intake (drinks/day)
None (%) 30.9 39.2
≤ 3 (%) 66.2 58.4
> 3 (%) 2,9 2.4
BMI 26.5 ± 4.2 25.9 ± 4.5
Smoking
Never (%) 40,5 32.3
Former (%) 42,5 52.6
Current (%) 17,0 15.0
Disease
Duration of disease, years 9.9± 9.3 10.7 ± 8.4
Activity of disease DAS28 2.16 ± 0.91 2.66 ± 1.00
Current medication use, n (%)
None 8 (5.2) 4 (2.9)
Prostagladinesynthetase inhibors 60 (39) 75 (55.1)
MTX 81 (52.6) 91 (66.9)
prednison 15 (9.7) 21 (15.4)
Other systemic medication 50 (32.5) 35 (25.7)
Biologicals 21 (13.6) 17 (12.5)
Laboratory data (non fasting) 
AST (U/L) 28.3±9.7 27.5±16.3
ALT (U/L) 31.2±22.2 26.2±16.7
GGT (U/L) 34.5±33.3 33.2±22.8
ALP (U/L) 76.6±19.7 82.3±31.9
CRP 5.7 ±10.5 9.9 ±19.0
Abbreviations: DAS28, Disease Activity Score 28; BMI, Body Mass Index; AST, aspartate aminotransferase; ALT, ala-
nine aminotransferase; GGT, gamma glutamyl transferase; ALP, alkaline phosphatase; CRP, C reactive protein.
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alcoholic use, CRP, anti-CCP, BSE and DAS28 were included. In the logistic multivariate 
analyses enter model for RA the following variables were included: Age, Sex, DAS28, CRP, 
BSE, and anti-CCP.
The study was approved by the Medical Ethics Committee of the Erasmus Medical 
Center in Rotterdam (MEC- 2007-181). Written informed consent was obtained from all 
participants.
RESULTS	
In total, 281 patients with eligible ELF values were included for further analyses, of 
whom 151 PsA patients (mean age 52.8±11.7; 45.7% female) and 130 RA patients (mean 
age 62.0±11.7; 64.6% female). For details regarding demographics and baseline data, 
see Table 1. 
Disease	characteristics	and	medication
The mean DAS28 score was 2.16±SD0.91 for PsA patients and 2.66±1.00 for RA. At the 
moment of inclusion 5.2% of PsA and 3% of RA patients used no disease specific medica-
tion. NSAIDs were used by 60 (39%) of the PsA and 75 (55%) of the RA patients. MTX was 
the most frequently used systemic drug in PsA and RA patients (81 (52.3%) vs 91(66.9%)), 
followed by hydroxychloroquine. Biologicals were use by 17(12,5%) of the RA patients 
and 21(13.6%) of the PsA patients. There were no known other causes of chronic liver 
disease. There were no subjects on MTX who had excessive alcoholic use. 
ELF	test:	distribution	and	categorization	
The mean ELF score was 8.96±0.76 within PsA and 9.55±1.04 in RA patients. In RA 10 
(7.7%) and PsA 1 (0.7%) of the subjects had an abnormal ELF test, based on the higher 
cutoff level for chronic liver diseases (ELF≥11), compared to 47 (36.2%) vs 20 (13.2%) 
based on the cutoff value for healthy blood donors (ELF>9.8). Table 2 
Table	2.	Different cut-off values of ELF and P3NP
% (n) PSA (151) RA (130) TOTAL
ELF (>9,8) healthy blood donors 13.2% (20) 36.2% (47) 23.8% (67)
ELF (>11) chronic liver disease 0.7% (1) 7.7% (10) 3.9% (11)
Elf >11(chronic liver disease), ELF >9.8( healthy blood donors)
Abbreviations: PSA: psoriatic arthritis; RA rheumatic arthritis. 
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After comparing the outcomes of subanalyses in PsA, DAS28 scores, CRP, anti-CCP, BSE 
and MTX use, showed no significant differences in the proportion with an ELF cut-off 
value of 9.8 and ≥11. By RA patients using the 9.8 cut-off value, significant differences 
were only seen for DAS and CRP (p=0.04 and 0.01) and on the cut-off value of 11 for 
BSE (Figure 1a-e). There was no significant difference between the different medication 
subgroups. 
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Figure	1 a to e.	Proportion of patients with elevated ELF values stratified on disease activity, disease sever-
ity, systemic inflammation and MTX use.
a: disease activity based on DAS score; b: disease severity based on anti-CCP levels; c: systemic inflammation based 
on CRP level; d: systemic inflammation based on BSE level; e: current, former and never MTX use. 
Abbreviations: PSA: psoriatic arthritis; RA rheumatic arthritis; MTX+ current methotrexate use; MTX= ever MTX use, 
but not current; MTX- never MTX use; ELF, Enhanced liver fibrosis test . * p=0.04; ** p=0.01; ***p=0.02
Vertical border are % of patients with a positive value. 
Cut-off values: ELF (>9,8) healthy blood donors, ELF (>11) chronic liver disease 
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Predictors	of	elevated	ELF	test
The univariate linear regression, stratification showed no association between ELF and 
CRP or anti-CCP. In both RA and PsA a positive relation was found on BSE and DASH28, 
in which a higher BSE or DASH28 related with a higher ELF. (Table 3) In the multivariate 
linear regression model, there was no longer a positive association with BSE or DAS28 
in RA or PsA patients. In RA patients only a positive association was seen with increased 
age. In PsA patients, ELF was associated with increased age and present MTX use and a 
negative association with smoking was found. (Table 4) 
Table	3.	Linear regression univariate model on the ELF
ELF RA PSA
CRP 0.12 (-0.003-0.16) 0.10 (-0.004-0.19)
Anti-CCP 0.15 (0.00-0.00)* 0.41 (0.002-0.007)
BSE 0.28	(0.007-0.03) 0.18	(0.001-0.026)
DASH28 0.38	(0.23-0.60) 0.20	(0.03-0.31)
Data shown represents B-coefficients (95% CI) 
*p=0.33 Abbreviations: ELF, Enhanced liver fibrosis test ; PSA: psoriatic arthritis; RA rheumatic arthritis; CCP: anti-
cyclic citrullinated peptides; CRP:C reactive protein ;BSE: blood sedimentation rate; DAS: disease activity score
Table	4.	Linear regression multivariate model examining the effect of ELF on known parameters of RA and 
PSA. 
ELF RA PSA
sex 0,19 (-0,15-0,92) -0.03 (-0.41-0.32)
age 0.59	(0,03-0.08) 0.52	(0.02-0.05)
mTX 0.22 (-0,04-0,59) 0.34	(0.04-0.42)
alcohol -0.02 (-0,60-0,51) 0.12 (-0.06-0.14)
BmI 0.10 (-0.03-0.09) -0.02 (-0.05-0.05)
Smoking -0,01 (-0,40-0,37) -0.47	(-0.65—0.18)
Anti-CCP 0.12 (0,00-0,00)* 0.01 (-0.03-0.03)
CRP 0,23 (-0,01-0,03) 0.35 (-0.001-0.13)
BSE 0.08 (-0,02-0,03) -0.33 (-0.06-0.01)
DAS28 0.19 (-0,22-0,57) 0.27 (-0.08-0.44)
R	square	adjusted 0.48 0.34
R	square 0.60 0.48
Results are expressed in B-coefficients with (95% CI)
*p=0.34 Abbreviations: ELF, Enhanced liver fibrosis test; PSA: psoriatic arthritis; RA rheumatic arthritis; MTX: metho-
trexate; BMI: body mass index; CCP: anti-cyclic citrullinated peptides; CRP:C reactive protein ;BSE: blood sedimen-
tation rate; DAS: disease activity score. 
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In the multivariable adjusted logistic regression model, using the cut of value of 9.8 
of the ELF test, in RA patients, age was no longer associated with a positive ELF test 
(adjusted OR 1.05 (0.92-1.19)), also no relation was found on the different factors of 
disease activity.
DISCUSSION
This cross sectional study explores the levels of ELF in PsA and RA in relation to inflam-
matory status and disease activity. RA patients had a higher value of ELF score on both 
cut off values compared to PsA in our study. Higher ELF in RA/PsA might suggest that 
a higher prevalence of (preclinical) liver fibrosis, however ELF is not yet validated for 
rheumatic diseases. Thus, further validation studies are needed.16,17 
These higher values of ELF in RA and PsA patients can have a couple of possible explana-
tions. First, the fact of measuring inflammation instead of fibrosis. It has been described 
previously that arthritis activity may affect the value of P3NP (part of the ELF test).18 
However, this was described in active or severe subgroup analyses of RA patients not 
in the PsA subgroup and this correlation does not yet prove a causal relation.19 Another 
study of 100 patients showed no relation between P3NP and disease activity, but the 
level of P3NP was correlated to early stage joint destruction.20 Joint erosions were not 
investigated in our study. In an article were ELF test was tested as an outcome measure 
in systemic sclerosis, no relation was found with arthritis or specific auto-antibodies, in 
line with our study results. They did find a relation with male gender, age and BSE.21 In 
the articles of Kikuchi and Toubi, no relation was found between rheumatic arthritis and 
TIMP-1.22,23 In patients with RA but not PsA, increased levels of circulating HA can be 
found, which may originate as a spillover from either the synovium, the synovial fluid 
and/or the cartilage. There is no close relation between HA levels and biomarker of the 
acute fase response in RA, which may reflect differFent processes of the inflammatory 
reaction.24 In this study, systemic inflammation measured by CRP was weakly related to 
the ELF value (ELF >9.8) for RA, but this was not confirmed in the linear regression mod-
els. No associations were found with disease activity or other inflammatory markers. This 
makes it unlikely that ELF can be seen as an inflammatory marker in arthritis patients. 
Furthermore ELF test has a correlation with liver inflammation (ALT), this inflammation 
does not influence the clinical reliability of the test and ELF is seen as a ‘good’ diagnostic 
tool in clinical practice for the staging of advanced liver fibrosis and cirrhosis in the 
hepatology.10,25
Another reason of this increased ELF score in RA patients can be though selection bias 
for the inclusion criterion to conduct a liver biopsy (i.e. long term MTX use). This may 
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have led to underestimating the true prevalence of liver fibrosis in RA patients in the 
literature.26,27 Among the limited number of studies with noninvasive imaging of liver 
fibrosis (e.g. transient or shear wave elastography) in RA patients, a higher prevalence 
(3.4% to 8%) of severe liver fibrosis was found compared to liver fibrosis detected by 
liver biopsy.26,27 In a systemic review, even a prevalence up to 15% of mild liver fibroses 
was found in RA patients who use MTX and in up to 9.1% of patients undergoing pre-
methotrexate biopsy.28
Strengths	&	Limitations
This cross-sectional study provides a useful comparison of the test outcomes for liver 
fibrosis in arthritis diseases, which makes extrapolation of the results to the clinical prac-
tice more possible. However due to the heterogeneity of the data, it is hard to find sig-
nificant associations. Furthermore, we have tried to investigate the association between 
the potentially important confounders using multivariable analyses and stratification of 
the data. However, the cross-sectional study design does not allow drawing conclusions 
about temporal relationships and causality. 
Advantages of using the ELF test are that it is non-invasive, simple test; it is well vali-
dated and readily available for clinicians. However the limitation of this study is the lack 
of validation of the ELF test by a golden standard. Although a liver biopsy is the golden 
standard for liver fibrosis, it is unethical to perform this on large groups of patients 
including healthy controls. Finally, the cut-off points for the ELF test have not been 
validated for PsA or RA, and were hence extrapolated from the hepatology literature. 
Given the considerable influence of disease prevalence on the predictive values of diag-
nostic tests, the results from liver disease hospital-based studies cannot be transferred 
to our own, ‘low prevalence’ population without resulting in an unacceptably number of 
false positive and negative results. This issue also probably holds true for healthy blood 
donors, which a priori have a lower prevalence of liver fibrosis than those patients with 
an inflammatory disease. 
Conclusion	&	Future	prospective	
ELF test has an increased prevalence in RA and PsA patients. Next step is to evaluate 
whether ELF test may be a promising noninvasive screening and monitoring tool for 
liver fibrosis by rheumatologists for PsA and RA patients. But further research is needed 
to validate the ELF-test by using another noninvasive test e.g. ultrasound transient 
elastography (FibroScan®) and determine the appropriate cut-off values in PsA and RA 
patients. Nevertheless (mild) liver fibrosis may more frequent in patients with inflamma-
tory arthritis than expected. 
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General discussion
The main aim of this thesis was to investigate the relationship between psoriasis and 
liver disease, with a main focus on steatosis and liver fibrosis. We determined different 
levels of inflammation in psoriasis (PSO), psoriatic arthritis (PsA) and rheumatoid arthritis 
(RA) patients; studied the prevalence and risk of steatosis and liver fibrosis irrespective 
of known risk factors in psoriasis patients; and finally discuss new ways to monitor liver 
disease during systemic treatment in these immunomodulatory inflammatory diseases 
(IMIDs). 
SySTEmIC	INFLAmmATION	
Over de past decades psoriasis has evolved from a single disease affecting only the skin, 
to a more systemic disease with a high disease burden. It is known that patients with 
psoriasis suffer more from components of the metabolic syndrome and its associated 
cardiovascular complications.1 The exact role of lifestyle and disease-specific factors 
related to the increased prevalence of these comorbidities remains unclear. It is being 
hypothesized that the causal link could be the systemic inflammation.1,2 In cardiovas-
cular disease increased pro-inflammatory markers are present, such as interleukin (Il)-6 
and C-reactive protein (CRP).3 In psoriasis patients, the effects of these increased inflam-
matory markers is not that clear as compared to cardiovascular disease and some other 
IMIDs like RA. The knowledge regarding the levels of inflammatory markers in psoriasis 
in the available literature remains scarce. Most research was conducted in small labora-
tory studies with inflammatory markers not being their primary area of interest. We have 
conducted a systemic review and meta-analysis on the available literature of a selected 
number of pro -and anti-inflammatory markers in patients with psoriasis.4 In this study, 
the level of inflammation was compared to a healthy control group. We observed a 
1,5 to 2-fold increased level of inflammatory markers in PSO patients as compared to 
healthy controls. However, the clinical relevance and their potential etiological role in 
comorbidities are still subject to future debate.
Nowadays, psoriasis is more and more being regarded as an IMID, such as PsA and RA. 
All share some common pathogenic pathways and several treatments options.5 PsA 
and RA, and especially RA, are generally accepted as well-known systemic diseases, 
as reflected by the ACR/EULAR RA Classification Criteria. An increased prevalence of 
comorbid disease is observed in PsA and RA patients, that are independent of con-
founding lifestyle factors such as obesity and smoking. Also the levels of inflammation 
as reflected by TNF-α, IL-6, and CRP are higher in these diseases affecting the joints as 
compared to PSO.6 A hypothesis on the role of inflammation and lifestyle factors causing 
comorbidities in PSO, PsA and RA is described in Figure 1. However, this knowledge is 
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mainly derived from evidence of in-between study comparisons. Studies comparing 
infl ammation between PSO, PsA and RA within the same study were not available. We 
have compared levels of pro-infl ammatory, and anti-infl ammatory markers and diff er-
ent cytokines, which are important targets for new biological treatments, and tried to 
correct for known confounders like disease severity and medication use in PSO, PsA and 
RA patients within the same study. We have demonstrated that RA patients have the 
highest level of systemic infl ammation followed by PsA and PsO.6 
Although psoriasis is nowadays being seen as an IMID and does seem to some extent 
comparable to RA regarding its etiology, observed infl ammatory markers and available 
treatment options, there are still clear diff erences between these two IMIDs.
HEPATO-PSORIATICA	VS	mETABOLIC	SyNDROmE	
In PSO patients, the prevalence of the metabolic syndrome is around 40% compared to 
15-25% in the general population.7-9 Although, numerous studies are published on this 
association, there is still no consensus whether PSO is an independent risk-factor for the 
metabolic syndrome and development of cardiovascular disease.10,11 
Non-alcoholic fatty liver disease (NAFLD) is considered as the hepatic manifestation of 
the metabolic syndrome.12 In the current epidemic of obesity, type 2 diabetes mellitus 
and other factors of the metabolic syndrome, NAFLD has become the most prevalent 
chronic liver disease in Western countries. The likelihood of having NAFLD increases 
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Figure	1.	A hypothetical model of the etiology of the prevalence of comorbidies, systemic infl ammation 
and organ involvement in PSO, PsA and RA
Abbreviations: PSO, psoriasis; PsA psoriatic arthritis; RA rheumatoid arthritis
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when more criteria of the metabolic syndrome are met.13 The prevalence can be as high 
as 85% in obese patients.14 Metabolic syndrome and NAFLD share insulin resistance and 
pathophysiological mechanisms and are bi-directionally associated.15 With an observed 
increased prevalence of the metabolic syndrome in PSO patients also NAFLD is expected 
to be more prevalent in PSO.
In small case-control studies the prevalence of NAFLD in PSO patients varies between 
46 to 59% in Western countries.16,17 We have studied the association of NAFLD and PSO 
in a large population-based cohort study, The Rotterdam Study, and found that PSO is 
independently associated with NAFLD in patients with mild disease.18 PSO increased 
the likelihood of having NAFLD by approximately 70%. In PSO patients, already having 
metabolic syndrome, this is the strongest predictor of concomitant NAFLD. Candia et 
al. confirmed in a recent systemic review and meta-analysis that psoriasis patients have 
a two-fold increase of having NAFLD as compared to controls without PSO.19 The risk 
of developing NAFLD seems to be correlated with the severity of PSO, and those with 
PsA have an even higher risk of developing NAFLD.19 Whilst all studies confirm this as-
sociation, causality cannot be proven due to the cross-sectional design of the above 
mentioned studies. 16,17,20-22 
Psoriasis and NAFLD are both multifactorial diseases, in which genetic and environ-
mental factors are involved. Figure 2 shows the complex interaction between PSO and 
NAFLD , which will be further explained in this paragraph. NAFLD is also believed to be 
associated with a state of low-grade chronic systemic inflammation, with a slightly el-
evated level of pro-inflammatory markers like Il-6, CRP and tumor necrosis factor-alpha 
(TNF-α).14 Inflammation and cytokine-mediated mechanisms play a central role in the 
pathogenesis of both PSO and liver disease. They also overlap with metabolic compo-
nents, which are frequently present in both PSO and NAFLD. The overlap of this “chronic 
inflammatory state” of PSO, metabolic syndrome and NAFLD does not prove any causal 
relationship between these different conditions.23 Other overlapping mechanisms of 
PSO with the metabolic syndrome and NAFLD which have been proposed in the re-
cent literature include: insulin resistance, dyslipidemia, angiogenesis, oxidative stress 
and endothelial dysfunction.24 Beside these factors also (still unknown) environmental 
components, such as nutrition or physical exercise, and genetic factors are likely to play 
a role as well. 
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HEPATO-PSORIATICA	AND	mEDICATION
Two diff erent meta-analyses conclude that methotrexate (MTX) is a risk factor for 
developing liver fi brosis in PSO patients.25,26 However, no dose-dependent eff ect was 
observed.25,26 Psoriasis patients receiving MTX have a higher risk of developing liver 
fi brosis compared to patients with PsA and RA receiving this same drug.27 This may be 
explained by the higher prevalence of unfavorable lifestyle factors and components of 
the metabolic syndrome in PSO patients compared to PsA and RA.2,28 In PSO patients 
with type 2 diabetes or pre-existing NAFLD, MTX can cause an increased risk of drug-
induced hepatic fi brosis compared to patients without these metabolic comorbidities.29 
Inconsistent results were found in two meta-analysis on the association between diabe-
tes, obesity and alcohol intake and the increased risk of liver fi brosis in PSO patients.25,26 
Furthermore, adopting a more healthy lifestyle is an eff ective therapeutic option in the 
treatment of NAFLD and also in PSO patients. It may reduce the psoriasis severity and 
treatment response.29,30 The association between PSO and liver disease is important 
from a therapeutic point of view, since treatment may involve the use of hepatotoxic 
drugs, such as MTX. Although medication and the metabolic syndrome are important 
Figure	2.	hepato-psoriatica; a complex interaction between psoriasis, NAFLD and co-existing factors
Psoriasis can be replaced by psoriatic arthritis or rheumatoid arthritis. Abbreviations; pso, psoriasis; MetS, meta-
bolic syndrome; Med, medication; NAFLD, non-alcoholic fatty liver disease; sys infl am, systemic infl ammation. 
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risk factors for the development of liver fibrosis in PSO patients, in our study we also 
found an increased prevalence of liver fibrosis in PSO patients without use of hepatotoxic 
medication. Even after adjusting for different components of the metabolic syndrome. 
This implies that other more disease specific factors may play an important role as well. 
mONITORING	OF	LIVER	DAmAGE
Several international guidelines of medical societies recommend using ALT to monitor 
liver toxicity. ALT is indeed a good marker for acute medication induced hepatitis. How-
ever, for the detection of NAFLD and liver fibrosis, ALT appears to be unresponsive.31,32 
Even in patients with NAFLD, it’s found that half of the NAFLD patients have normal 
ALT levels.33 In elderly patients with NAFLD this marker is even normal in up to 88%.34 
In our studies, ALT levels were within the normal range in almost all of the participants. 
Furthermore, median ALT levels were normal in the total study population as well as in 
the NAFLD population. Neither did any of the participants with advanced fibrosis show 
elevated ALT levels.35 However, ALT is still being recommended in the Dutch dermatology 
and rheumatology guidelines to monitor liver disease in patients receiving hepatotoxic 
drugs.36 
Use of amino terminal type III procollagen peptide (P3NP), additional to ALT, has also 
been recommended in the European Dermatology and British guidelines to monitor liver 
toxicity.37,38 However, P3NP has been abandoned by hepatologists a while ago because 
of several limitations. P3NP is not specific for fibrosis in the liver, is hampered by fre-
quent presence of hepatic steatosis. P3NP can only be interpreted serially, has not been 
properly validated as a diagnostic test and is quite expensive.39 Although, P3NP is being 
mentioned in the Dutch guidelines, it is only scarcely being used in daily dermatologi-
cal practice, related to the above mentioned limitations.40 The updated Dutch psoriasis 
guideline, that still needs to be approved by the Netherlands Society of Dermatology 
and Venereology will therefore probably omit P3NP measurements. 
A new non-invasive diagnostic test, the Enhanced Liver Fibrosis (ELF) Score, has recently 
become available. This ELF score has been proposed to be more reliable than P3NP 
and also interpretable as a single measurement.39 We have investigated the ELF Score 
compared to P3NP in detecting liver fibrosis in PSO, PsA and RA patients.41 The ELF score 
has a smaller range and is less influenced by inflammatory markers compared to a single 
P3NP measurement. Overall the ELF score showed better results in PSO and RA patients. 
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Evaluation and monitoring liver disease
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Figure	3.	Flowchart on evaluation and monitoring liver disease
Without	medication: 
High risk: When one or more risk factors are present further investigations are needed to exclude/confi rm diagnose 
of NAFLD or liver fi brosis. Patients can be referred to a hepatologist. A three years evaluation is recommended
Low risk: When risk factors of liver disease absent, no further investigations are needed. 
Before	start	hepatotoxic	medication:
High risk: ALT >3 times normal value, TE or ELF test indicating severe liver fi brosis (≥ stage 3), with or without fur-
ther risk factors of liver disease, referring the patient to a hepatologist. It is not recommended to start hepatotoxic 
medication in consultation with the hepatologist..
Intermediate risk: ALT ≤3 times normal value and one or more risk factors for liver disease are present or TE or ELF 
test indicating mild liver fi brosis (stage 1 or 2) referral to a hepatologist is recommended. When ALT ≤3 times 
normal value and no risk factors are available an intense monitoring program can be followed with yearly TE or 
ELF test. 
Low risk: No risk factors for liver disease, ALT and Fibroscan or ELF test within the normal range
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Transient elastography (TE) is another non-invasive test that is especially reliable in 
identifying more advanced stages of liver fibrosis.42,43 We have used ultrasound to detect 
steatohepatitis and TE to diagnose liver fibrosis in participants of the Rotterdam Study 
with and without psoriasis.35 We found a two-fold increased risk of liver fibrosis in PSO 
patients compared to the reference population. This risk increased even four times in the 
NAFLD subgroup. In field of hepatology, it has now been demonstrated that the diag-
nostic accuracy for liver fibrosis/cirrhosis improves when biomarkers or TE are used. This 
accuracy further increases by combining both measurements. In two recently published 
hepatological guidelines (NICE and EASL) this has led to the recommendation to use 
the Fibroscan and/or the ELF test as first line diagnostic test to detect liver fibrosis.32,44,45 
For now, TE is the preferred method for monitoring liver fibrosis is psoriasis patients. 
However, it is less readily available because of the requirement of a dedicated device and 
operator. When TE is not available, the ELF test seems the second best option in monitor-
ing liver fibrosis. In clinical practice, the ELF test has a high level of applicability (>95%), 
good inter-laboratory reproducibility, and has the clear advantage of widespread avail-
ability.45 In the current absence of validated ELF cut-off points for inflammatory diseases 
yet, we suggest to use the cut-off point for healthy people. Although, the use of the 
healthy cut-off values would lead to false positive cases, a negative test is sufficiently 
reliable to exclude those with liver conditions. Altogether if the ELF value is above the 
9.8 additional investigations such as transient elastography or referral to a hepatologist 
seems warranted.
Other diagnostic tests for liver fibrosis are the Fibrotest46 and Hepatoscore47 with a 
higher diagnostic accuracy compared to P3NP or APRI (asparate aminotransferase to 
platelet ratio index). 31,48 A more advanced, but promising imaging method for the evalu-
ation of chronic liver disease is gadoxetic acid enhanced-MRI which is currently under 
investigation.32,49
Based upon these findings, we therefore propose the following flowchart (Figure 3) to 
evaluate and monitor liver disease in psoriasis patients
During	hepatotoxic	medication:
High risk: ALT >3 times normal value, TE or ELF test indicating severe liver fibrosis (≥ stage 3) referring the patient to 
a hepatologist and stop the treatment is recommended in consultation with the hepatologist.
Intermediate risk: ALT ≤3 times normal value, or TE or ELF test indicating mild liver fibrosis (stage 1 or 2); new inves-
tigation is recommended ones yearly if the patient continuous with hepatotoxic medication. 
Low risk: ALT and TE or ELF test within the normal range
Abbreviations; LF, liver function; ELF, Enhanced Liver Fibrosis.
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CLINICAL	RELEVANCE	AND	FUTURE	RESEARCH	
As our knowledge evolves on the relationship between NAFLD and liver fibrosis in PSO 
patients, future investigation is necessary for better understanding of the pathophysiol-
ogy. It is important to obtain more reliable results before drawing strong conclusions. 
Therefore, it is necessary to use different datasets and study designs, assessing both 
the primary outcome and its risk factors, and to include genetic epidemiology as well. 
Besides epidemiological and clinical studies, translational and genetics studies are 
required in better understanding the possible association and to riddle its underlying 
mechanisms. Longitudinal studies are needed to confirm a possible causal relationship 
between PSO and NALFD over time. 
It is important that clinicians realize that ALT is not a good marker to monitor for NAFLD 
and liver fibrosis in patients on hepatotoxic drugs. New diagnostic tests have been 
developed with better test performance to diagnose these liver diseases. It is impor-
tant to validate, further develop and improve the accuracy of these existing tools for 
non-invasive diagnoses of liver steatosis, NASH and fibrosis, especially in IMIDs. These 
tools can help us to better investigate the role of disease-related liver comorbidities 
and to improve monitoring of hepatic side-effects during treatment. Although, these 
non-invasive tests are not perfect and need further validation before clinical implemen-
tation, some of them are already available in clinical practice like TE. The ELF test is a 
potential candidate test, but before this test is adapted in clinical practice for patients 
with IMIDs, further external validation is mandatory. 
In the upcoming updated Dutch psoriasis guideline, it is proposed to drop P3NP 
measurements in PSO patients that are considered for hepatotoxic drugs. Instead it is 
advised to screen for known risk factors of liver disease. It can be discussed that in the 
near future, other candidate diagnostic methods, for example TE or ELF will be adopted 
by this same guideline. However, the ELF test first needs reassuring results from further 
validation studies in patients with IMIDs.
We recommend, before the start of any hepatotoxic medication, to evaluate the risk of 
concomitant liver disease in PSO, PsA and RA patients. These risk factors include alcohol 
use, hepatitis, other liver diseases and components of the metabolic syndrome such as 
hypertension, insulin resistance, dyslipidemia and obesity. If one or more risk factors 
are present, further investigation of the liver is recommended (Figure 3), for which the 
newer serum panel marker (e.g. ELF) or imaging (e.g. TE) can be recommended. 
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There is no clear evidence or consensus on the monitoring frequency during use of hep-
atotoxic medication. In the EASL guideline it is recommended for patients with NAFLD 
to perform a follow-up assessment by either a serum biomarker or TE at three year 
intervals.45 The timeframe for NALFD to develop to steatosis and even cirrhosis can be as 
short as two years even without use of hepatotoxic medication.50 Based on these data, it 
seems reasonable that annual evaluation of liver fibrosis is reasonable for patients at risk 
using potential hepatotoxic drugs and biannual evaluation for those patients without 
further risk factors of liver disease. For patients without medication, but with risk factors 
(like NAFLD) an evaluation based on a three year interval seems sufficient.
Increasing the awareness of the risk of developing liver diseases in patients with IMIDs, 
especially during treatment with hepatotoxic drugs by dermatologists, rheumatologists, 
general practitioners and hepatologists and ways to diagnose liver toxicity is of utmost 
importance. Furthermore, the additional comorbidities in both IMIDs and NAFLD and 
the potential impact on possible treatment choices should be taken in account.
Based on the results of this thesis, we conclude that NAFLD and liver fibrosis is more 
prevalent than expected in PSO but also in PsA and RA patients. In psoriasis this risk is 
not only related to traditional risk factors, but also psoriasis itself seems to be an inde-
pendent risk factor for liver disease, with a modest role for systemic inflammation. New 
validated biomarkers or non-invasive diagnostic tests are therefore needed to evaluate 
and monitor for liver diseases in patients with IMIDs. 
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SUmmARy
This thesis focuses on the relationship between psoriasis and liver diseases, especially 
non-alcoholic fatty liver disease (NAFLD) and liver fibrosis. In the first part of this thesis, 
we will focus on the systemic inflammation in psoriatic patients and in the second part 
on the prevalence and monitoring of liver diseases in these immune-mediated inflam-
matory diseases (IMIDs). In addition, we also investigate the relationship between two 
other IMIDs, psoriatic arthritis (PsA) and rheumatoid arthritis (RA), and the prevalence of 
concomitant liver diseases. 
In chapter	1 we present a general introduction to this thesis. We describe the epide-
miology, clinical features, pathology, etiology, disease burden and therapy of psoriasis. 
Hereafter we provide a short overview of PsA and RA. In the third part of the introduc-
tion, we will focus on NAFLD and liver fibrosis. We will provide an insight on psoriasis 
and its comorbidities and the available evidence on the relation between psoriasis and 
liver diseases. In the last part of the introduction we describe ways to monitor liver tox-
icity, especially during methotrexate (MTX) use, according to national guidelines. This 
chapter ends with the motivation and aims of this thesis.
Part	1:	Systemic	inflammation	in	psoriasis	
In chapter	2 we performed a systematic review and meta-analysis of the literature to de-
termine the extent to which systemic inflammation is elevated in patients with psoriasis 
compared with healthy controls. We selected representative pro -and anti- inflammatory 
markers including interleukin (IL)-1β, IL-6, IL-10, C-reactive protein (CRP), intracellular 
adhesion molecule (ICAM)-1, E-selectin and tumour necrosis factor-alpha (TNFα). Dif-
ferences in these serum marker levels between patients and controls were pooled as 
standard mean difference (SMD) using a random-effects model. Seventy-eight studies 
were included, comprising a total of 7,852 individuals of which 3,085 had psoriasis. 
Overall, they had a severe (psoriasis area severity index (PASI) of 17.7) plaques (64%) 
psoriasis without signs of arthritis. The pooled SMDs were higher in patients with pso-
riasis than in healthy controls for IL-6 (1.32), CRP (1.83), TNFα (1.32), E-selectin (1.78) and 
ICAM-1 (1.77). No significant differences of the SMD were seen for IL-1β and IL-10. This 
meta-analysis suggests modest but significantly elevated levels of the pro-inflammatory 
cytokines in the serum of psoriasis patients with predominantly severe disease com-
pared with controls with at most a difference of two points. This is independent of age, 
gender, disease severity and psoriasis type 
In chapter	3 we compare the distribution of serological pro -and anti- inflammatory 
markers (IL-6, IL-10, IL12P70, IL17A, IL17F, IL22, IL23, TNFα and CRP) between patients 
with psoriasis (PSO), psoriatic arthritis(PsA), rheumatic arthritis (RA) and in healthy 
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controls. In addition, using data of a cross sectional study, we identify factors associ-
ated with elevated levels of systemic inflammatory markers. We included a total of 601 
patients, comprising 180 PSO, 154 PsA, 136 RA and 131 healthy controls. RA patients 
demonstrated to have the most pronounced pro-inflammatory status followed by PsA. 
The least amount of systemic inflammation was observed in PSO patients. In the multi-
variate analysis, CRP was associated with disease severity ( β6.9 SE 1.8), pain medication 
( β4.2 SE 1.9) and SF 36’s physical impairment ( β-0.25 SE 0.09). Furthermore, IL-6 was 
associated with type of disease, male gender and systemic medication and IL-10 with 
type of disease.
Part	2:	Liver	disease	in	relation	to	psoriasis
In chapter	4 we assess whether elderly persons with psoriasis have a higher prevalence 
of NAFLD compared to a reference population in a large population-based study; the 
Rotterdam Study. Furthermore, we evaluate to what extent this association depends 
upon other known risk factors for NAFLD. Of 2292 participants over 65 years old, abdom-
inal ultrasonography and psoriasis data were collected. The prevalence of NAFLD was 
46.2% in psoriasis subjects compared to 33.3% for the reference population (p=0.005). 
Psoriasis was significantly associated with NAFLD (adjusted OR=1.7, 95%CI 1.1-2.6). This 
association remained significant after adjustment for alcohol consumption, pack-years 
and smoking status, presence of metabolic syndrome and alanine aminotransferase 
(ALT). 
In chapter	5 we describe the association between psoriasis and liver fibrosis compared 
to subjects without psoriasis within the population-based Rotterdam study. 1535 par-
ticipants of this study had been screened for liver fibrosis using transient elastography. 
Prevalence of advanced liver fibrosis was 8.1% in psoriasis patients compared to 3.6% 
in the reference group (p=0.05). The increased risk of advanced liver fibrosis in psoriasis 
patients remained after adjustment for the following risk factors of liver fibrosis: age, 
gender, alcohol consumption, presence of the metabolic syndrome, steatosis and ALT 
(OR 2.57 (95%CI: 1.00-6.63). This study suggests that elderly persons with mild psoriasis 
without any systemic anti-psoriatic medication are two times more likely to have ad-
vanced liver fibrosis irrespective of common risk factors, especially in those participants 
with pre-existing NAFLD.
In chapter	6 we evaluate and compare the distribution of the enhanced liver fibrosis 
(ELF) test, apply existing cut-offs for hepatic patients and healthy controls, and compare 
it to the corresponding procollagen-3 N-terminal peptide (P3NP) test among patients 
with psoriasis (PSO), psoriatic arthritis (PsA), rheumatoid arthritis (RA) and healthy con-
trols. In total 531 patients were included in this cross-sectional study. The prevalence 
of an increased ELF (>11) and P3NP test was highest in RA patients ( 7.7% and 6.1% 
respectively) followed by PSO patients (1.7% and 5.2%) and PsA (0.7% and 1.3%). The 
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distribution of the ELF score was smaller compared to P3NP values (mean 9.15±0.92 
and 8.37±4.30; range 6.53-13.05 and 0.53-63.88). All subgroups with moderate to severe 
disease severity had higher ELF scores and P3NP values. Furthermore, increased ELF 
scores were associated with increased age, male gender and use of liver toxic medica-
tion. This explorative study suggests that the ELF test is worthwhile validating as a more 
accurate, non-sequential predictor of liver fibrosis in inflammatory diseases. Secondly, 
liver fibrosis may be seen more frequent in patients with inflammatory arthritis than 
would be expected based on the available literature. 
In chapter	7 we investigated the applicability of the ELF test among an outpatient 
group of patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA) and whether 
abnormal test outcomes are related to different markers of disease activity and level of 
inflammation present in PsA and RA patients. In addition, we evaluated the effect of 
MTX use on the ELF test outcomes. In total 281 patients with PsA or RA were included. 
An increased ELF test (>9.8 and >11) was found in 36.2% and 7.7% of RA patients and 
in 13.2% and 0.7% of PsA patients. In the multivariate linear model for PsA, ELF was not 
associated with disease activity. In RA patients using the 9.8 cut-off value, significant 
differences were only observed for disease activity score (DAS) and CRP (p=0.04 and 
0.01) and when using the cut-off value of 11 only for BSE. No association was found 
when using the logistic regression model. The ELF test may be a promising noninvasive 
screening and monitoring tool for liver fibrosis, which is minimally influenced by disease 
activity of PsA and RA, however further validation is necessary. 
General	discussion	and	perspectives
In chapter	8 the main findings of the studies as presented in this thesis are discussed 
and placed into its perspective. First, we discuss systemic inflammation in psoriasis fol-
lowed by the relationship between psoriasis and different liver diseases; summarized as 
“hepato-psoriatica”, and the influence of the metabolic syndrome and use of liver toxic 
medication. Next, we provide guidance for monitoring liver toxicity in patients with 
psoriasis summarized in a clear flowchart. The discussion ends with recommendations 
for future research related to concomitant liver disease in psoriasis patients.
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Dit proefschrift focust zich op de relatie tussen psoriasis en leverziekten en in het bijzon-
der de niet-alcoholische leververvetting (‘non-alcoholic fatty liver disease’, NAFLD) en 
leverfibrose. In het eerste deel van dit proefschrift focussen we ons op de systemische 
inflammatie bij psoriasis en in het tweede deel op het voorkomen van deze leverziekten 
bij patiënten met psoriasis en de monitoring van levertoxiciteit bij gebruik van medica-
tie tegen psoriasis. In aanvulling hierop bestuderen we nog een tweetal andere inflam-
matoire ziekten, namelijk artritis psoriatica en reumatoïde artritis en hun relatie tot het 
voorkomen van leverziekten, de monitoring van leverfibrose en inflammatoire status. 
In hoofdstuk	1 geef ik een algemene inleiding op dit proefschrift. Allereerst beschrij-
ven we de epidemiologie, klinische kenmerken, pathologie, etiologie, de ziektelast en 
de behandeling van psoriasis. Daarna geven we een kort overzicht van de twee andere 
inflammatoire ziekten namelijk artritis psoriatica en reumatoïde artritis. In het derde deel 
geven we een overzicht van NAFLD en leverfibrose. In het hierop volgende hoofdstuk 
gaan we in op de comorbiditeit bij psoriasis in het algemeen en daarna zoomen we in 
op de reeds bestaande kennis over de relatie tussen leverziekten en psoriasis. In de een 
na laatste paragraaf beschrijven we de manier van monitoring van leverfibrose, in het 
bijzonder bij methotrexaat gebruik, zoals het momenteel verloopt volgens de verschil-
lende richtlijnen in de dermatologie en reumatologie. Het hoofdstuk eindigt met de 
motivatie en doelen van dit proefschrift.
Deel	1:	Systemische	inflammatie	in	psoriasis	
In hoofdstuk	2 rapporteren we de resultaten van een meta-analyse waarvoor we de 
literatuur systematisch hebben onderzocht om te bepalen in welke mate systemische 
inflammatie verhoogd is bij psoriasis patiënten ten opzichte van een gezonde controle 
populatie. We hebben hiervoor de volgende representatieve pro -en anti-inflammatoire 
markers geselecteerd; interleukine (IL)-1β, IL-6, IL-10, C-reactive protein (CRP), intracel-
lular adhesion molecule (ICAM)-1, E-selectin en Tumour necrosis factor-alpha (TNFα). 
Om de verschillen weer te geven, is gebruik gemaakt van een random-effect model 
van het gepoolde verschil in de gemiddelde waarde ofwel standard mean difference 
(SMD). Achtenzeventig studies zijn geïncludeerd. Hierin bevinden zich 7852 personen 
waarvan er 3085 psoriasis hebben. De patiënten met psoriasis hebben voornamelijk een 
ernstige (Psoriasis Area Severity Index of PASI van 17.7) plaque vorm (64%) en hebben 
geen klachten van artritis. De gepoolde SMD’s waren hoger in psoriasis patiënten dan in 
de gezonde controles in geval van IL-6 (1.32), CRP (1.83), TNFα (1.32), E-selectin (1.78) en 
ICAM-1 (1.77). Er werd geen significant verschil van de SMD’s gezien voor IL-1β en IL-10. 
Deze meta-analyse suggereert dat er een beperkte maar significante verhoging is van 
het niveau van de pro-inflammatoire markers in psoriasis patiënten met voornamelijk 
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ernstige psoriasis in vergelijking met gezonde controles met ongeveer twee punten. 
Dit lijkt onafhankelijk te zijn van de leeftijd, geslacht, ernst van de ziekte en het type 
psoriasis. 
In hoofdstuk	 3 vergelijken we de distributie van serologische pro -en anti-inflam-
matoire markers (IL-6, IL-10, IL12P70, IL17A, IL17F, IL22, IL23, TNFα en CRP) in psoriasis 
patiënten (PSO), patiënten met artritis psoriatica(PsA), reumatoïde artritis (RA) en in 
gezonde controles. Hiernaast identificeren we factoren waarmee de verhoging van de 
inflammatoire markers geassocieerd zijn in een cross-sectioneel onderzoek. Hiervoor 
hebben we 601 patiënten geïncludeerd, bestaande uit 180 patiënten met PSO, 154 
met PsA, 136 met RA en 130 controles. In het algemeen hebben RA patiënten de meest 
uitgesproken inflammatoire status gevolgd door PsA patiënten. De laagste inflamma-
toire status werd gezien bij de patiënten met PSO. In de multivariate analyse blijkt CRP 
geassocieerd te zijn met de ernst van de ziekte ( β6.9 SE 1.8), pijnmedicatie ( β4.2 SE 
1.9) en mate van lichamelijke beperking volgens de SF36 vragenlijst ( β-0.25 SE 0.09); 
verder was Il-6 geassocieerd met het type diagnose, mannelijk geslacht en systemische 
medicatie, en IL-10 was geassocieerd met eveneens het type diagnose. 
Deel	2:	Leverziektes	in	relatie	tot	psoriasis	
In hoofdstuk	 4 bekijken we binnen de context van de “Rotterdam Studie”, naar de 
prevalentie van NAFLD bij ouderen met psoriasis in vergelijking tot controles. Bij 2292 
deelnemers van 65 jaar of ouder werd een abdominale echo vervaardigd en werd tevens 
bekeken of ze psoriasis hadden. De prevalentie van NAFLD was 46.2% bij deelnemers 
met psoriasis in vergelijking tot 33.3% in deelnemers zonder psoriasis (p=0.005). Pso-
riasis was significant geassocieerd met de aanwezigheid van NAFLD. Deze associatie 
bleef significant na correctie voor andere risicofactoren zoals alcoholgebruik, roken, de 
aanwezigheid van het metabool syndroom en verhoging van alanine aminoransferase 
(ALAT) (aangepaste OR=1.7, 95% CI 1.1-2.6).
In hoofdstuk	 5 beschrijven we de associatie tussen psoriasis en leverfibrose in 
deelnemers van de “Rotterdam Studie”. 1535 deelnemers zijn door middel van een 
Fibroscan ® (transiente elastografie) beoordeeld op de aanwezigheid van leverfibrose. 
Een leverstijfheidmeting boven de 9.5kPa is geassocieerd met de aanwezigheid van 
ernstige fibrose, dat wil zeggen fibrose stadium 3 of 4 op een totaalscore van 4. De 
prevalentie van ernstige leverfibrose in psoriasis patiënten was 8.1% vergeleken met 
3.6% in de referentie populatie (p=0.05). De verhoogde kans op aanwezigheid van 
ernstige leverfibrose in psoriasis patiënten bleef aanwezig als er werd gecorrigeerd voor 
andere bekende risicofactoren (leeftijd, geslacht, alcohol gebruik, aanwezigheid van het 
metabool syndroom, leververvetting en ALAT) die geassocieerd zijn met leverfibrose 
(OR 2.57 (95%CI: 1.00-6.63). Deze studie suggereert dat ouderen met een milde vorm 
van psoriasis zonder gebruik van systemische anti-psoriatische medicatie een tweemaal 
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verhoogd risico hebben op het ontwikkelen van leverfibrose onafhankelijk van andere 
risicofactoren. Dit gold speciaal voor de groep deelnemers met al reeds aanwezige le-
ververvetting. 
In hoofdstuk	 6 evalueren we een bekende diagnostische test voor leverfibrose 
binnen de hepatologie, die momenteel nog niet wordt toegepast binnen diagnostiek 
naar leverfibrose bij inflammatoire aandoeningen zoals psoriasis, artritis psoriatica en 
reumatoïde artritis. Deze ELF test (“enhanced liver fibrosis test”) vergelijken we met de 
momenteel gebruikelijke procollagen-3 N-terminal peptide (P3NP) test. We zijn speci-
fiek geïnteresseerd in de mate van spreiding van ELF testuitslagen in psoriasis patiënten 
(PSO), patiënten met artritis psoriatica(PsA), reumatoïde artritis (RA) en in gezonde 
controles. In het geval van de ELF test gebruiken we een tweetal bestaande referentie-
waarden; die voor gezonde personen (>9.8) en voor patiënten met bekende leverziekten 
(ELF>11). In dit cross-sectionele onderzoek werden 531 patiënten geïncludeerd. In RA 
patiënten werd het vaakst een verhoogde testuitslag gezien: bij de ELF (>11) en P3NP 
test respectievelijk in 7.7% en 6.1% van de patiënten, gevolgd door PSO patiënten (1.7% 
en 5.2%) en PsA patiënten (0.7% en 1.3%). ELF had een kleinere mate van spreiding 
vergeleken met P3NP (gemiddelde 9.15±0.92 en 8.37±4.30; reikwijdte 6.53-13.05 en 
0.53-63.88). De patiënten met een ernstigere vorm van PSO, PsA en RA hadden hogere 
scores van de ELF test en de P3NP waardes. Verder bleek de ELF testuitslag geassocieerd 
met een hogere leeftijd, mannelijk geslacht en het gebruik van levertoxische medicatie. 
De ELF test dient verder onderzocht te worden als potentieel eenvoudigere en mogelijk 
meer betrouwbare test in het opsporen van leverfibrose in patiënten met inflammatoire 
ziekten. Op basis van dit cross sectioneel onderzoek kan voorzichtig geconcludeerd 
worden dat leverfibrose mogelijk wel meer voorkomt in artritis patiënten dan op basis 
van eerder literatuuronderzoek verwacht kan worden. 
In hoofdstuk	 7 onderzoeken we specifiek of verhoogde ELF waarden gerelateerd 
zijn aan de mate van ziekte activiteit en inflammatoire status bij patiënten met artritis 
psoriatica (PsA) en reumatoïde artritis (RA). In aanvulling evalueren we of het gebruik 
van methotrexaat effect heeft op de ELF testuitslag. In totaal werden er 281 artritis 
patiënten geïncludeerd. Een verhoogde ELF waarde (>9.8 en >11) was aanwezig bij 
36.2% en 7.7% van de RA patiënten en bij 13.2% en 0.7% of PsA patiënten. ELF was niet 
geassocieerd met de ziekte activiteit van PsA in het multivariabel model. In RA patiënten 
werd een associatie gezien tussen DAS (disease activity score) en CRP (p=0.04 en 0.01) 
en de referentiewaarde tot 9.8 en bij de referentie waarde van de ELF tot 11 lijkt alleen 
BSE geassocieerd. Geen associaties werden gevonden in het logistische regressie model. 
De ELF test is een veelbelovende methode voor screening op leverfibrose in artritis pa-
tiënten welke maar minimaal lijkt te worden beïnvloed door de ziekte activiteit. Verdere 
validatie van de ELF test in deze patiëntengroep is nodig. 
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Algemene	discussie	en	toekomst
In hoofdstuk	 8 worden de belangrijkste bevindingen in dit proefschrift besproken 
en in perspectief geplaatst. Eerst bediscussiëren we weer de systemische inflammatie 
gevolgd door de relatie van psoriasis met leverziekten, samengevat in de term “hepato-
psoriatica”. We bespreken de invloeden van het metabool syndroom en medicatie. Het 
volgende gedeelte zal aanbevelingen geven rondom monitoring van de lever vormge-
geven in een stroomdiagram. Het discussie hoofdstuk eindigt met aanbevelingen en 
suggesties voor toekomstig onderzoek. 
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Abbreviations
ABBREVIATIONS
ALP   Alkaline phosphatase
ALT  Alanine aminotransferase
AST  Aspartate aminotransferase
BMI  Body Mass Index
BP  Blood pressure
BSA  Body Surface Area
BSE  Blood sedimentation rate
CCP  Cyclic citrullinated peptides
CI  Confidence interval
CRP  C-reactive protein
CVD  Cardiovascular disease
DAS28  Disease Activity Score 28
ELF  Elevated Liver Fibrosis test
ELISA  Enzyme Linked Immuno Sorbant Assay
GGT  Gamma glutamyl transferase
GP  General practitioners
HA  Hyaluronic acid
HBV  Hepatitis B viral infection
HCV  Hepatitis C viral infection
HDL-C  High-density lipoprotein cholesterol 
HOMA-IR  Homeostasis Model Assessment of Insulin Resistance
HRQoL  Health Related Quality of Life
ICAM-1  Intracellular adhesion molecule-1
IL-1β  Interleukin-1 beta
IL  Interleukin
IQR  Interquartile range
IMID  Immunomodulatory inflammatory disease
MTX  Methotrexate 
NAFLD  Non alcoholic fatty liver disease
NASH  Non-alcoholic steatohepatitis 
OR  Odds ratio
P3NP  Amino terminal type III procollagen peptide
PASI  Psoriasis Area and Severity Index
PsA  Psoriatic arthritis
PSO  Psoriasis
PGA  Physician’s Global Assessment
RA   Rheumatoid arthritis
SF-36  Short Form with 36 questions
SMD  standardized mean difference
TE  Transient elastography 
TIMP1  Tissue inhibitor of matrix metalloproteinase 1
TNFα  Tumor necrosis factor-alpha
UV  Ultraviolet 
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- 4th Congress of the Psoriasis International Network, Paris, France 2013 1 ECTS 
-  14th Wetenschappelijke vergadering van de Nederlandse 
Vereniging voor Experimentele Dermatologie, Lunteren 
2013 1 ECTS 
- 22st Congress of the EADV, Istanbul, Turkey 2014 1 ECTS 
- Euroderm Excellence, Nice, Paris 2014 1 ECTS 
- 23st Congress of the EADV, Amsterdam, The Netherlands 2015 1 ECTS 
Other
- Editor Nederlands Tijdschrift voor Dermatologie en Venereologie
- Organizing AAV research day Erasmus MC
2013-2015
2015
2.	Teaching
- DOO course: Teach the Teacher 2 2014 0.5 ECTS
Supervising	master’s	theses
- Charlotte Jantien Janssen 2012 2 ECTS
Occasional	reviewer	for	the	following	journals:
- British Journal of Dermatology
- Journal of Investigative Dermatology
- Endocrine
- Acta D-V
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DANKWOORD
Elke reis die we maken begint gewoon met een eerste stap, en zo ben ik ook begonnen 
het “pad” van promoveren te bewandelen. En zoals de reis begint, eindigt hij ook, met 
een laatste stap. Voor mijn promotietraject is dat hier: het dankwoord!
Als student geneeskunde had ik al vroeg interesse in het doen van medisch weten-
schappelijk onderzoek en mocht ik al in de bachelor fase van de opleiding geneeskunde 
participeren in onderzoek op de afdeling kinderoncologie van het Sophia Kinderzieken-
huis. Mijn interesse in wetenschappelijk onderzoek bleef bestaan na het afronden van 
mijn afstudeeronderzoek in het St Jude Children’s Hospital in Memphis, Tennessee, USA. 
Tijdens mijn ANIOS periode heb ik een RCT mogen opzetten op de afdeling dermatologie 
van het Amphia ziekenhuis te Breda. Na de start van mijn specialisatie tot dermatoloog 
in het Erasmus MC kreeg ik de kans om te starten aan mijn promotietraject, onder lei-
ding van professor Tamar Nijsten, wat uiteindelijk heeft geresulteerd in dit proefschrift 
dat voor u ligt. De inspanningen van heel veel mensen hebben er uiteindelijk toe bij-
gedragen dat ik dit proefschrift met succes heb kunnen afronden. Ik kijk dan ook met 
veel voldoening terug op deze leerzame periode, en heb het “promoveren” altijd met 
veel interesse en plezier gedaan. De laatste pagina’s van dit proefschrift wil ik dan ook 
gebruiken om een aantal mensen speciaal te bedanken voor hun steun, vertrouwen, 
begeleiding en inzet. 
In de eerste plaats wil ik natuurlijk mijn promotor, Prof. Dr. T. Nijsten, Tamar, bedanken. 
Na mijn coschappen wist ik het zeker: ik wilde dermatoloog worden! Op advies van Prof. 
Neumann ben ik eens met jou gaan praten. Plek voor een promotietraject had je op dat 
moment niet, maar wel een ANIOS baan in Breda. Hier heb ik met veel plezier gewerkt 
en de eerste echte klinische ervaring binnen de dermatologie opgedaan. Na ruim een 
jaar kon ik beginnen aan de opleiding dermatologie in het Erasmus MC in Rotterdam. 
Ondanks het feit dat je liever had gezien dat je promovendi full-time promoveren, heb 
je mij toch de kans en het vertrouwen gegeven mijn promotietraject te combineren 
met mijn klinische opleiding. Hier ben ik je heel dankbaar voor. Het was een genoegen 
om te mogen profiteren van je goede begeleiding en je uitgebreide wetenschappelijk 
ervaring. Ik heb genoten van je schema’s die in een oogopslag meer vertellen dan hele 
lappen tekst. Het is dan ook logisch om jou van doctor naar professor en uiteindelijk 
afdelingshoofd te zien groeien in de afgelopen jaren. Het lijkt je allemaal even makkelijk 
af te gaan. Momenteel ben ik tevens heel blij met de fijne samenwerking op het gebied 
van de Mohs’ micrografische chirurgie.  
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Ik wil ook mijn copromotor bedanken, dr. M. Wakkee. Beste Marlies, ik heb het fijn ge-
vonden dat je gedurende het tweede deel van mijn promotie, naast collega AIOS ook 
mijn copromotor bent geworden. Samen met jou heb ik kunnen brainstormen hoe we 
het onderzoek op de best mogelijk manier konden doen. Ik waardeer je oprechte kijk, 
en je bevlogenheid in het wetenschappelijk onderzoek. 
Prof. Neumann, ik wil je nogmaals heel graag bedanken dat u toentertijd ruimte in uw 
agenda heeft gemaakt om mij als coassistent te ontvangen en mij uiteindelijk voor te 
stellen aan Tamar. Een gouden zet blijkt achteraf! En natuurlijk ook voor de ruimte die u 
mij als opleider hebt geboden om aan mijn onderzoek te werken naast de opleiding tot 
dermatoloog.
Ik wil alle co-auteurs die hebben meegewerkt aan de artikelen in dit proefschrift be-
danken voor hun wetenschappelijk input, opbouwende kritiek en verbeteringen. In het 
speciaal wil ik Edith bedanken voor de fijne samenwerking. Ik waardeer de tijd die je 
voor me vrij hebt gemaakt, je statistische en hepatologische kennis en het kritisch door-
lezen van mijn artikelen. Het voelde alsof je een beetje mijn copromotor bent geweest 
in het eerste deel van mijn promotietraject. Lieve Emmilia, samen hebben we ons door 
de meta-analyse geworsteld en er een heel mooi artikel van gemaakt, wat inmiddels 
al vaak is geciteerd. Hierbij heb ik enorm kunnen profiteren van je “perfecte” Engels! Ik 
ben blij dat je mijn nieuwe collega bent geworden in het Groene Hart ziekenhuis. Loes, 
ontzettend bedankt voor het delen van je statistische kennis en dat waar nodig, je altijd 
met mij wilde meedenken. 
Leden van de promotiecommissie; Prof. dr. E.P. Prens, Prof. Dr. J.M.W. Hazes, Prof. Dr. 
E.M.G.J. de Jong, bedankt voor de deelname aan de kleine commissie en het kritisch 
beoordelen van het manuscript. Prof. Dr. J.N.L. Schouten, dr. S Darwish Murad, dr. P.L.A. 
van Daele en Prof. dr. J.L.W. Lambert wil ik graag ook bedanken voor het plaatsnemen in 
de grote commissie. 
Graag wil ik ook alle medewerkers en deelnemers van het ERGO onderzoek in Rotterdam 
Ommoord bedanken. Dankzij jullie is er een schat aan informatie beschikbaar gekomen 
waarmee belangrijk wetenschappelijk onderzoek gedaan kan worden met als uiteinde-
lijke inzet het verbeteren van de gezondheid van de mens. 
Lieve paranimfen Gaby en Armanda. Ik ben erg blij en vereerd dat jullie mij bij willen 
staan op deze bijzondere dag. Gaby, we zijn al meer dan de helft van ons leven vriendin-
nen. Heerlijk dat je mijn vriendin bent met je oprechte vrolijkheid en gezelligheid. Ik 
waardeer hoe jij je carrière pad bewandeld om uiteindelijk je doel te verwezenlijken. 
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Momenteel ben je zelf ook aan het promoveren binnen de gezondheidszorg, maar dan 
vanuit een hele andere invalshoek. Dit ga jij zeker tot een succes maken! 
Lieve Armanda, je bent een “super” collega, we hebben naast de opleiding dermatologie 
en het onderzoek naar psoriasis, ook allebei een passie voor fotografie. Samen hebben 
we 4 maanden lang een cursus photoshop gevolgd. In de tijd dat je mijn kamergenootje 
was hebben we tegelijk ons nieuwe huis verbouwd en zijn we verhuisd. Het is alweer 2 
jaar geleden dat jij hier ook op het onderwerp psoriasis bent gepromoveerd.
Alle (oud) collega’s en dermatologen van de afdeling Dermatologie van het Erasmus MC, 
bedankt voor de prettige samenwerking de afgelopen jaren. Alle (oud) arts-assistenten 
en arts-onderzoekers bedankt voor jullie steun, interesse en begrip op de werkvloer 
maar ook voor de gezelligheid tijdens de congressen, borrels, feestjes en skireizen. 
Dankzij jullie heb ik een top opleidingstijd gehad! Athena club, tijd weer voor een gezel-
lig (refereer)etentje??!! Michelle het was bijzonder om samen de zwangerschap mee te 
maken en wat hebben onze mannetjes het 2,5 jaar samen naar hun zin gehad bij Baloe: 
“de berenkelder van het Sophia”. 
Alle collega’s van het Amphia ziekenhuis, bedankt voor de fijne ANIOS en AIOS tijd.
Beste Ineke, Remco, Anke en Emmilia, dermatologen uit het Groene Hart ziekenhuis in 
Gouda, jullie zijn de beste collega’s die ik maar kan wensen. Ik waardeer de fijne samen-
werking met jullie en de ruimte die jullie mij gaven voor het afronden van mijn promo-
tietraject. Hans en Ben geniet van jullie pensioen, jullie hebben een mooie afdeling aan 
ons overgedragen. En dames op de poli, het is heerlijk om met jullie samen te werken. 
Lieve vrienden, wat geniet ik enorm van het afspreken met jullie en de gezelligheid. Tijd 
om een aantal van jullie eens te bedanken. In het bijzonder, lieve Sandra, wat hebben 
we samen al veel van de wereld gezien. Ik heb genoten van onze reizen samen, maar 
ook van de vele etentjes en feestjes in ons eigen kleine kikkerlandje. Het is voor jou 
nooit een probleem om naar Breda te komen en gezellig bij te kletsen, dat waardeer ik 
enorm. Lieve Esther, je bent een schat van een vriendin! Wat hebben we samen al veel 
dingen gedeeld: de opleiding geneeskunde, een prachtige reis door Australië, ontelbare 
rondjes hardlopen rond de Kralingse Plas ter voorbereiding voor de 10 km loop, allebei 
twee zoontjes van dezelfde leeftijd, en de natuurlijk gezellige afspraakjes met de rest 
van de RPG-groep ( Evelien, Robert-Jan, Arjen en Jos) waar ik onderdeel van uitmaak, 
maar eigenlijk niet officieel toe behoorde. Lieve Arjan en Ilse, wat heerlijk wat we jullie 
buren zijn geworden! En Inge en Jaap, wat fijn dat jullie uiteindelijk ook in Breda zijn 
gaan wonen. Jet en Noud, hopelijk dat we onze wintersport traditie nog lang kunnen 
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voorzetten! Marieke, samen fietsen en squashen is nu vervangen door bootcamps in 
het Mastbos. Lieve Esther (Beekman), wij zijn ook al meer dan de helft van ons leven 
vriendinnen. Heel veel dank hiervoor! Spannend hoor je eerste kindje op komst! Kristel 
en Sijbren, bedankt voor alle gezellige rondjes hardlopen en heerlijke etentjes. Lieve 
meiden van de zwangerschapszwemclub en de Mom in Balance groep, wat heerlijk 
om het over onze kindjes en het moederschap te hebben op de groepsapp of tijdens 
sporten en onze etentjes. 
Dan mijn lieve schoonouders, ik heb het maar met jullie getroffen. Altijd beschikbaar 
om te helpen en altijd staan jullie voor ons klaar. Heel erg bedankt voor het oppassen 
op Nathan en Mats tijdens de afrondende fase van mijn promotietraject. Ook bij on-
voorziene omstandigheden, als ze bijvoorbeeld weer eens een “crèchevirusje” te pak-
ken hadden, sprongen jullie altijd voor ons in de bres.  Bedankt voor alle gezelligheid, 
gastvrijheid en steun. Maris, Harmen, Pepijn en Norah, bedankt voor jullie gezelligheid. 
Lieve familie, pap, mam, woorden schieten te kort om jullie te bedanken voor alles wat 
jullie voor mij betekenen. Jullie steunen me in alles wat ik doe en staan altijd voor me 
klaar. En hartstikke fijn voor het oppassen op Nathan en Mats. Dank je voor deze liefde. 
Lieve Anke en Jetty. Jullie zijn niet alleen superzussen, maar ook supervriendinnen! En 
natuurlijk ook Mark, Vincent, en mijn supernichtjes Noa en Evi. 
Mijn schatjes en kindjes, Nathan en Mats. Wat ben ik blij dat jullie in mijn leven zijn 
gekomen. Wat kan ik (meestalJ) van jullie genieten, jullie zijn mijn toppertjes!
Lieve Jeroen, alweer 15 jaar samen. Wat ben jij een geweldige man en een schat van een 
vader voor je kinderen, en heerlijk dat je die van mij bent. Ik bewonder je doorzettings-
vermogen en je gedrevenheid in je werk en onderzoek. Mede door jouw steun, kritische 
blik bij het doorlezen van de teksten, en bovenal je vertrouwen, is na de afronding van 
jouw promotie in 2015 nu ook eindelijk die van mij aan de beurt. We zeggen dan ook 
regelmatig tegen elkaar ondanks onze drukke leventjes: “wat hebben we het toch maar 
goed voor elkaar zo samen met ons gelukkige gezinnetje”. Ik ❤ van je!
Het leven bestaan niet uit mijlpalen maar uit momenten;
hoewel het moment van promotie toch een echte mijlpaal is!
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